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Abstract 
This thesis demonstrates that the Proline Rich Homeodomain transcription factor 
(PRH/HHEX) plays an important role in regulating the proliferation and migratory behaviour 
of breast cells. In tumourigenic MCF-7 breast cells, shRNA knockdown of PRH results in a 
pro-invasive and pro-proliferative phenotype. Key genes regulated by PRH in MCF-7 cells 
include TP53, endoglin (ENG) and e-cadherin (CDH1), which regulate migration/invasion in 
breast cells. Significantly, exogenous PRH functions as an inhibitor of cell 
proliferation/survival and migration/invasion in all breast cell types examined. Furthermore, 
the effects of exogenous PRH on cell proliferation/survival are dependent on the DNA 
binding activity of PRH. This work provides an explanation for the finding that PRH 
expression is associated with increased overall survival in breast cancer patients. In contrast 
with this work, MCF-7 xenograft experiments reveal that expression of exogenous PRH in 
MCF-7 cells is oncogenic. Furthermore, shRNA knockdown experiments in MDA-MB-231 
cells show that endogenous PRH increases proliferation of these cells. This thesis therefore 
demonstrates that the role of PRH can differ dramatically between breast cell types and 
between ex vivo and in vivo conditions. 
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1.  Introduction 
1.1 Transcriptional regulation and cancer 
 
1.1.1 Transcription and gene regulation 
 
The human genome contains approximately 20,000-25,000 protein coding sequences 
(Baltimore, 2001, Collins et al., 2004). This was surprising, as it was initially thought that 
complex organisms such as humans would contain substantially more genes than relatively 
simple organisms; for example, the nematode worm (Caenorhabditis elegans) genome 
contains nearly 20,000 genes (Consortium, 1998). One way in which complex organisms can 
arise from a relatively limited gene set is by generating greater complexity in the control of 
transcription of these genes (Levine and Tjian, 2003).  
 
Transcription is the process by which the DNA genetic code is copied into a single stranded 
RNA molecule. This is carried out by four DNA-dependent RNA polymerases in eukaryotic 
cells. When the RNA is used as a template to synthesise protein it is known as messenger 
RNA (mRNA) and this is transcribed by RNA polymerase II. The mRNA is used as a template 
for the production of protein in a process called translation (Geiduschek and Tocchini-
Valentini, 1988, Roeder, 1996, Ringel et al., 2011).  
 
The process of transcription starts with pre-initiation. This is where the promoter (the 
sequence upstream of the region coding for the protein molecule) is recognised by RNA 
polymerase II. The RNA polymerase II holo-enzyme pre-initiation complex (which is 
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composed of RNA polymerase II and many accessory general transcription factors (GTFs)), 
binds to the core promoter sequence around 30-100 base pairs upstream of the 
transcription start site (TSS) (reviewed in Fuda et al., 2009). The most characterised of these 
is a core sequence of 5’-TATAAA-3’ 25-30 bases upstream of the transcription start site 
(known as the TATA box) (Lifton et al., 1978). This is bound by the GTF known as TFIID (Starr 
and Hawley, 1991). The DNA double strands are then unwound by another GTF, TFIIH, which 
has helicase activity (Kim et al., 2000). RNA polymerase II binds to the promoter and 
commences transcription, however this interaction is mediated by a number of co-
activators and co-repressors associated with the holoenzyme complex, which respectively 
increase or decrease the rate of transcription and initiation (Roeder, 1996). The RNA 
polymerase then elongates the RNA, until the polymerase reaches the end of the gene, 
where the process is terminated. This occurs by the addition of adenosines on the 3’ end of 
the mRNA, in a process called polyadenylation. This allows the recruitment of termination 
factor proteins, destabilising the DNA:RNA interaction (reviewed in Kuehner et al., 2011).  
 
In addition to promoter sequences, other DNA sequence elements, such as enhancers, 
silencers and initiators, are bound by other sequence-specific transcription factors. These 
DNA sequence elements are typically located up to 50 kilobases upsteam or downstream of 
the gene. These help to determine the rate of transcription and initiation for the gene in 
question, and to ensure that the expression of the gene is appropriate for the cellular 
context (reviewed in Smallwood and Ren, 2013).  
 
Transcription factors are often characterised by containing domains which enable sequence 
specific DNA binding. These domains include basic helix-loop-helix domains, leucine zippers, 
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zinc fingers and homeodomains (reviewed in Mitchell and Tjian, 1989). To prevent 
transcription factors from permanently binding to DNA and activating/repressing 
transcription, they are regulated by various mechanisms. This includes ligand binding (for 
example androgen receptor, which is activated by testosterone), phosphorylation (such as 
the STAT proteins), and proteasomal processing (such as NF-κB) (Weigel and Moore, 2007, 
Gilmore, 2006).  
 
Transcription factors also alter the rate of transcription and initiation by recruiting 
chromatin modifying or binding proteins to the vicinity of the gene. This alteration in the 
chromatin environment is vital for transcription because nuclear DNA is not freely available 
to the RNA polymerase pre-initation complex. Rather, nuclear DNA is condensed and 
wrapped round a histone protein octamer, forming chromatin (Richmond and Finch, 1984). 
Each octamer:DNA complex is called a nucleosome and these occur approximately every 
200 DNA base  pairs (around 150 base pairs are wrapped around the histones, plus there is 
an approximate 50 base pair “linker”) (Richmond and Finch, 1984). The histones are basic 
proteins, and their positive charge allows them to associate with the negatively charged 
DNA (reviewed in Szerlong and Hansen, 2010).  
 
Examples of chromatin modifying or binding proteins that alter the chromatin environment 
are histone modifying enzymes, such as histone acetyltransferases (HATs), histone 
deacetylases (HDACs) and histone methyltransferases (HMTs) (reviewed in Bannister and 
Kouzarides, 2011). Some modifications of histones allow dissociation of the histone:DNA 
interactions, and therefore makes the DNA more accessible to transcription factors (such as 
acetylation of lysine 9 on histone 3) (Brownell and Allis, 1996). Histone modifications also 
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allow chromatin binding-proteins to interact with chromatin, via protein domains such as 
bromodomains (e.g. CREB binding protein) and chromodomains (e.g. the Polycomb group of 
proteins) (Filippakopoulos and Knapp, 2012, Sanchez and Zhou, 2009, Boyer et al., 2006). 
Chromatin structure can also be remodelled by protein complexes, such as the SWI/SNF and 
chromatin structure remodelling (RSC) complexes. These complexes alter the position of 
nucleosomes on the DNA, destabilising the DNA:histone interaction, and thus enable the 
transcriptional machinery to interact with the DNA (Flaus and Owen‐Hughes, 2003, Tang et 
al., 2010). In addition there are proteins that modify DNA, and thereby alter chromatin 
structure. DNA methyltransferases methylate cytosine in CpG dinucleotides, which leads to 
binding of methyl-CpG-binding domain proteins (MBDs). This in turn leads to transcriptional 
silencing of the target gene (Brenner et al., 2004, Kulis and Esteller, 2010).  
 
It has recently been discovered that small RNAs can also regulate transcription. It is well 
established that small and micro RNAs transcribed in the genome can lead to a decrease in 
gene expression via RNA interference. This is through the destruction of specific mRNA 
molecules by the RNA-induced silencing complex (RISC), which are targeted by 
complementary RNAs (reviewed in Hannon, 2002). However small RNAs targeting the 
promoter sequences has been shown to increase expression of certain genes, such as E-
cadherin and VEGF (Vascular endothelial growth factor), in a phenomenon termed RNA 
activation (RNAa) (Li et al., 2006). This process is dependent on the Argonaute 2 protein, a 
protein which is involved in RNA interference, as well as heterogeneous nuclear 
ribonucleases (hnRNPs) A1, A2/B1 and C1/C2 (Jia et al., 2012). H3K9 trimethylation (a 
marker for gene silencing) is also lost at target sites (Li et al., 2006). However, the precise 
mechanism of how this occurs in not fully understood (reviewed in Portnoy et al., 2011). In 
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conclusion, although many factors influence the rate of transcription and initiation, 
transcription factors are key players in determining the expression level of target genes.  
 
1.1.2 Transcription factors and cancer 
 
Genes involved in transcriptional regulation are the second most common class of genes 
that are mutated in cancer, after genes encoding protein kinases (Futreal et al., 2004). One 
example of a transcription factor gene which is frequently mutated in cancer is MYC. MYC 
codes for Myc protein, which through dimerization with its partner Max can bind to 
Enhancer-box sequences (E-boxes), via their helix-loop-helix domains (Blackwood and 
Eisenman, 1991). MYC is commonly translocated in Burkitt’s lymphoma to a transcriptionally 
active region, hence causing upregulation of Myc/Max target genes, which promote cell 
growth and proliferation (Li et al., 2003).  
 
Another group of transcription factors often misregulated in cancer are the Hox proteins. 
Many of these proteins are important in development, specifying positional identity along 
the anterior-posterior axis (Grier et al., 2005). The HOXA9 gene is frequently translocated in 
human AML patients, and fused to the NUP98 gene. The HOXA9-NUP98 fusion gene codes 
for a fusion protein with the homeodomain of Hoxa9 and the transcriptional activation 
activity of NUP98. (Cillo et al., 1999). This leads to the upregulation of genes associated with 
cell proliferation and survival, including cyclin d2 and ID1 (Ghannam et al., 2004). 
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1.1.3 Cancer 
 
Cancer is commonly defined as a group of diseases, whereby a group of cells divide 
uncontrollably and spread throughout the body. There have been over 200 different types 
of cancers recorded in humans (CRUK, 2013). Cancer is the cause of around 13% of all 
deaths worldwide, and is on the increase as global life expectancy increases (Jemal et al., 
2011).  Most deaths from cancer (90%) are due to the cancer metastasis; the colonisation of 
tissues which are far away from the primary tumour (Mehlen and Puisieux, 2006).  
 
For normal cells to become cancerous, they must acquire certain properties, or “hallmarks” 
of cancer (Hanahan and Weinberg, 2000). Some of these hallmarks are to do with cell 
proliferation, such as sustaining proliferative signalling, resisting cell death and evading 
growth suppressors. Most, if not all, tumours inactivate “tumour-suppressor genes”, such as 
those encoding the p53 and Rb proteins, which act to supress cell proliferation and promote 
apoptosis (Weinberg, 1991). Both p53 and Rb influence transcription and the cell cycle. P53 
is an oligiomeric DNA binding transcription factor, whereas Rb is a co-repressor of 
transcription. Tumours also up-regulate “proto-oncogenes”, which are genes which code for 
proteins that increase cell growth and proliferation, or evade apoptosis, such as MYC (He et 
al., 1998). Tumour cells can also become insensitive to extracellular growth signals, by either 
expressing permanently active forms of proteins in downstream signalling pathways (such 
as BRAF in melanomas), or by upregulating ligand expression themselves, and signalling in a 
paracrine and/or autocrine manner (such as VEGF expression)  (Davies et al., 2002, Fiedler 
et al., 1997). 
Chapter 1. Introduction 
 
8 
 
Another hallmark of a tumour cell is that it is immortal, and can undergo an unlimited 
number of cell divisions. This is partly because cancer cells lengthen their repetitive 
sequences present at the telomeres that are required for cell division, either by 
upregulating the enzyme telomerase, or by the ALT (alternative lengthening of telomeres) 
mechanism (Henson et al., 2002, Kim et al., 1994). In normal cells, various DNA repair 
pathways are used to preserve the integrity of the genome, and to keep the mutation rate 
very low. However, in tumour cells, many of these DNA repair pathways are perturbed. For 
example, mutation of the genes encoding DNA repair proteins BRCA1 and BRCA2 is often 
seen in hereditary breast cancer, and mutation of the ERCC1 gene is often seen in non-small 
cell carcinoma (Olaussen et al., 2006, Farmer et al., 2005).  
 
Once a cell becomes immortal, the tumour will grow to less than 1mm3 in size unless 
additional nutrients and oxygen are supplied and waste products and carbon dioxide are 
removed (Folkman, 1990). Therefore, for this to occur, tumours must create their own 
blood vessels (angiogenesis) (Hanahan and Folkman, 1996). Tumours typically upregulate 
pro-angiogenic factors, such as increased vascular endothelial growth factor (VEGF), for this 
to occur (Ferrara et al., 2004). This process is further referred to later in this chapter. 
 
For tumours to become cancers, they must break away from their site of origin and move to 
a secondary organ. For this to happen cells must detach from the primary tumour, by losing 
their cell-to-cell contacts and cell-to-ECM (extracellular matrix) contacts, in a process called 
the epithelial-to-mesenchymal transition (EMT). The tumour cells then enter the circulatory 
or lymphatic systems, in a process known as intravasation, and they are transported to 
secondary sites. The cells then undergo extravasation - that is escape from the vessel lumen 
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- and then it is thought they undergo a conversion from a migratory mesenchymal 
morphology to a more epithelial morphology (mesenchymal-to-epithelial transition (MET)), 
although this has not yet been proven (Kalluri and Weinberg, 2009). This then allows the 
tumour to form at the secondary site (Fidler, 2003). The English surgeon Stephen Paget 
discovered in 1889 that cancers do not metastasise to random places in the body, 
suggesting the metastatic tumour cells have a specific affinity for certain organs (Paget, 
1889). For example, hepatocellular carcinomas tend to metastasise to the lungs, abdominal 
lymph nodes and the bone (Katyal et al., 2000). This led to Paget putting forward the “seed 
and soil” theory, that the environment in which the tumour is in also has an effect on 
tumour colonisation and growth, as well as the aberrations present in the tumour cell itself 
(Paget, 1889). Some progress has been made into what genes allow tumours to metastasise 
to certain sites, for example, ST6GALNAC5 expression enhances metastasis to the brain (Bos 
et al., 2009). However, whilst there has been progress over the last ten years, the 
mechanisms which determine why cancers metastasise to certain sites in the body still 
requires further investigation (Chaffer and Weinberg, 2011).   
 
It has long been understood that the immune system plays a role in preventing tumour 
progression, in that the immune system can target and destroy transformed cells, and hence 
prevent tumour growth (reviewed by Hanahan and Weinberg, 2000). However, the immune 
system can also have pro-tumourgenic effects. For example, mice which are deficient in 
tumour necrosis factor (TNF), or NF-κB, both proteins associated with inflammation, showed 
decreased tumourgenesis (Moore et al., 1999, Maeda et al., 2005).  
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1.1.4 Epithelial-mesenchymal transition  
 
The epithelial-mesenchymal transition (EMT) is thought to play a role in cancer progression, 
as it promotes tumour cell invasiveness through the basement membrane and into the 
bloodstream, thus allowing the cancer to metastasise (Chaffer and Weinberg, 2011). EMT is 
a process that also occurs during development, and is critical for the generation of tissues 
and organs. It involves the loss of tight, gap and adherens junctions, cytoskeletal 
reorganisation, loss of apical polarity and the acquisition of spindle shaped cell morphology 
(figure 1.1) (Thiery and Sleeman, 2006). EMT during development is involved in several 
processes; including gastrulation (formation of the mesoderm from the embryonic 
epithelium) and neural crest delamination, where the neural crest cells migrate throughout 
the embryo and differentiate in various tissues and organs (Theveneau and Mayor, 2012, 
Thiery and Sleeman, 2006). EMT is characterised by the loss of epithelial marker proteins, 
such as E-Cadherin, and increased expression of mesenchymal markers such as N-Cadherin, 
Vimentin, and the transcription factors Slug, Twist and Snail (Kalluri and Weinberg, 2009) 
(see figure 1.1).  
 
EMT can be induced by several mechanisms. Hypoxia was found to induce EMT in many 
breast cancer cell lines, via the uPAR and notch signalling pathways, and this leads to a more 
invasive and migratory phenotype (Chen et al., 2009b, Lester et al., 2007). The EMT process 
in cancer cells can itself influence the external environment, further contributing to cancer 
progression. For example, Twist-induced EMT in luminal MCF-7 breast tumour cell line 
xenograft experiments showed increased angiogenesis, which was due to VEGF secretion 
(Mironchik et al., 2005).  
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Figure 1.1: Epithelial-to-mesenchymal transition.
Figure 1.2: Diagram of the human breast. Taken from Cancer Research UK website.
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1.1.5 Breast cancer 
 
Breast cancer is the most common cancer in the world, with 1.4 million people being 
diagnosed globally in 2008 (GLOBOCAN). Breast cancer primarily affects women; although 
men can get breast cancer (49,564 women were diagnosed with breast cancer in the UK in 
2010, compared with 397 men (Cancer Research UK)). The breasts are apocrine glands, 
which produce milk to feed an infant child. The breast consists of many alveoli, which 
contain milk secreting lactocytes. These alveoli form clusters together, making up a lobule 
(Hassiotou and Geddes, 2013). During lactation, lobules secrete milk into the milk ducts, 
which are connected to the nipple (Ramsay et al., 2005) (see figure 1.2). Breast cancers 
typically show similar histochemistry to the milk ducts (ductal carcinoma) or the breast 
lobules (lobular carcinoma).  
 
1.1.6 Types of breast cancer 
 
Breast cancer can be sub-classified into many different sub-types, such as lobular and ductal 
as described above. Breast cancer is also histopathically distinguished by grade, grade 1 
being the most differentiated cancers (with the best prognosis), whilst grade 3 cancers are 
poorly differentiated (and have the worst prognosis) (Richardson, 1957).  Breast cancers are 
also distinguished by stage, with stage IA showing no evidence of tumour metastasis 
towards the lymph nodes, whilst stage IV cancer shows metastasis distant from the original 
tumour (Woodward et al., 2003).  
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Breast cancer can also be distinguished dependent on which receptors are present in the 
cell. The three most important receptors are Oestrogen Receptor (ER), Progesterone 
Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2). The presence or 
absence of these receptors has a substantive effect on prognosis and on the treatment of 
the cancer.  
 
ERs are ligand-activated transcription factors. ER in its transcriptionally inactive state is 
present in the cytoplasm of the cell. When a suitable ligand (such as 17β-oestradiol) binds to 
ER, this causes ER to dimerise and translocate to the nucleus, causing it to be 
transcriptionally active (Htun et al., 1999). ER then binds to DNA with other transcriptional 
activators, such as nuclear receptor coactivator 1 (NCOA1) which then turn off transcription 
of target genes (Hall and McDonnell, 2005). ER is upregulated in around 70% of breast 
tumours (Shakur Mohibi, 2011). ER activity can be targeted using ER antagonists, such as 
tamoxifen and aromatase inhibitors. Aromatase is an enzyme which converts testosterone 
to oestradiol, and thus inhibition of aromatase leads to decreased oestrogen and decreased 
activation of ERs (reviewed in Wood et al., 2003).  
 
PR is also a ligand-activated transcription factor, which is regulated in a similar way to ER.  
Binding of the ligand progestin causes dimerization of PR, as well as translocation of PR from 
the nucleus to the cytoplasm (Mockus and Horwitz, 1983). PR regulates transcription of 
genes involved in regulation of cell growth and migration, including VEGFA (Yin et al., 2012, 
Tamm et al., 2009). PR is upregulated in around 60-70% of breast carcinomas (Kammori et 
al., 2005). Breast tumours which are positive for both ER and PR are much more likely to 
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respond to anti-hormornal therapies, such as tamoxifen, than ER+/PR- breast tumours 
(Osborne et al., 1980).  
 
HER2 is a plasma-membrane bound tyrosine kinase, and is a member of the epidermal 
growth factor receptor (EGFR) family. Ligand binding to HER2 leads to homodimerisation or 
heterodimerisation with other receptors of the EGFR family. This then results in the 
activation of genes associated with cell survival and proliferation, via signaling pathways 
such as the mitogen-activated protein kinase (MAPK) pathway, and the JAK/STAT pathway 
(Roy and Perez, 2009, Olayioye, 2001). Amplification of HER2 has been detected in 25-30% 
of breast cancers, and patients with HER2 amplifications have more aggressive cancers 
(Slamon et al., 1989). HER2 positive breast cancers are currently treated with the 
monoclonal antibody trastuzumab, which prevents dimerization of the HER2 receptor, as 
well as targets HER2-positive cells for destruction by the immune system (Cho et al., 2003, 
Clynes et al., 2000).  
 
Breast cancers which are negative for ER, PR and HER2 amplification are commonly referred 
to as “triple-negative breast cancers” (TNBCs), and will not respond to hormone or HER2 
specific treatments. TNBCs tend to be diagnosed in women who are younger compared to 
other breast cancers, and are more likely to recur before 5 years (Bauer et al., 2007, Dent et 
al., 2007).   
 
Breast cancers can also be classified into 5 clusters based on their gene expression;  luminal 
A, luminal B, basal, HER2 amplified and normal-like breast cancers (Sørlie et al., 2001). 
Luminal A breast cancers show the highest expression of luminal-specific genes, such as 
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ESR1 (which codes for ERα protein), GATA binding protein 3 (GATA3) and X-box binding 
protein 1 (XBP1) (Sørlie et al., 2001). Luminal B subtypes express these luminal enriched-
genes, but at a much lower level (Sørlie et al., 2001). The luminal breast cancers broadly 
correlate with ER+ breast cancers, as ESR1 is a luminal-specific gene.  The basal breast 
cancer subtype is characterised by high transcript levels of laminin γ2, keratins 5 and 17 and 
integrin-β4, and low mRNA expression of ESR1 and genes associated with it (Perou et al., 
2000). Basal-breast cancer is sometimes used as an analogous term for TNBC, however 
these terms are not synonyms, not all basal breast cancers are TNBC or vice versa (Seal and 
Chia, 2010). HER2 amplified breast cancers are characterised by amplified expression of 
genes in the 17q22.24 region, including HER2, growth factor receptor bound protein 7 
(GRB7), as well as TNF-receptor associated factor 4 (TRAF4) (Sørlie et al., 2001). HER2 
tumours are typically characterised by low expression of ER and genes associated with ER 
expression, much like basal breast tumours (Perou et al., 2000). “Normal-like” breast 
cancers typically have low expression of genes associated with luminal epithelial cells, and 
Breast 
Cancer type
Luminal Basal HER2 
amplified
“Normal-
like”
Genes which 
are typically 
highly 
expressed
ESR1
GATA3
XBP1
prolactin 
receptor
HNF3α
laminin gamma 2
keratin 5 
keratin 7
integrin beta 4
caveolin 2
MMP-14
HER2
GRB7 
TRAF4
flotillin 2
TIAF1
CD36
GPDH1
ALDH2
integrin
alpha 7
Table 1.1: Genes associated with breast cancer subtypes. Genes typically upregulated
in various breast cancer subtypes (Data from Sørlie et al., 2001, Perou et al., 2000).
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high expression of genes characteristic of adipose and basal epithelial cells (such as CD36 
and glycerol-3-phosphate dehydrogenase 1 (GPDH1)) (Perou et al., 2000, Sørlie et al., 2001) 
(see table 1.1).  
 
1.1.7 Breast cancer initiating cells 
 
One model for the development of cancer is the “Cancer Initiating Cell (CIC) model” (see 
figure 1.3) (Al-Hajj et al., 2003b). CICs are a small sub-population of the total tumour, but 
are highly tumourgenic compared to the rest of the tumour cell population. Breast CICs are 
characterised by high CD44 expression, low CD24 expression, and high expression of Alcohol 
dehydrogenase 1  (ALDH1) (Ricardo et al., 2011). CICs are 50 times more tumourgenic than 
unsorted cells (Al-Hajj et al., 2003a). Similar to normal stem-cells, CICs have been shown to 
undergo self-renewal, as they can form 3D mammosphere structures from single cell 
Chemotherapy 
kills bulk 
tumour but 
CICs remain
CICs then proliferate 
and “differentiate” 
again, causing 
tumour relapse
Tumour starts 
with cancer 
initiating cell 
(CIC)
CIC then 
proliferates and 
“differentiates” 
to form bulk 
tumour
Chemotherapy
Figure 1.3: Cancer initiating cell model 
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suspensions. CICs also show limited “differentiation”, as CICs will form tumours with 
phenotypically diverse populations (Ponti et al., 2005, Al-Hajj et al., 2003a). 
 
Markers for breast CICs, such as ALDH1, as well as the gene signature for CD44high/CD24low 
cells have been shown to be predictors for poor clinical outcome (Ginestier et al., 2007, Liu 
et al., 2007). Breast CICs are thought to play a major role in the recurrence of tumours, as 
typical chemotherapy treatments enriches for CICs, which could therefore lead to the 
regrowth of a more aggressive tumour (Tanei et al., 2009, Creighton et al., 2009, Velasco-
Velázquez et al., 2012).  
  
There is a relationship between EMT and CICs. Transformed breast epithelial cells which 
have undergone EMT, through expression of transcription factors Snail or Twist, produce a 
greater number of mammospheres and form a greater number of colonies in soft agar 
(Mani et al., 2008). This implies that induction of EMT leads to an increased number of CICs. 
Conversely, CD44high/CD24low cells enriched from human mammary epithelia express 
increased transcript levels of mesenchymal markers, such as vimentin, n-cadherin and twist, 
and a decreased amount of e-cadherin mRNA, compared to CD44low/CD24high cells (Mani et 
al., 2008, Creighton et al., 2010). This relationship could provide one explanation as to why 
markers associated with EMT are correlated with chemotherapy resistance (Farmer et al., 
2009). Indeed, residual breast cancer cells surviving both chemotherapy and endocrine 
therapy show increased markers for both CICs and EMT (Creighton et al., 2009).  
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1.2 PRH protein 
 
1.2.1 Overview of PRH  
 
PRH (Proline-Rich Homeodomain) protein, also known as HHex (haematopoietically 
expressed homeobox) is a transcription factor which binds to DNA via a 60 amino acid 
conserved protein sequence known as the homeodomain. PRH is unusual as it is a 
homeodomain protein which can form homo-oligomers in vivo and in vitro (Soufi, et al., 
2006). Like many homeodomain-containing proteins, PRH is involved in development 
processes, such anterioposterior axis formation, the development of multiple organs, and 
the development of vascular and blood systems in the early embryo (reviewed in Soufi and 
Jayaraman, 2008). PRH is also known to be expressed in the thyroid and liver tissues, and 
the haemopoietic compartment in adults (reviewed in Kershaw et al., 2013a). There is also 
increasing evidence that expression of PRH may play a role in type 2 diabetes. Single 
nucleotide polymorphisms (SNPs) rs1111875 and rs7923837, which  are located in a region 
3’ to the PRH gene, have been shown to be significantly associated with type II diabetes 
(Sladek et al., 2007).  PRH has also been shown to be involved in the regulation of lactating 
breast tissue, and there is some evidence that PRH may be disregulated in breast cancers 
(Puppin et al., 2006). Similar studies have also implicated disregulation of PRH as an 
important transcription factor in thyroid cancer and in hepatocarcinomas (D’Elia et al., 2002, 
Su et al., 2012).  
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1.2.2 PRH Structure 
 
Human PRH is 270 amino acids long and has a calculated molecular mass of 30kDa. The 
homeodomain is highly conserved between species, with human and chicken 
homeodomains sharing 97% homology, and the mouse and human homeodomains only 
differing by 1 amino acid (Crompton et al., 1992). PRH contains three domains, an N-
terminal domain which is 20% proline (amino acids 1-136), the homeodomain (amino acids 
137-196) and an acidic C-terminal domain (amino acids 197-270) (see figure 1.4) (reviewed 
in Kershaw et al., 2013a). 
 
1.2.3 The N-terminal domain 
 
The isolated N-terminal domain of PRH forms dimers in vitro (Soufi, et al., 2006). It has also 
been shown that a PRH truncation mutant that lacks the first 46 amino acids is 
transcriptionally inactive, whilst this same mutant is transcriptionally active if it is fused to a 
dimeric GAL4 binding domain, suggesting that the N-terminal domain is critical for PRH 
transcriptional activity (Brickman, et al., 2000). The N-terminal dimer is partially resistant to 
unfolding by SDS, and has neither an alpha-helix or beta-sheet structure, but exhibits an 
extended and mobile structure reminiscent of Elastin (Soufi, et al 2006).  The N-terminal 
domain also allows PRH to bind to other proteins. PRH binds to the co-repressor TLE, and 
amino acids 32-38 within PRH are involved in this interaction (Swingler et al., 2004). 
Mutation of phenylalanine at amino acid 32 abolishes the interaction with TLE, and 
repression by PRH at some PRH-dependent target genes (Noy, et al., 2010). The PRH N-
terminus can also bind to eIF-4E and inhibit the mRNA transport activity of eIF-4E on specific 
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growth related mRNAs (like cyclin d1). PRH also antagonises oncogenic transformation of 
immortalised cell lines by eIF-4E (Topisirovic, et al., 2003). PRH has also been shown to 
interact with the promyelocytic leukaemia protein (PML), a transcription factor which acts 
as a tumour suppressor, in K562 leukaemic cells (Topcu et al., 1999).  
 
1.2.4 The homeodomain 
 
Homeodomains consist of a short N-terminal arm and 3 alpha-helices. The N-terminal arm 
and third helix are involved in recognising DNA sequences, with the N-terminal arm binding 
to the minor groove, and the third alpha helix making specific contacts with the DNA bases 
in the major groove (Gehring et al., 1994). Glutamine at position 50 and asparagine at 
position 51 of the PRH homeodomain have been shown to be important in the formation of 
PRH-DNA interactions in computational models (Jalili and Karami, 2012).  The consensus 
DNA sequence for protein binding as determined by SELEX (systematic evolution of ligands 
by exponential enrichment) and DNaseI footprinting with purified PRH homeodomain and C-
terminal domain is 5’-C/TA/TATAAA/G-3’ (Crompton et al., 1992). However, the isolated 
PRH homeodomain alone recognises relatively short DNA consensus sequences, including 
5’-TAAT-3’, 5’-CAAG-3’ or 5’-ATTAA-3’ in electrophoretic mobility shift assays (Pellizzari, et 
al., 2000).  The homeodomain is also able to repress gene transcription without binding to 
DNA, via interaction with the transcription factor Activator protein-1 (AP-1). AP-1 consists of 
dimers of either c-Fos, c-Jun, Activating transcription factor (ATF) and Jun dimerization 
protein (JDP) proteins. AP-1 dependent activation of genes is repressed by helix 3 of the PRH 
homeodomain binding to the N-terminus of c-Jun, resulting in inhibition of Fos/Jun 
heterodimerization (Schaefer, et al., 2001). 
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Proline-rich Homeodomain Acidic region
TLE
c-Jun
TBP
HNF-1A
Interaction
Sites
Figure 1.4: A diagram of PRH protein. This diagram shows the different domains and interaction
sites of PRH with DNA and other interacting proteins (adapted from R. M. Kershaw, 2013).
1 137 196 270
eIF-4E
Dimerisation
PP
163   177
Oligomerisation
Repression DNA binding Activation
PML
Figure 1.5: A model proposing how PRH forms octamers in vivo. ‘P’ refers to the proline-rich region, ‘R’
refers to the repression region, and ‘H’ refers to the homeodomain and C-terminal region of PRH
protein (from Soufi and Jayaraman, 2008).
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1.2.5 The C-terminal domain 
 
The C-terminal domain of PRH is acidic, and acidic domains are characteristic of 
transcriptional activators (Triezenberg, 1995). PRH is known to activate the transcription of 
the bile-acid transporter NTCP (sodium-dependent bile acid co-transporter). It is thought 
that PRH activates transcription by interacting with TBP (TATA box binding protein) 
(Kasamatsu, et al., 2004). However, TBP-PRH interactions have also been proposed to 
repress transcription (Guiral et al., 2001). It has been shown that PRH binds to Hepatocyte 
nuclear factor-1α (HNF-1α) and stimulates the transcriptional activator activity of HNF-1α 
(Tanaka et al., 2005). The PRH homeodomain and C-terminal domain are required for this 
activity (Tanaka, et al., 2005). PRH protein without the C-terminal activation domain acts as 
a dominant negative mutant of PRH, with regards to its transcriptional activation activity 
(Kasamatsu et al., 2004).  
 
1.2.6 Oligomerisation of PRH 
 
In gel filtration assays, PRH elutes at a molecular weight of about 250kDa, as well as much 
larger molecular weight species (Soufi et al., 2006). Analytical untracentrifugation 
sedimentation experiments show that PRH also forms complexes of about 280 kDa, as well 
as larger molecular weight species (Soufi, et al., 2006). In vivo cross-linking experiments 
have shown that PRH is oligomeric, and in vitro cross-linking experiments have shown PRH 
forms homo-oligomers. Pull-down and yeast two-hybrid assays show that the N-terminal 50 
amino acids of PRH are needed for dimerisation (Soufi, et al., 2006). PRH octamers have 
been shown to form oblate spheroids in vitro, with two of these octamers coming together 
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to form spherical hexadecameric PRH species (Soufi et al., 2010). It has been shown using 
dynamic light scattering experiments that the dominant PRH species in vitro is either a PRH 
octamer or hexadecamer (Shukla et al., 2012).  
 
A model has been proposed to describe how PRH octamers form. The proline-rich 
dimerisation regions (hereafter known as “P” regions) self-associate with each other and 
form dimers. This leaves two other regions, the “R” repression region in the N-terminal 
domain, and the “H” region, which contains the homeodomain and the C-terminus. The “R” 
regions then associate with the “H” regions on another dimer, forming tetramers. This 
leaves two “R” regions and two “H” regions free per tetramer to interact with another PRH 
tetramer, resulting in a PRH octamer where there are no free regions (figure 1.5) (Soufi et 
al., 2006).  
 
As stated previously, the homeodomain of PRH recognises short DNA sequences, which 
would make it difficult for the PRH protein to recognise its target promoters, as these 
sequences will occur quite frequently in the genome (once every 256 base pairs for a 4 base 
sequence). It has been shown that in the human goosecoid promoter, individual TAAT 
motifs are protected from DNaseI digestion by the PRH homeodomain, but full-length PRH 
protects long stretches of DNA containing multiple PRH binding motifs from digestion 
(Williams, et al., 2008). Since PRH exists as a homo-oligomer, and PRH binds to multiple 
TAAT motifs in the human goosecoid promoter, it has been suggested that the oligomeric 
nature of PRH allows for greater binding specificity and affinity (Soufi et al., 2010, Williams 
et al., 2008).  Additional experiments which assess the distortion of DNA have also been 
carried out, and suggest that DNA is wrapped around the PRH oligomer (Williams, et al., 
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2008). PRH can cause compaction of DNA in vitro, and this compaction is increased when 
multiple PRH binding sites are present  (Soufi et al., 2010). A model has been proposed, 
whereby PRH compacts the DNA and forms nucleosome-like particles that repress 
transcription (Williams, et al., 2008). 
 
1.2.7 PRH as a phosphoprotein 
 
Human PRH binds to the β subunit of Protein Kinase CK2 (CK2), and PRH gets 
phosphorylated in vivo by CK2 on serines 163 and 177 (Soufi et al., 2009). Phosphorylation 
of PRH inhibits its ability to bind to DNA, thus blocking the ability of PRH to act as a 
transcriptional repressor (Soufi et al., 2009). A PRH phosphorylation mimic, that is a mutant 
protein having glutamic acid residues in place of serines at positions 163 and 177, is less 
tightly bound in the nucleus suggesting that phosphorylation decreases nuclear retention of 
PRH. Phosphorylation also leads to cleavage of PRH by the proteasome, resulting in the 
formation of a PRHΔC product (Noy et al., 2012c).  
 
PRHΔC is formed when the entire C-terminal domain (amino acids 211-270) is removed, 
leaving the repression domain and central PRH homeodomain. PRHΔC has been shown to 
act as a transdominant negative regulator of PRH. Over-expression of exogenous PRHΔC 
leads to de-repression of VEGFR1 transcription in K562 leukaemic cells (Noy et al., 2012c). 
PRHΔC is thought to exert this effect by sequestering the co-repressor TLE from full length 
PRH protein. Since less TLE can bind to full-length PRH, transcriptional repression by PRH at 
some PRH-dependent promoters is decreased (see figure 1.6).  Alternatively, PRH/PRHΔC 
oligomers may form, blocking the function of full length PRH.  
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1.2.8 PRH in development 
 
PRH is required for embryonic development, and Prh-/- mice embryos die between 13.5-16.5 
days post coitum (Martinez Barbera et al., 2000, Keng et al., 2000). PRH has also been shown 
to be a marker for anterior asymmetry in Xenopus embryos. Overexpression of PRH in these 
embryos causes suppression of the dorsal mesoderm, whilst expression of a mutant form of 
PRH (which cannot repress gene transcription) leads to anterior truncations (Brickman et al., 
2000). 
 
PRH is also required for the development of various organs (reviewed in Soufi and 
Jayaraman, 2008). PRH is essential for liver development, as a null-mutation of Prh stops 
PRH
PRH
PRHPRHPRH
TLE
TLE CK2
DNA
PP
PPPPPP Proteasome
Figure 1.6: Proposed mechanism of PRHΔC-mediated regulation. 1) PRH binds to co-repressor TLE,
and binds to DNA to repress transcription. 2) PRH is phosphorylated by Protein Kinase CK2, causing PRH
to no longer bind to DNA and to translocate to the cytoplasm. 3) PRH is then cleaved by the
proteasome, giving a truncated product with no C-terminal domain. 4) PRHΔC then binds to TLE. 5) TLE
can no longer translocate to the nucleus, and hence cannot repress PRH-target genes.
1.
2.
3.
4.
5.
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formation of the liver bud (Hunter et al., 2007). Loss of Prh in the hepatic diverticulum (the 
precursor to the embryonic liver liver), leads to a smaller and cystic liver, loss of gall bladder 
and bile duct, and embryonic lethality (Hunter et al., 2007). Furthermore, loss of Prh in the 
embryonic liver leads to irregular bile duct development, and polycystic liver disease in the 
adult mouse (Hunter et al., 2007). PRH is also required for development of the thyroid 
gland, as well as the pancreas (Elsalini et al., 2003, Parlato et al., 2004, Bort et al., 2004). 
PRH is involved in haematopoiesis, and loss of Prh in the haemangioblast (the precursor of 
both blood and endothelial cells) leads to decreased differentiation into haematopoietic 
cells, and into endothelial cells to a lesser extent (Guo et al., 2003).  PRH levels are high in 
haematopoietic stem cells, and PRH expression generally decreases during the 
differentiation process, with the exception of granulocytes (Manfioletti et al., 1995, 
Jayaraman et al., 2000).  
 
1.2.9 PRH as an inhibitor of proliferation and survival 
 
PRH is known to be a regulator of cell proliferation. Overexpression of PRH in myb-ets (E-
twenty six) transformed chicken blastoderm cells inhibits their transformation and 
proliferation (Jayaraman, et al., 2000). As mentioned previously, PRH can repress 
proliferation by inhibiting eIF-4E dependent cyclin d1 mRNA nucleocytoplasmic transport in 
U937 leukaemic cells (Topisirovic, 2003). PRH also induces apoptosis (a form of programmed 
cell death) in K562 leukemic cells, by repressing genes encoding components of the VEGF 
signalling pathway (VSP) (Noy, et al., 2010). Forced expression of PRH also suppressed 
proliferation of embryonic stem cells, while PRH knockout embryonic stem cells showed 
enhanced proliferation compared to wild-type stem cells (Kubo, 2005), although this has not 
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always been observed (Guo et al., 2003). In keeping with the growth inhibitory properties of 
PRH, knockout of PRH has been shown to increase survival by decreasing apoptosis by 75% 
in the endocardial cushion of mouse embryos (Hallaq et al., 2004).    
 
PRH has also been suggested to be a negative regulator of hepatocyte proliferation during 
liver development. PRH is sequestered into the hepatocyte cytoplasm by binding to CD81 (a 
transmembrane protein which regulates cell proliferation and motility) during peak 
hepatocyte proliferation (Bhave et al., 2013). PRH has also been shown to be a negative 
regulator of  proliferation in solid cancer cells, decreasing hepatocarcinoma growth in 
xenograft models (Su et al., 2012). 
 
As mentioned previously, PRH transcriptional activity and stability is regulated by CK2. CK2 is 
a kinase that promotes tumourgenesis in many cancers, including mammary cells (Romieu-
Mourez et al., 2001). It does this by phosphorylating a variety of proteins, which leads to 
increased activity of oncoproteins and a decrease in tumour suppressor protein activity 
(reviewed by Ahmed et al., 2002). It has been demonstrated that CK2 can influence K562 
leukaemic cell survival through phosphorylation of PRH (Noy et al., 2012c). Inhibition of CK2 
by inhibitors of upstream kinases, that indirectly decrease CK2 activity, leads to a reduction 
in cell survival. For example, dasatinib/imatinib are inhibitors that block the fusion tyrosine 
kinase protein BCR-ABL found in chronic myeloid leukaemia (CML) cells, and dasatinib also 
blocks Src kinases (Rix et al., 2007). BCR-ABL phosphorylates CK2, which promotes CK2 
kinase activity (Heriche and Chambaz, 1998). Treatment of the CML K562 cell line with 
dasatinib results in inhibition of BCR-ABL, decreased phosphorylated PRH, and decreased 
cell number (see figure 1.7) (Noy et al., 2012a). The effect of dasatinib on cell number was 
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reduced when PRH expression was knocked down using PRH shRNA (Noy et al., 2012b). The 
implication of this work is that PRH expression is important for inhibition of survival by 
dasatinib in leukaemic cells, and that reagents that block CK2 activity will affect PRH activity 
and cell proliferation/survival  (Noy et al., 2012b). This illustrates the importance of PRH to 
the control of cancer cell proliferation, survival and tumour growth.  
 
1.2.10 PRH as an oncogene 
 
Forced expression of PRH can also act as an oncoprotein in T-cell lineages. Overexpression 
of PRH in transgenic mice results in increased immature myeloid cell proliferation (Mack et 
BCR
-ABL
Src
kinases
CK2
PRH
VEGF/VEGFR1/VEGFR2 transcription
Increased 
cell survival
Dasatinib
Figure 1.7: Model of PRH misregulation in CML. 1) BCR-ABL and Src kinases phosphorylate
protein kinase CK2, activating its protein kinase activity. 2) CK2 phosphorylates PRH, so that
PRH can no longer bind to DNA. 3) Phosphorylated PRH can then no longer repress VEGF,
VEGFR1 and VEGFR2 transcription, leading to an increase in cell survival (adapted from Noy, et
al., 2012a).
1.
2.
3.
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al., 2002). Furthermore, mice which had been injected with bone marrow cells 
overexpressing PRH developed tumours from a precursor T cell population (George, et al., 
2003). Additionally, it has been shown that PRH overexpression leads to an increase of 
thymocyte self-renewal (Curtis and McCormack, 2010). Interestingly, induction of T cell 
acute lymphoblastic leukaemia by the LMO2 (LIM domain only 2) oncogene, leads to 
upregulation of PRH expression (Curtis and McCormack, 2010). Taken together, these 
results show that PRH can act as an oncogene depending on the context.  
 
1.2.11 PRH and cell migration 
 
PRH has been shown to be involved in regulating migration and invasion of cells. 
Atrioventricular explants (from the developing heart) of Prh knockout mouse embryos 
showed a greater number of collagen-invasive cells (Hallaq et al., 2004). Furthermore, 
overexpression of PRH in human umbilical vein endothelial cells led to decreased cell 
migration and decreased invasion of these cells through Matrigel (extracellular matrix 
secreted from murine sarcomas) (Nakagawa et al., 2003).  Overexpression of PRH also 
decreased expression of matrix metalloproteinase-1 (MMP1) (Nakagawa et al., 2003), which 
has been shown to play a role in tumour cell invasion, by degrading components of the 
extracellular matrix (reviewed in Duffy et al., 2000). 
 
1.2.12 PRH and cancer 
 
Misregulation of PRH protein has been associated with cancer. Expression of a PRH-NUP98 
transgene was shown to be necessary for disease induction in an acute myeloid leukaemia 
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(AML) patient (Jankovic et al., 2008) This is thought to occur by the PRH-NUP98 fusion 
protein activating transcription of genes normally targeted for repression by wild-type PRH 
(Jankovic et al., 2008). It has been shown that PRH is mislocalised in breast and thyroid 
tumours; PRH expression in normal breast and thyroid tissue is both nuclear and 
cytoplasmic, whereas its nuclear localisation is reduced in breast and thyroid carcinomas, 
suggesting there is a decrease in the transcription factor activity of PRH in these diseases 
(Puppin et al., 2006, D’Elia et al., 2002). It has also been shown that in hepatocarcinomas, 
PRH expression is significantly higher in more differentiated tumours, which tend to be less 
aggressive (Su et al., 2012). Taken together, this suggests that in a variety of tumour cell 
types, reduction of PRH activity is correlated with increased tumourgenesis.  
 
1.2.13 PRH and breast cancer 
  
In normal breast cells, it has been reported that PRH protein is expressed in both the 
nucleus and cytoplasm (Puppin et al., 2006). In breast tumour cells however, PRH is 
predominantly cytoplasmic, and this finding was used to suggest that PRH may no longer act 
as a transcription factor in breast tumour cells (Puppin et al., 2006). In MCF-7 luminal breast 
tumour cells, it was reported that PRH is sequestered by the nucleolus, and thus cannot act 
as a transcriptional repressor in this cell type (Puppin et al., 2006), however this hypothesis 
was not tested in this study. Moreover, knockdown of PRH in MCF-7 cells leads to an 
increase in cell number, and de-repression of genes in the VSP, suggesting that at least some 
endogenous PRH must still be active in the nucleus of MCF-7 cells despite the 
predominantly nucleolar localisation previously reported (Noy et al., 2010).  
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1.3 Potential PRH target genes that are involved in breast cancer 
 
Several microarray studies with Prh-/- cells and PRH protein overexpression studies have 
identified genes that are perturbed by manipulation of PRH activity in specific contexts 
(Nakagawa et al., 2003, Guo et al., 2003, Kubo et al., 2010). The following genes and 
proteins have been shown to be affected by PRH expression in certain contexts, and are 
known to be relevant to breast cancer and cancer progression.  
 
1.3.1 VEGF and VEGF receptors 
 
PRH has been shown to affect the VEGF signalling pathway (VSP) in human umbilical vein 
endothelial cells (HUVECs) (Guo et al., 2003). One of the ligands of this pathway, VEGF-A, is 
part of a family of VEGF-related proteins, which includes VEGF-B, VEGF-C, VEGF-D and PIGF 
(Phosphatidylinositol-glycan biosynthesis class F protein). These proteins have been shown 
to be involved in embryonic angiogenesis and lymphangiogenesis (Mandriota et al., 2001). 
VEGF is alternatively spliced, and at least 9 different isoforms have been discovered in 
humans, with VEGF-A165 being the dominant isoform (Harris et al., 2012, Ferrara et al., 
2003). VEGF-A acts to activate angiogenesis by binding to the receptors VEGF receptor 1 and 
2 (VEGFR-1 and VEGFR-2), as well as the co-receptors Neuropilin-1 and Neuropilin-2 (NRP1 
and NRP2) (Gille et al., 2001, Herzog et al., 2011, Gluzman-Poltorak et al., 2000).  VEGFR-2 is 
the major mediator of angiogenesis, whilst VEGFR-1 seems to have a more context 
dependent-role depending on the cell type (Ferrara et al., 2003). However, NRP1 and NRP2 
have very small cytoplasmic domains, and thus cannot transduce signals when ligand 
binding occurs. NRP1 can bind to VEGF-A165, which can then form complexes with VEGFR-2,  
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which results in increased VEGF-A binding to VEGFR-2 (see figure 1.8) (Mamluk et al., 2002, 
Soker et al., 2002). VEGFR-3, along with its ligand VEGF-C, has also been shown to be 
upregulated in breast carcinomas, and are involved in the formation of lymphatic vessels in 
breast tumours (Valtola et al., 1999, Skobe et al., 2001). See figure 1.8 for an overview of 
VEGF signalling. 
 
Angiogenesis is the formation of blood vessels from pre-existing blood vessels. It is a process 
which is vital during embryonic development, as well as during wound healing. VEGF-A has 
been shown to induce proliferation of vascular endothelial cells in response to hypoxia, and 
this is mediated in part through activation of the transcription factor HIF-1α (Forsythe et al., 
1996, Shweiki et al., 1992). Since angiogenesis also plays a vital role in tumour progression, 
Figure 1.8: VEGF signalling pathway. A) VEGF-A binds to a VEGFR-2 homodimer, which signals to activate
angiogenesis in endothelial cells, and tumour growth in epithelial cells. B) VEGF-A binds to a VEGFR-1
homodimer, which signals to activate survival and EMT in epithelial cells. Soluble VEGFR-1 (sVEGFR-1)
sequesters VEGF-A ligand, inhibiting VEGF-A signalling. C) VEGF-A binds to a NRP1/VEGFR-2 heterodimer,
activating survival, metastasis and production of CICs. This pathway is inhibited by SEMA-3A
(Semaphorin-3A) (adapted from Kowanetz et al., 2006).
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inhibition of angiogenesis (and therefore VEGF-A) has been a major field in cancer 
therapeutics in the last decade, and has led to FDA (U.S. Food and Drug Administration) 
approved therapies such as bevacizumab (Avastin), sorafenib (Nexavar) and sunitinib 
(Sutent).  
 
Importantly, VEGF signalling is also associated with non-angiogenic functions in many 
tumour cells, for example it plays a role in cell proliferation, survival and migration. MT mice 
(which spontaneously develop mammary tumours) overexpressing VEGF showed tumours 
with increased cell proliferation and anti-apoptotic activities (through a decreased BAX/BCL-
2 ratio) (Schoeffner et al., 2005). Furthermore, Vegf conditional knockout mice showed 
decreased cell proliferation, through increased accumulation of cells in the G1 phase of the 
cell cycle (Schoeffner et al., 2005). Knockdown of VEGF expression in metastatic breast 
cancer cells also promoted apoptosis, via signalling through NRP1 and the PI3-kinase 
signalling pathway (Bachelder et al., 2001). Conversely, VEGF-A expression increased 
Heparin and Fibronectin mediated migration of breast cells (Miralem et al., 2001), and 
increased breast carcinoma invasion, through upregulation of the chemokine receptor 
CXCR4 (Bachelder et al., 2002). Taken together, these experiments show that VEGF-A plays 
an important role in breast cancer cell survival, migration and invasion.  
 
The receptors in the VEGF pathway also play roles in increasing cell survival, proliferation 
and migration. Treatment of breast tumour xenografts with an anti-VEGFR-1 antibody led to 
a decrease in tumour growth (Wu et al., 2006b). Knockdown of VEGFR1 in metastatic MDA-
MB-231 breast cancer cells lead to decreased tumour growth and metastasis in nude mice 
models (Ning et al., 2013). Treatment of chemotherapy-resistant tumours in xenograft 
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models with an anti-VEGFR-2 antibody inhibited growth of the primary tumour (Klement et 
al., 2002). Taken together, this evidence suggests a role for VEGFR-1 and VEGFR-2 in breast 
tumour growth.  
 
A peptide which blocked VEGF binding to the NRP1 co-receptor increased apoptosis of 
MDA-MB-231 breast cancer cells (Barr et al., 2005). Knockdown of neuropilin-1 expression 
by siRNA, as well as inhibiting NRP1 function by using an anti-NRP1 antibody, inhibited 
mammosphere formation of MDA-MB-231 cells (Glinka et al., 2012). This shows that VEGF 
receptors can also affect cell proliferation and survival independent of angiogenic pathways.   
 
VEGF-A, VEGFR-1 and VEGFR-2 expression have all been shown to be markers for decreased 
overall survival in breast cancer (Linderholm et al., 2000, Ghosh et al., 2008). As mentioned 
earlier, overexpression of PRH led to the repression of VEGFR-1, VEGFR-2 and NRP1, and 
stopped VEGF-mediated proliferation, migration and invasion in endothelial cells (Nakagawa 
et al., 2003). Repression of VEGFR2 in these cells was shown to involve PRH binding to 
GATA-2, and hence prevent GATA-2 mediated activation of transcription of the VEGFR2 
gene (Minami et al., 2004). PRH also regulates these genes in other contexts, for example, 
VEGF-A protein levels are also 2-3 fold higher in 9-14 day old Prh-/-  mice embryos (Hallaq et 
al., 2004). Sequestration of VEGF-A by soluble VEGFR-1 in these mice inhibited PRH-
mediated EMT (Hallaq et al., 2004). Forced expression of PRH in mouse ES cells led to the 
repression of VEGFR2 expression (Kubo et al., 2005). PRH has also been shown to regulate 
VEGF, VEGFR1 and VEGFR2 mRNA expression in both K562 leukaemic cells, and in MCF-7 
breast cancer cells (Noy et al., 2010). Furthermore, this repression occurred by PRH forming 
a complex with the co-repressor TLE, and binding directly to the promoters of these genes 
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(Noy et al., 2010). This repression by PRH is inhibited by CK2, which phosphorylates PRH and 
prevents it binding to the VEGFR1 promoter (Noy et al., 2012c, Noy et al., 2012b).  
 
1.3.2 SATB1 
 
In Prh-/- embryoid bodies, special AT-rich binding protein 1 (SATB1) transcript expression is 
upregulated, suggesting that PRH directly or indirectly regulates SATB1 expression (Guo, et 
al., 2003). SATB1 is a nuclear protein, and acts as a global regulator of gene expression.  It 
binds to base-unwinding regions in the DNA, and forms a cage-like structure, that recruits 
chromatin-remodelling enzymes to regulate gene expression. SATB1 expression is 
significantly associated with higher tumour grade and poorer prognosis (Han et al., 2008a, 
Patani et al., 2009). Knockdown of SATB1 in MDA-MB-231 cells causes a decrease in growth 
and invasiveness in vitro and in vivo, whilst causing a restoration in cell polarity and 
anchorage-dependent growth (Han et al., 2008b). Overexpression of SATB1 in SKBR3 cells 
causes increased tumour growth and lung metastases (Han, et al., 2008).  SATB1 is also 
known to upregulate many metastasis-associated genes (like HER2), whilst down-regulating 
many tumour-supressor genes (like e-cadherin) (Han, et al., 2008).  
 
1.3.3 Endoglin 
 
Overexpression of PRH in human umbilical vein endothelial cells (HUVECs) leads to a 
decrease in invasion and migration of these cells (Nakagawa et al., 2003). Western blotting 
showed that the Endoglin protein is significantly upregulated in PRH overexpressing HUVECs 
(Nakagawa et al., 2003).  Endoglin is a type III TGF-β receptor, meaning that it can bind the 
Chapter 1. Introduction 
 
36 
 
TGF-β ligand, but lacks a kinase domain, so that it cannot signal to downstream pathways by 
itself (Guerrero-Esteo et al., 2002). Endoglin is expressed at high levels in endothelial cells 
(Alt et al., 2012). TGF-β has been shown to act as a suppressor of tumour growth in 
endothelial cells, however TGF-β can also increase cell invasiveness and migration in a 
number of contexts (reviewed in Bierie and Moses, 2006). See figure 1.9 for a overview of 
TGF-β signalling.  
 
Mutations in endoglin are responsible for Hereditary Hemorrhagic Telangiectasia (HHT), a 
disease characterised by telangiectasia (spider veins) on the mucosa and skin, frequent nose 
bleeds and arteriovenous malformations in the liver, lungs and brain (Gallione et al., 1998). 
Endoglin expression is upregulated in proliferating endothelial cells, and is thought to play a 
role in angiogenesis by modulating TGF-β signalling pathways (Dijke et al., 2008). Endoglin 
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Figure 1.9: Mechanism of TGF-β signalling. 1) The TGF-β complex is activated by MMP-2, MMP-9 or
plasmin. 2) TGF-β binds to a type II receptor (and Endoglin, depending on the context) which causes the
phosphorylation of a type I receptor. 3) This causes phosphorylation of a R-SMAD (regulator-regulated
SMAD) protein, which causes the formation of a dimeric R-SMAD:co-SMAD (common-mediator SMAD)
complex. 4) This complex then translocates to the nucleus, activating the transcription of target genes
(adapted from Massagué et al., 2012).
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exists in three isoforms, L-Endoglin (the long form), S-Endoglin (the short form, which differs 
from the long form by 33 amino acids), and a soluble form of Endoglin (Bellón et al., 1993, 
Hawinkels et al., 2010). Interestingly, in rat myoblast cells, increased expression of L-
Endoglin increased cell proliferation, whilst increased expression of S-Endoglin reduced cell 
proliferation (Velasco et al., 2008). Tumour-bearing mice treated with an oral DNA vaccine, 
coding for murine endoglin, suppressed metastasis and had increased survival, compared to 
tumour-bearing mice injected with a control vaccine (Lee et al., 2006), suggesting that 
Endoglin is expressed and important in proliferating tumour endothelial cells. 
 
Endoglin has seemingly dual roles in breast cancer, independent of its role of tumour 
angiogenesis. Soluble Endoglin levels have been found to be elevated in breast cancers, and 
breast cancer patients with increased plasma Endoglin levels have decreased overall survival 
(Vo et al., 2010). However, breast tumours which are positive for Endoglin expression 
significantly correlate with improved overall survival and metastasis-free survival (Henry et 
al., 2011). Therefore, Endoglin may be a positive or negative marker for breast cancer 
survival, depending on whether the Endoglin is in the soluble or membrane bound form.   
 
Endoglin appears to suppress or enhance the invasive phenotype of breast cancer cells 
depending on the context. Oxmann et. al. found that Endoglin was overexpressed in MDA-
MB-231 metastases, compared to parental tumours (Oxmann et al., 2008). This study also 
found that the high Endoglin expressing cells migrated and invaded more than low-
expressing endoglin cells, and that Endoglin overexpression led to an increase in MMP-1 and 
MMP-19 levels (Oxmann et al., 2008). In contrast, Henry et. al. found that downregulation 
of Endoglin in HER2-overexpressing MCF-10A cells led to an increase in cancer cell invasion 
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(Henry et al., 2011). Furthermore, this study found that MDA-MB-231 cells which had been 
transfected with endoglin complementary DNA significantly reduced breast cancer 
colonisation of the lung compared to controls (Henry et al., 2011). This study also found that 
the effects on Endoglin in these experiments were independent of Smad signalling, which is 
a pathway involved with TGF-β activation (Henry et al., 2011). These seemingly 
contradictory results could be due to TGF-β signalling having different effects in different 
cells types, depending on how transformed they are (Bierie and Moses, 2006). Endoglin 
seemed to inhibit invasion and metastasis in parental MDA-MB-231 cells in (Henry et. al. 
2011), whilst the effects of Endoglin increasing invasiveness of breast cancer cells was seen 
in brain metastases with MDA-MB-231 cells in (Oxmann et. al 2008), and were selected to 
be a more “transformed” cell than the cells used in (Henry et. al. 2011).  
 
1.3.4 TP53 
 
TP53 is a gene that can be regulated by PRH in hepatocarcinoma cells, since overexpression 
of PRH in these cells leads to decreased expression of p53 compared to control cells (Su et 
al., 2012). However, it is not known whether this regulation is direct or indirect. P53 is 
largely thought of as a “guardian of the genome”, due to the role it plays in regulating the 
cellular response to stress, such as DNA damage, telomere erosion and aberrant expression 
of oncogenes (Horn and Vousden, 2007, Walerych et al., 2012). In unstressed cells, p53 has 
a relatively-short half life, as it is targeted for degradation by the proteasome by the E3 
ubiquitin-ligase mouse double minute homolog 2 (MDM2) (Honda et al., 1997). However, 
when cells undergo cytotoxic stress, this leads to phosphorylation of p53 in the N-terminal 
domain by a number of kinases, causing stabilisation of the protein (Tibbetts et al., 1999, 
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She et al., 2000). This allows p53 to form a tetramer, which binds to DNA and acts to 
regulate of transcription of p53 target genes. P53 target genes encode proteins that 
regulate the cell cycle, cell survival and proliferation (reviewed in McLure and Lee, 1998).  
 
TP53 is the most commonly mutated gene in cancer overall, being mutated in approximately 
31% of all cancers but it is only mutated in approximately 23% of breast cancers (Forbes et 
al., 2011). TP53 is more frequently mutated in basal and HER2 amplified breast tumours, 
which are the most aggressive forms of breast cancer (34% and 22% respectively) (Curtis et 
al., 2012). TP53 mutations also correlate with lymph node-positive and higher-grade breast 
cancers, leading to a worsening prognosis (Curtis et al., 2012). Together these studies show 
that TP53 mutations are associated with increased breast cancer aggressiveness. 
 
P53 has been shown to be a regulator of breast cancer cell invasion, and a regulator of EMT. 
Zhang et. al showed that expression of p53 R248W, R175H and R273H mutants in MCF-10A 
immortalised mammary cells led to the formation of irregular and multiacinar spheroids 
(described later), decreased expression of E-Cadherin and β-Catenin, and increased 
expression of Snail, Slug and Twist, which taken together suggest the cells are undergoing 
EMT (Zhang et al., 2011). Chang et. al. showed that knockdown of wild-type TP53 in MCF-
12A cells led to an decrease in E-Cadherin expression and enhanced ZEB1 expression, which 
are markers of EMT, via miR-200c (Chang et al., 2011).  It was also shown by Nielsen et. al. 
that wild-type p53 also inhibits EMT, via inhibition of transcription of the micro RNA miR-
155 (Neilsen et al., 2013).  
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As has been discussed previously, the concepts of EMT and cancer initiating cells (CICs) are 
closely related. Therefore, it is of no surprise to discover that p53 also affects the stem cell 
population of mammary tumours. In murine mammary tumours, there are a greater number 
of stem-cells from Tp53 knockout mice compared to control mice, as determined by limiting 
dilution transplantation (Cicalese et al., 2009). Tp53 knockout stem-cells also have an 
increased frequency of symmetric division, and increased levels of the stem-cell marker 
nanog (Cicalese et al., 2009). P53 knockdown also led to an increase in the CD44high/CD24low 
compartment in normal breast epithelial MCF-12A cells (Chang et al., 2011).  
 
1.3.5 Goosecoid 
 
PRH has been shown to be a direct transcriptional repressor of goosecoid in Xenopus ES cells 
(Brickman et al., 2000). PRH has also been shown to bind to the goosecoid promoter, as 
determined by chromatin immunoprecipitation (ChIP) and luciferase assays in human K562 
leukaemic cells (Williams et al., 2008, Soufi et al., 2010). Therefore, it is of interest to note 
whether PRH has any effect on the expression of goosecoid in human breast cells.  
 
Goosecoid is a homeodomain-containing transcription factor, involved in mammalian and 
Xenopus development. Injection of goosecoid mRNA in the ventral side of Xenopus embryos 
leads to the formation of a twinned body axis (Cho et al., 1991). As EMT is involved in both 
development of the embryo and in tumour metastasis, it was hypothesised that Goosecoid 
may be involved in tumour metastasis as well (Hartwell et al., 2006). Overexpression of 
Goosecoid led to increased cell motility of the immortalised human mammary epithelial cell 
line (HMECs), increased expression of EMT markers in HMECs, and resulted in increased 
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metastasis of MDA-MB-231 cells to the lungs in mouse xenograft experiments (Hartwell et 
al., 2006, Taube et al., 2010). Furthermore, Goosecoid expression was increased by TGF-β 
signalling in HMECs (Hartwell et al., 2006). Goosecoid expression was also found to be 
elevated in ductal breast carcinomas, compared to patient-matched normal breast tissue 
(Hartwell et al., 2006), however expression was not found to be a prognostic marker of 
clinical outcome (Taube et al., 2010).    
 
1.3.6 Endothelial cell-specific molecule 1 (ESM1) 
 
ESM1 expression is downregulated by PRH overexpression in HUVEC cells by direct binding 
of PRH to the ESM1 promoter (Cong et al., 2006). Also, In E10.5 Prh-/- mouse embryos, Esm1 
expression was 11 fold greater compared to E10.5 Prh+/+ embryos (Cong et al., 2006). 
Therefore, as PRH can repress ESM1 expression, it is of interest to determine whether it 
represses ESM1 in breast cells.  
 
ESM1 (also known as Endocan), is a protein which is strongly expressed in the endothelial 
cells of the lungs (Lassalle et al., 1996). ESM1 is overexpressed in clear cell renal cell 
carcinoma, and in gastric cancer (Leroy et al., 2010, Liu et al., 2010). ESM1 and VEGF show 
similar expression patterns in renal cell carcinomas, and it has been proposed that ESM1 
could play a role in VEGF-induced angiogenesis (Aitkenhead et al., 2002). ESM1 was shown 
to be a marker for poor prognosis in breast cancer patients (van't Veer et al., 2002), 
although no correlations were found between ESM1 expression and breast cancer grade,  
stage or ER/PR/HER2 status (Congyun et al., 2008).  
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1.4.2 Cell lines used in this study 
 
In this study, experiments will be carried out predominantly using three cell lines, MCF-10A, 
MCF-7 and MDA-MB-231 cells. MCF-10A cells are an immortalised cell line, which arose 
spontaneously from a normal diploid mammary epithelium (Soule et al., 1990b). MCF-10A 
cells do not undergo anchorage-independent growth in Matrigel, nor do they form tumours 
in nude mice (Soule et al., 1990b). MCF-10A cells do not show HER2 amplification, express 
wild-type p53, and unlike other immortalised cell lines, do not contain the SV40 T antigen 
(Merlo et al., 1995, Soule et al., 1990b). MCF-10A cells form acinar structures, when grown 
in 3D culture, which are phenotypically similar to mammary glandular structures (Debnath 
et al., 2003b). These acini are growth arrested, and contain a hollow lumen, due to the 
apoptosis of cells lacking contact with the basement membrane (Debnath et al., 2003a). 
Therefore, MCF-10A cells represent a good model for normal untransformed breast cells. 
They do however have some cytogenetic abnormalities, although not as many as MCF-7 and 
MDA-MB-231 cells (Soule et al., 1990b). 
 
MCF-7 cells are a cell line derived from pleural effusion from a breast cancer patient (Brooks 
et al., 1973). They have a luminal epithelial phenotype, and they are positive for both ER and 
PR, although they do not have amplified HER2 expression, and they express wild-type p53 
(Brooks et al., 1973, Nagle et al., 1986, Subik et al., 2010, Fan et al., 1995). Their karyotype 
shows that MCF-7 cells have a mean chromosome number of 88 (Soule et al., 1973). MCF-7 
cells are tumourgenic in nude mice, but only with supplementation with 17β-oestradiol 
(Seibert et al., 1983). As MCF-7 cells express high levels of E-cadherin, low levels of 
Vimentin, and in Matrigel are weakly invasive and form spherical colonies, it is thought that 
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MCF-7 cells represent a more “epithelial-like” phenotype with respect to EMT (Lacroix and 
Leclercq, 2004b). 
 
MDA-MB-231 cells are derived from a pleural effusion from a breast cancer patient, and 
they have a near-triploid karyotype, containing between 60-70 chromosomes (Cailleau et 
al., 1974). They do not express ER, PR or have amplified HER2 status, and they have a basal 
like phenotype (Lacroix and Leclercq, 2004a). MDA-MB-231 cells express a mutated form of 
p53 (R280K), which promotes cell survival in this cell-type (Hui et al., 2006, Roger et al., 
2010). MDA-MB-231 cells are tumourgenic in nude mice, and do not require 
supplementation with 17β-oestradiol (Cailleau et al., 1974). As MDA-MB-231 cells are highly 
invasive, form stellate colonies in Matrigel, express low levels of E-Cadherin and high levels 
of Vimentin, it is thought they represent a “mesenchymal-like” cell with regards to EMT 
(Lacroix and Leclercq, 2004b). 
 
1.4 Aims of my project 
 
PRH is a known regulator of cell proliferation and migration in various cell types; however 
whether PRH regulates the growth of normal breast or breast cancer cells has not been 
studied extensively. The first aim of this thesis is to determine whether there is a correlation 
between PRH mRNA or PRH protein expression levels with breast tumourgenesis. To do this 
PRH mRNA expression will be examined in a database, where gene expression microarray 
data has been correlated with breast cancer subtype and prognosis. We will also examine 
the expression levels of PRH protein, its phosphorylation status, stability and sub-cellular 
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localisation in a variety of breast cell lines.  The second aim of this thesis is to determine 
whether overexpression and knockdown of PRH has any effect on cell proliferation and 
survival in MCF-10A, MCF-7 and MDA-MB-231 cells. Thirdly, the effect of PRH on breast cell 
migration and invasion will also be examined. Finally, the effect of PRH on the transcription 
of several candidate genes relevant to breast cancer and EMT will be analysed in each of 
these cell lines to determine whether regulation of these genes by PRH occurs in breast 
cells, and whether this control is deregulated in breast cancer cells. Selected genes will also 
be analysed for direct or indirect regulation by PRH. 
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2. Materials and methods 
 
2.1 Data-mining the GOBO database 
 
Data mining from the GOBO database is described in (Ringnér et al., 2011). Briefly, after 
loading the following URL: http://co.bmc.lu.se/gobo/gsa.pl, the Gene Set Analysis was 
carried out on tumour samples, using the gene set with the gene symbol “HHEX”. All 
tumours were selected, using 3 quantiles and 10 years censoring, with the end point being 
overall survival and all multivariate parameters selected.  For Gene Set Analysis of cell lines, 
the gene set with the gene symbol “HHEX” was used, and the cell line selection was “Neve 
et al”.  
 
2.2 Cell culture protocols 
 
2.2.1  Adherent cell culture  
 
MDA-MB-231, MCF-7, T47D, BT20, BT474, ZR-75-1 and HB2 cells were cultured in RPMI-
1640 media (Sigma), supplemented with 10% foetal bovine serum (FBS) (Sigma) (which was 
heat-inactivated at 56°C for 30 minutes), 100 units/ml of penicillin and 0.1 mg/ml of 
streptomycin (Sigma). MCF-10A cells were grown in DMEM/F12 media (Sigma), 
supplemented with 5% heat-inactivated horse serum (Sigma), 20ng/µl epidermal growth 
factor (EGF) (Peprotech), 0.5µg/ml hydrocortisone (Sigma), 100ng/µl cholera toxin (Sigma), 
10µg/ml insulin (Sigma), 100 units/ml of penicillin and 0.1 mg/ml of streptomycin (Sigma).  
Chapter 2. Materials and methods 
 
47 
 
HEK-293 and HEK-293T cells were grown in DMEM (Sigma) with 10% FBS (Sigma) which was 
heat-inactivated as before, 100 units/ml of penicillin and 0.1 mg/ml of streptomycin (PAA). 
Cells were subcultured by diluting one in four when they reached 80% confluency. To 
propagate adherent cells, they were first washed with 1x phosphate-buffered serine (PBS) 
(Sigma). They were then treated with 1x trypsin (PAA) for 5 minutes at 37°C (apart from 
MCF-10A cells, which were incubated with trypsin for 20 minutes, or until cells detached). 
Once the cells were in suspension the trypsin was neutralised by plating the cells in the 
required volume of fresh media. Cells were cultured in a humidified atmosphere at 37°C and 
5% CO2. MCF-10A cells were grown in Falcon brand tissue culture flasks, whilst all other cell 
types were grown in Starstedt brand tissue culture flasks.  
 
2.2.2 MTT assays 
 
For MTT assays, approximately 5 x 104 cells were seeded into 16 wells each (4 wells in 4 96-
well plates). After 0, 24, 48 or 72 hours, 4 wells from 1 plate for each infection was then 
incubated with 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) in 200 µl RPMI  for 2 hours. The formazan dye was solubilised with 200μl dimethyl 
sulphoxide (Fisher Scientific). The optical density was then taken for each well at 595nm.  
 
2.2.3 Lipofectamine 2000 transfections 
 
Lipofectamine transfections were carried out according to manufacturer’s instructions. 
Briefly, 5µl of Lipofectamine (for 6-well transfection, 40µl for transfection in a 75cm2 flask) 
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was then added to 100µl of serum-free media (750µl for a 75cm2 flask). To another tube 
2.5µg of DNA (21µg for a 75cm2 flask) was added to 100µl of serum-free media (750µl for a 
75cm2 flask). The diluted DNA was added to the lipofectamine mixture, and was incubated 
for 5 minutes at room temperature. This complex was then added to the cells.  
 
2.2.4 Cumulative growth curves 
 
After 7 days induction with IPTG, cumulative growth curves with the lentiviral knockdown 
cells was set up. 1 x 105 cells were seeded into a 25 cm2 tissue culture flask, and cells were 
counted every 6 days after replating (or cells reached 90% confluency, whichever was 
earlier). This process was repeated, and the cumulative cell number was then calculated by 
the following equation: 
(Number of cells counted in flask) x (Cumulative number of cells from previous count) 
(100,000 or the number of cells originally seeded previously) 
For example: 
Day 1: 100,000 cells seeded 
Day 6: 1 x 106 cells counted, 1 x 105 cells seeded (Cumulative cell number: 1 x 106) 
Day 12: 5 x 105 cells counted, 1 x 105 cells seeded (Cumulative cell number: (5x105 x 1x106 / 
1 x 105) = 5x106) 
Day 18: 1 x 106 cells counted, 1 x 105 cells seeded (Cumulative cell number: (1x106 x 5x106 / 
1 x 105) = 5x107) 
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2.2.5 Mammosphere formation assay 
 
For mammosphere formation assays, 4x104 cells were plated into ultra-low adherrant 6 well 
plates (Corning), containing mammosphere media (see table 2.2). After 7 days of culturing 
at 37°C in 5% CO2, the number of cells was quantified in each well by using a counting grid 
with 2mm by 2mm squares. To form secondary mammospheres, primary mammospheres 
were centrifuged at 350g (Eppendorf 5810R) for 5 minutes. The supernatant was decanted 
and the remaining mammospheres were incubated in 1x Trypsin-EDTA (Sigma) for 2 
minutes. Five millilitres of cold mammosphere media was added to inactivate the Trypsin, 
and the cells were then centrifuged at 350g for 5 minutes. The number of single cells was 
counted, and 4x104 cells were seeded into ultra-low adherrant 6 well plates (Corning), 
containing mammosphere media. The formation of secondary mammospheres was 
quantified 7 days later after culturing at 37°C in 5% CO2. 
 
2.3 Western blot protocols 
 
2.3.1 Whole cell extracts 
 
To make cell extracts, approximately 5x105 MCF-7 or 5x105 MDA-MB-231 cells were used. 
These cells were centrifuged at 1800g for 5 minutes at room temperature.  The cell pellet 
was washed twice in PBS. The cells were resuspended in 150 µl of RIPA buffer (see table 
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2.2). The lysates were incubated on ice for 15 min and then centrifuged at 13000 rpm for 15 
minutes at 4°C in a table-top microcentrifuge (Eppendorf 5424).  
 
2.3.2 Quantification of proteins 
 
Protein lysates were then quantified for their protein concentration. Protein Assay reagent 
(Bio-Rad) was diluted 1 in 5 with dH2O, and 5µl of protein lysate was then added to 995µl of 
diluted Bradford solution. The optical density was then measured at 600nm using a Bio-Rad 
cuvette and measured using an INPLEN P300 nanophotometer. The equation used to 
determine the protein concentration was: 
Protein concentration (µg/µl) = (OD - 0.0662)/ 0.0695 
 
This equation was determined in the laboratory from a standard curve, as determined using 
set concentrations of bovine serum albumin.  
 
2.3.3 Separation of proteins 
 
Proteins were separated using SDS-PAGE. The resolving gel consisted of a final 
concentration of 1x resolving buffer (see table 2.2), 12% v/v acrylamide (Geneflow), 0.1% 
w/v ammonium persulphate (APS) (Sigma) and 0.12% v/v of tetramethylethylenediamine 
(TEMED) (Sigma). The stacking gel consisted of a final concentration of 1x stacking buffer 
(see table 2.2), 4.5 % v/v acrylamide, 0.1% w/v APS and 0.2% v/v of TEMED. The gel was 
then placed in a Bio-Rad Mini-PROTEAN electrophoresis tank filled with 1x running buffer 
(see table 2.2). The proteins were then loaded onto the gel after boiling with SDS gel loading 
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buffer (final concentration 1x) at 105°C for 5 minutes, and underwent electrophoresis at 140 
V for 2 hours. Pageruler Plus protein ladder (Thermo Scientific) was also loaded onto the gel 
to determine the approximate protein sizes. 
 
2.3.4 Transfer of proteins 
 
The proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore 
IPVH00010). The membrane was activated by placing in methanol (Fischer Scientific) for 30 
seconds, distilled water for 5 minutes, before being placed in transfer buffer for 15 minutes. 
The gel and the membrane were then sandwiched between two pieces of blotting paper 
(Whatmann 3030917), and placed in a cassette. This was placed in a Bio-Rad Mini Trans-Blot 
cell, which was filled with 1x transfer buffer (see table 2.2), which was kept cool using an ice 
pack. The proteins were then transferred at 70 V for 1 hour. 
 
 
2.3.5 Detection of proteins with antibodies 
 
The PVDF membrane was then stained with Ponceau S dye to confirm the complete transfer 
of proteins. The membrane was washed 5 times for 5 minutes with 1x PBS with 0.05% 
Tween-20 (PBS-T), and then blocked with 10% w/v milk (Tesco) in PBS-T overnight. After 
washing as before, the membrane was stained with the primary antibody (antibodies were 
diluted 1 in 5000 (unless otherwise stated), in 1x PBS-T with 3% w/v bovine serum albumin 
and 3mM sodium azide (Sigma)) for 1 hour. After washing, the membrane was then stained 
with the secondary antibody (diluted 1 in 2500 in PBS-T with 10% w/v milk) for 1 hour. The 
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membrane was washed and then stained with Enhanced Chemiluminescence solution (GE 
healthcare). Membranes were exposed to Hyperfilm (Amersham) for 2 minutes, before 
being developed using a Xograph developer.  
 
2.3.6 Densitometric analysis 
 
Densitometric analysis was carried out using ImageJ software. Briefly, an appropriate 
exposure (usually 2 minutes) of Western blot film was scanned, ensuring that the bands 
were not saturated. A box was drawn round the PRH triplet of proteins as detected by the 
M6 antibody, and lane plot analysis was performed. The area under the peak was then 
quantified. The same process was then carried out, but using the band which corresponds to 
Lamin C protein, to control for protein loading. The densitometry for PRH was then divided 
by the densitometry for Lamin C to obtain the relative band intensity.  
 
 
2.3.7 Biochemical fractionations 
 
Half a million MCF-10A, MCF-7 and MDA-MB-231 cells were used for biochemical 
fractionation (for Ad-PRH infected cells, fractionation was carried out 24 hours post-
infection). Cells were harvested, and then pelleted by centrifuging at 11000prm (Thermo 
Scientific Heraeus Fresco 21). The pellet was resuspended in 150µl of fractionation buffer A 
(see table 2.2), and was incubated on ice for 15 minutes. The cytoplasmic membrane was 
disrupted by adding NP-40 (Sigma) (final concentration 1%) and vortexing for 10 seconds. 
The lysate was centrifuged at 4°C for 1 minute at 14000 rpm. The supernatant (post-nuclear 
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fraction) was removed, protein concentration was quantified, and then stored in 1X SDS-
loading buffer (see table 2.2) at -20°C. The pellet (containing the nuclei) was resuspended in 
fractionation buffer B (see table 2.2), and incubated for 15 minutes on ice. The lysate was 
then centrifuged at 4°C for 1 minute at 14000 rpm. The supernatant (nuclear fraction) was 
then removed and stored in 1X SDS-loading buffer at -20°C. An equal percentage of nuclear 
and post-nuclear fractions was loaded onto a SDS-PAG electrophoresis gel, and the proteins 
were Western blotted as described in sections 2.3.2 - 2.3.5.  
 
2.4 Adenovirus protocols 
 
2.4.1 Stock adenovirus production 
 
The virus were initially produced by Graciela B. Sala-Newby (Sala-Newby et al., 2003). The 
vectors pDC515 (coding for Myc-PRH, Myc-PRH N187A or no transgene) and 
pBHGfrt△E1,3FLP were co-transfected into HEK-293 cells. The pBHG vector contains 
expression casettes for the viral proteins (apart from E1 and E3), an inverted tandem repeat 
(ITR), a FLP recombinase and an frt sequence which is targeted by the FLP recombinase. The 
pDC515 plasmid contains the transgene, an ITR, the adenoviral packaging element (ψ) and 
an frt sequence. Co-transfection into HEK-293 cells leads to FLP producing a recombinant Ad 
vector, which contains the viral proteins and the transgene, but does not code for FLP. As 
HEK293 cells also produce viral E1 protein, the virus can replicate in this cell type. The 
adenovirus however cannot replicate in normal cell lines, and neither plasmid alone can 
produce adenovirus in HEK-293 cells. After a cytopathic effect was observed, the virus was 
then purified as explained in section 2.4.2.  
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2.4.2 Large-scale adenovirus production 
 
To produce adenovirus, 10 x 75cm2 flasks of HEK 293 cells were infected with stock 
adenovirus at a MOI of 2 in serum free DMEM for 2 hours, before returning the cells to their 
normal growth media. After a cytopathic effect was observed (usually 2-3 days), cells were 
harvested and resuspended in 7ml PBS. Cells were lysed by freezing in liquid nitrogen for 2 
minutes, and thawing at 37°C for 5 minutes. This freeze-thaw process was repeated 3 times. 
The cell lysate was purified on a caesium chloride (CsCl) gradient using Beckmann 14 x 95 
mm tubes by adding 2ml of 1.45 g/ml of CsCl, 2ml of 1.32 g/ml of CsCl, 2ml of 40% glycerol, 
and then the cell lysate in that order. The tube was then centrifuged for 18 hours at 32000 
rpm using a Beckmann SW40 rotor, with no brake for deceleration. The purified virus was 
then visible as a band between the two CsCl layers. The virus was taken up by a 19G needle, 
and then placed in a Slide-a-Lyzer (Thermo scientific, 3500 MWCO, 0.5-3ml capacity, 
catalogue number 66330) for dialysis in adenovirus dialysis buffer (see table 2.2) for two 
hours, then in fresh dialysis buffer again for two hours, before dialysing overnight with fresh 
dialysis buffer with 10% glycerol. 
 
2.4.3 Adenovirus titration  
 
To titre the adenovirus, a modified version of the Clontech Adeno-X rapid titer protocol was 
used. Serial 10-fold dilutions of virus were made (starting from 10-2 to 10-7), and 100µl from 
each dilution was used to infect 5x105 HEK 293 cells, which were then seeded in 1 well of a 
12 well plate. The cells were left to grow in DMEM with 10% FBS. After 48 hours the media 
was aspirated off, and the cells were fixed by adding 1ml of methanol and leaving at -20°C 
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for 10 minutes. The cells were washed 3 times with PBS containing 1% w/v bovine serum 
albumin, and then incubated for one hour at 37°C with a murine anti-Hexon antibody 
(Abcam) diluted 1/2000 in PBS with 1% BSA. After washing again 3 times in PBS with 1% 
BSA, the cells were incubated for one hour at 37°C with horseradish peroxidase conjugated 
goat anti-mouse IgG antibody (Santa Cruz Biotech) diluted 1/500 in PBS with 1% BSA. After 
washing 3 times with PBS plus 1% BSA, the DAB staining kit (Vector laboratories) was used 
to visualise infected cells. The titre was determined by the following equation: 
(infected cells/field) x (fields/well) 
Volume virus (ml) x dilution factor 
 
2.4.4 Adenovirus infection 
 
For the adenovirus infection the adenovirus used is described in (Soufi and Corinne Smith, 
2006).  One million MCF-10A, MCF-7 or MDA-MB-231 cells were infected with either empty 
adenovirus or Myc-PRH containing adenovirus at a multiplicity of infection (MOI) of 50. Cells 
were then plated straight away in 2 x 75cm2 flasks in RPMI as before (but containing only 2% 
heat-inactivated FBS, 5x105 cells in each flask). Cells were then counted using a 
haemacytometer and trypan blue exclusion dye (Sigma) before being used for protein 
extraction, RNA extraction, cell cycle analysis or Annexin-V staining after 2 or 4 days.   
 
 
 
 
 
 
Chapter 2. Materials and methods 
 
56 
 
2.5 Lentivirus protocols 
 
2.5.1 Generating inducible knockdown lentiviruses 
 
To produce lentiviruses, five million HEK-293T cells were seeded into a 75cm2 tissue culture 
flask and left overnight, so that they would reach a confluency of over 50%. Cells were 
transfected using Lipofectamine 2000 (Invitrogen), with 7µg each of plasmids psPAX2 
(containing GAG and POL), pMD2.G (containing ENV) and the corresponding pLKO plasmid 
containing the shRNA of interest. The media was replaced after 24 hours, and the media 
containing the lentivirus was harvested 2 and 3 days post-transfection. The lentivirus was 
purified from the media by ultracentrifugation, using 14x95mm polyallomer centrifuge 
tubes (Beckmann), at a speed of 16600 rpm using a SW40 rotor. The supernatant was 
poured off and the pellet was left on ice for 2 hours, before being resuspended in the 
remaining supernatant (approximately 100µl).  
 
2.5.2 Generating inducible knockdown cell lines 
 
To produce IPTG-induceable knockdown cell lines, cells were infected with 20µl of purified 
lentivirus (this translates to an approximate MOI of 0.1, i.e. 10% of the cells will be selected 
for using puromycin). The media was replaced after 24 hours, and 48 hours post-infection 
infected cells were selected for, by culturing cells in 0.5µg/ml puromycin (Sigma) for 7 days. 
Uninfected cells were used as a negative control for the selection process, and there were 
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no viable cells after 7 days. After selection shRNA expression was induced by incubating the 
cells in 1mM IPTG for 7 days. Knockdown of PRH protein was then confirmed using Western 
blotting.  
 
2.6 Antibody staining protocols 
 
2.6.1 Immunofluorescence and confocal microscopy 
 
To carry out immunofluorescence, firstly 5x105 cells were seeded onto a 22x22 mm 
Surgipath premier cover glass, which was pre-sterilised with 70% ethanol. Cells were then 
left overnight to attach to the cover glass. The cells were washed 3 times with PBS, and 
were fixed using 4% w/v formaldehyde for 10 minutes. After washing with PBS 3 times, the 
cell membrane was then permeabilised using 0.2% triton diluted in PBS, and being placed on 
ice for 15 minutes. The cells were incubated with 0.5% w/v SDS for 5 minutes on ice, for 
antigen presentation. The coverslips were washed four times with PBS, and were blocked by 
incubating with 3% bovine serum albumin for 20 minutes at room temperature. After 
washing three times with PBS, the cover slips were incubated with the relevant primary 
antibody, which was diluted 1 in 200 in 3% bovine serum albumin in PBS (apart from M6 
antibody which was diluted 1 in 1000), for 1 hour in the dark at room temperature. After 
washing 3 times with PBS, the relevant secondary antibody was diluted 1:200 in 3% bovine 
serum albumin in PBS, and was then placed on the cover slip for 1 hour at room 
temperature in the dark. After washing twice with PBS, cells were incubated with TO-PRO-3 
(Invitrogen), diluted 1 in 1000 in PBS, for 10 minutes at room temperature. The cover slips 
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were then placed onto a microscope slide using Immumount (Thermo Scientific), and each 
coverslip was then sealed using clear nail varnish. Images were then taken using a Leica TCS 
SP2 confocal microscope, using a 63x objective immersed in oil and a numerical aperture of 
1.4. The excitation laser wavelength was 633nm for TO-PRO-3, and was 488nm for FITC and 
543nm for TRITC. 
 
2.6.2 Bromodeoxyuridine assay 
 
For bromodeoxyuridine (BrdU) assays, 5 x 105 cells were plated onto a 6-well plate, and 
were left to attach overnight. Cells were then incubated with 10µM BrdU (Sigma) for 6 
hours. The media was removed, and cells were then washed with PBS. Cells were fixed with 
4% w/v formaldehyde for 10 minutes at room temperature. Cells were washed three times 
with PBS before the cell membrane was permeabilised using 1% v/v triton in PBS. Cells were 
washed in PBS, before endogenous peroxidase activity was blocked by incubating the cells in 
3% v/v H2O2 (Sigma) freshly diluted in distilled water for 5 minutes at 4°C.  Cells were then 
washed twice in PBS, before the DNA double strands were denatured by incubating with 2M 
HCl for 30 minutes at 37°C.  Cells were washed in PBS, and cells were incubated in murine 
anti-BrdU antibody (Sigma), diluted 1 in 500 in 1% w/v bovine serum albumin, 10% v/v horse 
serum in PBS overnight at 4°C. Cells were then washed three times before incubating with 
biotinylated horse anti-mouse IgG (Vector Laboratories), diluted in 1% w/v Bovine serum 
albumin in PBS for 30 minutes at room temperature. Cells were washed twice in PBS, before 
being incubated with Extravadin-peroxidase (Sigma), diluted in 1% w/v bovine serum 
albumin in PBS for 30 minutes at room temperature. Cells were then washed twice, before 
being stained with 3,3’-diaminobenzidine (DAB) solution (consisting of 1 DAB gold and 1 
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DAB silver tablet (Sigma), diluted in 5ml distilled water) for 10 minutes at room 
temperature. The percentage of positive to total number of cells was then counted using an 
inverted microscope at 100x magnification.  
 
2.7 DNA protocols 
 
2.7.1 Preparation of competent Escherichia coli (E. coli) XL-1 blue cells 
 
XL-1 blue E. coli cells were inoculated into 5ml of LB broth (Sigma) and incubated into a 
shaking incubator at 200rpm at 37°C for 16 hours. 0.5ml of this culture was then diluted into 
50ml of LB broth, and incubated at 37°C until the cells were in the exponential phase of 
growth (determined by an OD of >0.5 and <1 at 650nm). The culture was kept at 4°C for 10 
minutes, before centrifugation at 4000 rpm for 5 minutes at 4°C (Thermo Scientific Heraeus 
Fresco 21). The pellet was resuspended in 25ml of sterile 0.1M CaCl2, and was incubated at 
4°C for 20 minutes. This suspension was centrifuged at 4000 rpm at 4°C for 5 minutes, and 
the pellet was resuspended very gently in 2ml of 0.1M CaCl2. Glycerol was added to the cell 
suspension, to give a final concentration of 40% glycerol. This was aliquotted into 100μl per 
Eppendorf tube, and stored at -80°C.  
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2.7.2 Transformation of XL-1 blue E. coli cells 
 
To transform XL-1 blue cells, 50ng of plasmid was mixed with 100μl of XL-1 blue cells, and 
was left to incubate on ice for 20 minutes. The cells were placed in a waterbath set at 42.5°C 
for 90 seconds, and were then placed on ice for 2 minutes. Following this cells were 
recovered by adding 1ml of LB broth, and incubating the cells at 37°C for 45 minutes. The 
cell cultures were then centrifuged at 13000 rpm in a tabletop centrifuge (Eppendorf 5424), 
for 30 seconds. The supernatant was discarded, and the remaining cells were spread on an 
LB agar plate (LB broth + 1.5% w/v Bacteriological agar), containing 50μg/ml ampicillin. 
Plates were incubated at 37°C overnight.  
 
2.7.3 Purification of plasmid DNA 
 
Plasmid DNA was purified using the QIAGEN maxi prep kit (QIAGEN 12163) according to 
manufacturer’s instructions. Briefly, one colony from the agar plate was inoculated into 5ml 
of LB broth containing 50μg/ml ampicillin for 8 hours at 37°C, shaking at 300 rpm. 0.1ml of 
this starter culture was diluted into 100ml of LB broth, and left to grow overnight at 37°C, 
shaking at 300 rpm. The bacterial cells were centrifuged at 4000 rpm (Eppendorf 5810 R). 
The cells were resuspended in 10ml buffer P1. The cells were lysed by adding 10ml of buffer 
P2, inverting the tube 5 times, and leaving at room temperature for 5 minutes. The reaction 
was neutralised by adding 10ml of buffer P3, inverting 5 times, and incubating on ice for 20 
minutes. The lysate was filtered using Whatmann filter paper (Catalogue number 1441 150). 
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After equilibrating a QIAGEN-tip 500 by flowing 10ml of buffer QBT through the tip, the 
filtered supernatant was then loaded onto the QIAGEN-tip. The QIAGEN-tip was then 
washed with 60mls of buffer QC, and the DNA was then eluted from the tip using 15ml of 
buffer QF. The DNA was precipitated by adding 10.5ml of isopropanol, and centrifuging at 
4000 rpm at 4°C for 1 hour (Eppendorf 5810R). The DNA pellet was washed with 5ml of 70% 
ethanol, and centrifuged again at 4000 rpm at 4°C for 1 hour (Eppendorf 5810R). The pellet 
was then left to air dry for 15 minutes, and finally resuspended in 100μl TE buffer.  
 
2.7.4 Phenol:chloroform:isoamylalchohol (PCI) extraction and DNA precipitation 
 
The bottom layer of the phenol:chloroform:isoamylalcohol (25:24:1) mixture was added in 
equal volume to the DNA solution, and was vortexed for 30 seconds. This mixture was 
centrifuged at 13000 rpm (Eppendorf 5424) for 5 minutes, with the resulting upper layer 
carefully removed. Sodium acetate was added (pH 5.2) to give a final concentration of 0.3M, 
and also 50µg of glycogen and 2.5 volumes of ice-cold 100% ethanol. After vortexing for 30 
seconds, the solution was incubated at -20°C for 10 minutes, and was then centrifuged at 
13000 rpm at 4°C for 10 minutes. The supernatant was poured off and the pellet was 
washed with 1ml 70% ice cold ethanol. This was centrifuged at 13000 rpm at 4°C for 10 
minutes, with the resultant pellet being air-dried for 15 minutes. The pellet was 
resuspended in the appropriate volume of TE buffer.   
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2.8 Quantitative PCR protocols 
 
2.8.1 RNA extraction 
 
RNA was extracted from cells using a Bioline ISOLATE II RNA mini kit.  For details see 
manufacturer’s instructions. Briefly, 5x105 cells were pelleted, and resuspended in 450 µl of 
lysis buffer R, which was then incubated for 3 minutes at room temperature. This was 
transferred to spin column R1, and centrifuged at 10000g for 2 minutes (Eppendorf 5424). 
An equal volume of 70% ethanol was added to the filtrate, and was placed into spin column 
R2. This was then centrifuged at 10000g for 2 minutes. 500µl of wash buffer AR was added 
to the column, and was centrifuged at 10000g for 1 minute. 700µl of wash buffer BR was 
added to the column, and was centrifuged at 10000g for 1 minute. The collection column 
was centrifuged at 10000g for 3 minutes, to remove any residual alcohol. The RNA was 
eluted, by adding 30µl of nuclease free water to the spin column, and then spinning at 
6000g for 1 minute. The RNA concentration was then quantified using a NanoDrop.   
 
2.8.2 Complementary DNA production 
 
To produce the reaction mixture, 0.5µg of RNA was added to a final concentration of 1mM 
dNTPs and 20ng/µl random hexamer primers (Thermo Scientific), to a final reaction volume 
of 12µl. This solution was then incubated at 65°C for 5 minutes. To this reaction, Superscript 
III reverse transcriptase (Invitrogen) was added (to a final concentration of 10U/µl), 1x First 
Strand buffer (Invitrogen), Ribolock RNase inhibitor (Thermo Scientific) (to a final 
concentration of 10 units/µl) and dithiothreitol (DTT) (Invitrogen) to a final concentration of 
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10mM, giving a final reaction volume of 20µl. This reaction was incubated at 25°C for 10 
minutes, 42°C for 90 minutes, and finally 72°C for 10 minutes. The final cDNA concentration 
was then quantified using a NanoDrop.  
 
2.8.3 Quantitative PCR 
 
Quantitative PCR was performed by using SYBR-green as a fluorescent dye, using a final 
reaction composition of: 100ng cDNA template, 1x Sensimix SYBR sensimix no ROX (Bioline), 
200nM forward primer and 200nM reverse primer (final reaction volume was 15µl) (Primers 
were ordered from MWG Eurofins). The reaction was placed in a Corbett Research RG-3000 
Rotorgene thermocycler, using the following thermal parameters: 95°C for 10 minutes, 45 
cycles of 95°C for 15 seconds, 60°C for 20 seconds (55°C for GAPDH, and 62°C for VEGFA), 
and 72°C for 5 seconds. A melting step of between 72°C and 95°C was then carried out (hold 
at 72°C for 45 seconds, then inclining by 1°C for 5 seconds thereafter), to determine 
whether one specific PCR product was formed. Each biological replicate was carried out as a 
technical triplicate. The data were analysed using Rotorgene 6 Software (Corbett Research, 
Rotorgene RG-3000). GAPDH was used as the internal control (unless stated otherwise). 
Results for relative expression ratios were calculated according to the Efficiency Calibrated 
Mathematical Model (as described in (Pfaffl, 2001a). Briefly, the following equation was 
carried out for each biological replicate: 
ECt (GAPDH) / Ect (Gene of Interest) 
The log of this equation was then taken, and a statistically significant difference was 
determined between control and knockdown/overexpression of PRH using a two-tailed 
Student’s t-test (heteroscedasticity or homoscedasticty was determined using an F-test).  
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2.9 Flow cytometery protocols 
 
2.9.1 Cell cycle analysis 
 
Approximately 5 x 105 cells were centrifuged at 3000 rpm (Thermo Scientific Heraeus Fresco 
21) and resuspended in 300µl RPMI media. IGEPAL and propidium iodide was added to a 
final concentration of 1% and 50µg/ml respectively. The sample was then put through a 
Beckton Dickson FACSCalibur flow cytometer, and analysed using FloJo software, after 
gating out dead cells using a FSC vs. SSC plot, which identifies debris/dead cells based on 
morphology. 
 
2.9.2 Annexin-V apoptosis assay 
 
Approximately 5 x10 5 cells were centrifuged at 3000 rpm (Thermo Scientific Heraeus Fresco 
21) and resuspended in 100µl binding buffer (see table 2.2). 5µl of Annexin-V was added (BD 
Biosciences) and 5µl of 50µg/ml propidium iodide (Sigma), before incubating for 20 minutes 
in the dark. Another 200 µl of binding buffer was then added. The sample was then put 
through a Beckton Dickson FACSCalibur flow cytometer, and analysed using FloJo software, 
after gating out dead cells using a FSC vs. SSC plot. 
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2.9.3 CD24/CD44 staining 
 
To analyse CD24/CD44 expression, 1 x 105 cells were resuspended in 100μl of PBS. Cells 
were stained with 5μl of CD24-FITC (BD Biosciences) and 5μl of CD44-TRITC (BD 
Biosciences), and were left on ice in the dark for 15 minutes. Cell staining was analysed 
using a FACSCalibur flow cytometer (BD Biosciences), using laser channels FL1 and FL3. 
Analysis was carried out using FloJo software.  
 
2.10 Migration and invasion assays 
 
 2.10.1 Transwell migration assay 
 
Transwell migration assays were set up as follows; 4x104 cells were seeded into the upper 
chamber of a 8μm transwell insert (Greiner Bio-One), in 200μl growth media containing only 
2% fetal calf serum (for MDA-MB-231 and MCF-7 cells), or growth media lacking EGF (for 
MCF-10A cells). The transwell was inserted into a 24-well plate, and the lower chamber 
contained 1ml of appropriate growth media, containing all supplements for each cell line. 
After either 24 or 48 hours  at 37°C in 5% CO2 (dependent on the cell line, see chapter 5), 
the upper and lower chambers were washed three times with PBS, and cells were then fixed 
with 2% w/v formaldehyde, which also contained 2μg/ml bisbenzimide to stain the cell 
nuclei. After washing three times with PBS, the membrane of the transwell chamber was cut 
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out using a scalpel, and was placed onto a microscope slide. The slide was then sealed using 
a coverslip (Surgipath), Vectamount (Vector Laboratories) and clear nail varnish. The 
number of cells was then counted in three fields on the upper and lower parts of the 
membrane, using a Zeiss Axioplan 2 fluorescent microscope, at 200x magnification under UV 
light. The number of cells on the lower part of the membrane was then divided by the total 
number of cells, to give the percentage of migrated cells.  
 
2.10.2 Matrigel invasion assay 
 
Matrigel (BD Biosciences) was thawed by storing overnight at 4°C. Matrigel was then diluted 
1 in 2 in serum-free media, and 50μl of the diluted Matrigel was pipetted into 8μm transwell 
inserts (Grenier Bio-One), which were inserted into 24 well plates. The plates were kept at 
37°C for two hours to allow the Matrigel to set. 4 x 104 cells were seeded into the upper 
chamber in 200μl growth media containing only 2% fetal calf serum (for MDA-MB-231 and 
MCF-7 cells), or no EGF (for MCF-10A cells). After either 24 or 48 hours at 37°C in 5% CO2 
(dependent on the cell line, see chapter 5), the Matrigel was removed using a cotton bud. 
The upper and lower chambers were then washed three times with PBS, and cells were then 
fixed with 2% w/v formaldehyde, which also contained 2μg/ml bisbenzimide to stain the cell 
nuclei. After washing three times with PBS, the membrane of the transwell chamber was cut 
out using a scalpel, and was placed onto a microscope slide. The slide was then sealed using 
a coverslip (Surgipath), Immumount (Thermo Scientific) and clear nail varnish. The total 
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number of cells which had reached the transwell membrane was then quantified using a 
Zeiss Axioplan 2 fluorescent microscope, at 50x magnification under UV light. 
 
2.10.3 Scratch wound assay 
 
The day before scratch wound assays were to be carried out, 1x106 cells were plated into a 
6-well plate, so that the cells would be 100% confluent on the day of the assay. Twenty four 
hours later, the media was aspirated off, and a black horizontal line was drawn on the back 
of the 6-well plate. Three vertical scratches were then made with a P200 pipette tip, and 
excess cells were washed off with PBS. The media was replaced with media containing 1mM 
hydroxyurea, to prevent cell proliferation. Images were taken at each scratch above and 
below the black horizontal line, using an AMG Evos XL core Amex 1200 microscope on 100x 
magnification. Images were taken at 6 and 24 hours post wounding, and the area of each 
scratch was quantified using ImageJ software. The area of the scratch at either 6 or 24 hours 
was divided by the area of the scratch at 0 hours, to determine the percentage wound 
closure.  
 
2.11 Mouse xenograft assay 
 
The day before tumour cell injection, 8x107 MCF-7 cells were infected with either Ad-PRH or 
Ad, at a multiplicity of infection of 50. Twenty four hours later, cells were harvested and 
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resuspended at a concentration of 5x107 cells/ml. 100μl of cells (5x106 cells) were injected 
into each mammary fat pad of a 6 week old Balb/c female nude mouse, so that 8 mice were 
injected with cells containing Ad-PRH or Ad (16 mammary fat pads each). Four mice were 
also injected with MCF-7 cells which were not infected with adenovirus (8 mammary fat 
pads), and therefore 20 mice in total were used in this experiment. Mice were also had 
0.72mg 17β-oestradiol tablets 60 day release (Innovative Research of America) tablets 
surgically implanted subcutaneously in their dorsal side. Tumour size was measured using 
callipers three times per week, and tumour volume was determined using the ellipsoid 
formula 0.5 x length x width x width (Euhus et al., 1986). Mice were then sacrificed when 
the tumours reached Home Office limits for tumour size.  
 
2.12 Plasmids 
 
pMUG1 Myc-PRH 
This plasmid expresses a fusion protein consisting of an N-terminal Myc 9B11 epitope fused 
to amino acids 7-270 of human PRH (as described in Bess et al., 2003a). 
pEGFP-PRH 
This plasmid was created by inserting the PRH cDNA from a pBlueScript clone into the KpnI 
and EcoRI sites of pEGFP-C1 (as described in Desjobert et al., 2009). 
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Figure 2.2: Schematic of the pMUG1 Myc-PRH plasmid.
Figure 2.1: Schematic of the EGFP-PRH plasmid.
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pEGFP-C1 
This plasmid expresses an enhanced green fluorescence protein. Commercially available 
from Clontech.  
pLKO-puro-IPTG-3xLacO (PRH and control shRNA) 
These constructs were obtained from Sigma. The DNA sequence for PRH shRNA knockdown 
is CTGTGATCAGAGGCAAGATTT (Clone ID TRCN0000274008), whilst the control sequence 
targets no known mammalian gene. The vector has a Woodchuck Hepatitis Post-
Transcriptional Regulatory Element (WPRE), allowing for enhanced transgene expression. 
The vector also codes for LacI repressor protein, which binds to the three LacO sequences 
present in the human U6 promoter when no IPTG is present. IPTG, when present, binds 
allosterically to LacI protein, changing the conformation of the LacI so it can no longer bind 
to LacO sequences, and hence allows expression of the shRNA.  
psPAX2 
This vector was obtained from Addgene. This vector expresses a variant of the human HIV 
Gag and Pol proteins, needed for lentivirus production.  
pMD2.G 
This vector was obtained from Addgene. This vector expresses the VSV-G envelope protein 
from the vesicular stomatitis virus, needed for lentivirus production.  
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Name Description
cppt Central polypurine tract
hPGK
Human phosphoglycerate kinase 
eukaryotic promoter
PAC Puromycin N-acetyl-tranferase
WPRE
Woodchuck Hepatitis Post-
Transcriptional Regulatory Element
SIN/LTR
3' self inactivating long terminal 
repeat
f1 ori f1 origin of replication
AMP
resistance
Ampicillin resistance gene for 
bacterial selection
PUC origin pUC origin of replication
5' LTR 5' long terminal repeat
Psi RNA packaging signal
RRE Rev response element
LacI Lac Repressor
GSG-F2A
Gly-Ser-Gly foot-and-mouth disease 
virus IRES 2A
RSV Respiratory syncytial virus promoter
Figure 2.3: Schematic of the pLKO_IPTG_3XLacO
plasmid.
Name Description
Amp Ampicillin resistance
CMVenh Cytomegalovirus enhancer
CApro Chicken beta-actin 
promoter
Gag HIV Gag
Pro HIV Pro
Pol HIV Pol
RRE Ribosomal response 
element
pA Rabbit beta-blobin poly 
adenylation signal
SV40 ori SV40 origin of replication
SD Splice donor
SA Splice acceptor
CA intron Chicken beta-actin intron
AEVpr, dVpu, 
dEnv
Inactivated  genes from 
HIV genome
Figure 2.4: Schematic of the pSPAX2 plasmid.
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Name Description
CMV CMV promoter
VSV-G Vesicular 
stomatitis 
Indiana virus  G 
envelope protein
Beta-globin pA Chicken beta-
globin poly 
adenylation site
Figure 2.5: Schematic of the pMD2.G plasmid.
Name Description
ITR Inverted tamdem
repeat
FLP FLP recombinase
frt Flippase
recombination target
Δψ Deletion – adenoviral 
packagine element
ΔE1, E3 Deletion- adenoviral 
E1 and E3 proteins
Figure 2.6: Schematic of the pBHGfrtΔE1,E3FLP plasmid.
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pDC515 
This vector is the viral shuttling vector, which is used for adenovirus production. For Ad 
(empty virus), the empty vector was used (i.e. did not code for any transgene). To produce 
Ad-PRH and Ad-PRH N187A, the coding regions from the pMUG1-PRH and pMUG1-PRH 
N187A plasmid described in (Noy et al., 2010) was excised using restriction endonucleases 
EcoRI and BamHI, blunted with micrococcal nuclease and ligated into pDC515 (as described 
in Palmer and Ng, 2008).  
pBHGfrt△E1,3FLP 
This vector codes for the viral proteins (minus E1 and E3) (as described in Palmer and Ng, 
2008).  
 
 
 
Figure 2.7: Schematic of the pDC515 plasmid. To produce Ad-PRH and Ad-PRH N187A, the 
coding regions from the pMUG1-PRH and pMUG1-PRH N187A plasmid (described in Noy et al., 
2010) was excised using restriction endonucleases EcoRI and BamHI, blunted with micrococcal 
nuclease and ligated into pDC515. The vector is as described in Palmer and Ng 2008.  
Polylinker 
sequence: 
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2.13 Reagents and solutions 
Table 2.1 – List of reagents 
Reagent Code  
17β-Oestradiol tablets (0.72mg, 60 day release) Innovative research of 
America SE-121 
5-Bromo-2'-deoyuridine (BrdU) Sigma B5002 
Acrylamide (30%) Geneflow A2-0074 
Agarose Sigma A9539 
Ammonium persulphate Sigma A3678 
Anisomycin  Sigma A9789 
Annexin-V  BD Biosciences 550474 
Bacteriological Agar  Sigma A5306 
Bisbenzimide Sigma B1155 
Bovine serum albumin Sigma A2153 
Bromophenol blue Sigma B8026 
Caesium chloride Sigma 289329 
Calcium chloride Sigma C4901 
Cholera Toxin Sigma C8052 
DAB (SIGMAFAST DAB with metal enhancer) Sigma D0426 
Dimethyl sulphoxide Fischer BP231 
Dithiothreitol (DTT) Sigma D9779  
Invitrogen 18080-044 
DMEM:F12 Sigma D8737 
DNA 100 base pair ladder New England Biolabs N3231S 
DNA loading biffer (comes with ladder) New England Biolabs N3231S 
dNTP mastermix Invitrogen 10297018 
Dulbecco's modified Eagle's medium (DMEM) Sigma D5796 
Dynabeads Protein A Invitrogen 10001D 
Enhanced Chemiluminescense solution GE Healthcare RPN2106 
Epidermal Growth Factor Peprotech AF-100-15 
Ethanol Fischer Scientific BP2818 
Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid 
(EGTA) 
Sigma E3889 
Ethylenediaminetetraacetic acid (EDTA) Sigma E5134 
Fetal Bovine Serum Sigma F7524 
First strand buffer (comes with Superscript III) Invitrogen 18080-044 
Formaldehyde (37%) Fischer Scientific BP531 
Glycerol Fischer Scientific  G30 
Glycine Sigma G8898 
Glycine  Sigma 241261 
Glycogen Calbiochem CAS 9005-79-2 
Hanks' Balanced Salt Solution Sigma H6648 
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Reagent Code  
Heparin StemCell Technologies 07980 
HEPES Sigma H3375 
Horse Serum Heat Inactivated Sigma H1138 
Human Insulin Solution Sigma I9278 
Hydrochloric acid (33%) Sigma H1758 
Hydrocortisone Sigma H0888 
Hydrogen peroxide (30%) Sigma 216763 
Hydroxyurea Sigma H8627 
Igepal CA-630 Sigma I8896 
Immumount Thermo Scientific 9990402 
Isopropanol Sigma I9516 
Isopropyl β-D-1-thiogalactopryanoside (IPTG) Bioline 37036 
LB Broth  Sigma L3152 
Lipofectamine 2000 Invitrogen 11668 
Magnesium chloride Sigma M8266 
MammoCult Basal Medium StemCell Technologies 05621 
MammoCult Proliferation Supplements StemCell Technologies 05622 
Matrigel  BD Biosciences 356234 
Methanol Fischer Scientific A413 
NP-40 Sigma I8896 
Pageruler Plus protein ladder Thermo Scientific  SM1811 
PBS tablets Sigma P4417 
Penicillin/Streptomycin (x100) PAA P11-010 
Phenol:chloroform:isoamyl alcohol 25:24:1 Sigma P3803 
Ponceau S solution Sigma P7170 
Propidium iodide Sigma P4170 
Protease inhibitor tablet Roche 04 693 124 001 
Protein Assay reagent Bio-Rad 500-0006 
Proteinase K Sigma P2308 
Puromycin dihydrochloride Sigma P8833 
Random hexamer primer Thermo Scientific SO142 
REDTaq readymix PCR reaction mix  Sigma R2523 
Ribolock RNase inhibitor Thermo Scientific EO0381 
RPMI-1640 Sigma R8758 
Sodium azide Sigma S8032 
Sodium chloride Sigma S9265 
Sodium deoxycholate Sigma D6750 
Sodium dodecyl sulphate Sigma L4509 
Superscript III reverse transcriptase Invitrogen 18080-044 
SYBR safe DNA gel stain 10000x  Invitrogen S33102 
SYBR sensimix no ROX Bioline QT650 
Tetramethylethylenediamene Sigma T9281 
Thiazolyl blue formazan [1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan] (MTT) 
Sigma M2003 
TO-PRO-3 Iodide  Invitrogen T3605 
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Reagent Code  
Triton X-100 Sigma T8787 
Trizma base Sigma T4661 
Trypsin-EDTA (X10) PAA L11-003 
Tween-20 (Polyoxyethylene sorbitan monolaurate) Sigma P1379 
 
2.14 Solutions  
Table 2.2 – List of solutions 
Solution Composition 
Adenovirus dialysis buffer 135 mM NaCl 
10mM Tris-Cl (pH 7.5) 
1mM MgCl2 
Annexin-V binding buffer 10mM HEPES pH 7.4 
140mM NaCl 
2.5 mM CaCl2 
ChIP elution buffer 20mM Tris-Cl (pH 7.5) 
50mM NaCl 
5mM EDTA 
ChIP lysis buffer 50mM Tris-Cl (pH 8.0) 
10mM EDTA 
1% SDS 
Protease inhibitor tablet 
ChIP RIPA buffer 10mM Tris-CL (pH 8.0) 
140mM NaCl 
1% v/v Triton X-100 
1mM EDTA 
1mM EGTA 
0.1% w/v SDS 
0.1% sodium deoxycholate 
Fractionation buffer A 20mM Tris-Cl (pH 7.5) 
5mM MgCl2 
1 mM DTT 
Protease inhibitor tablet 
Fractionation buffer B 50mM Tris-Cl (pH 7.5) 
500mM NaCl 
1% v/v NP-40 
0.1% w/v SDS 
Protease inhibitor tablet 
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Solution Composition 
Mammosphere media 10% v/v MammoCult Proliferation 
Supplements 
4μg/ml heparin 
0.5μg/ml hydrocortisone 
100 units/ml penicillin 
0.1mg/ml streptomycin 
In MammoCult Basal Medium 
QIAGEN Buffer P1 50mM Tris-Cl (pH 8.0) 
10mM EDTA (pH 8.0) 
100μg/ml Rnase A 
QIAGEN Buffer P2 200mM NaOH 
1% w/v SDS 
QIAGEN Buffer P3 3.0 M potassium acetate pH 5.5 
QIAGEN Buffer QBT 750mM NaCl 
50mM MOPS (pH 7.0) 
15% isopropanol 
0.15% Triton X-100 
QIAGEN Buffer QC 1M NaCl 
50mM MOPS (pH 7.0) 
15% isopropanol 
QIAGEN Buffer QF 1.25M NaCl 
50mM MOPS (pH 7.0) 
15% isopropanol 
Resolving Buffer (1x) 0.1% w/v SDS 
375mM Tris-HCl  
Final pH 8.8 
RIPA Buffer 150mM NaCl  
1% v/v NP-40 
0.5% v/v sodium deoxycholate 
0.1% v/v SDS 
50mM Tris-Cl (pH7.5) 
Protease inhibtor tablet  
Running Buffer (1x) 0.1% w/v SDS 
25mM Tris 
192mM Glycine 
SDS gel loading buffer (1x) 50mM Tris-Cl (pH 6.8) 
100mM DTT 
2% w/v SDS 
0.1% bromophenol blue 
10% glycerol 
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Solution Composition 
Stacking buffer (1x) 0.1% w/v SDS 
125mM Tris-HCl 
Final pH 6.8 
TAE buffer 40mM Tris-Acetate 
1mM EDTA 
TE buffer 10mM Tris-Cl (pH 8.0) 
1mM EDTA (pH 8.0) 
Transfer buffer (1x) 10mM Tris 
100mM glycine 
0.05% w/v SDS 
20% v/v methanol 
 
2.1  Antibodies 
Table 2.3 – List of Antibodies 
Antibody Source Code 
Anti-BrdU antibody  Murine Sigma B2531 
Anti-CD24 antibody FITC 
conjugated 
Murine BD 555427 
Anti-CD44 antibody TRITC 
conjugated 
Murine BD 555479 
Anti-hexon antibody  Murine Abcam ab8249 
Anti-Lamin A/C (H-110) Rabbit Santa Cruz Biotech sc-20681 
Anti-mouse IgG biotinylated Horse Vector Laboratories BA-2000 
Anti-mouse IgG HRP conjugated Goat Santa Cruz Biotech sc-2005 
Anti-Myc antibody Murine New England Biolabs 2276 
Anti-rabbit IgG HRP conjugated Goat Santa Cruz Biotech sc-2313 
ExtrAvadin-Peroxidase Egg white Sigma E2886 
Normal IgG Murine Santa Cruz Biotech sc-2025 
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2.16 PCR primers  
Table 2.4 – List of qPCR primers 
 
Primer  Sequence (5' - 3') 
VEGF-A Forward  ATC AGC GCA GCT ACT GCC ATC C 
VEGF-A Reverse TCT CCT ATG TGC TGG CCT TGG TG 
PRH Forward  CAC CCG ACG CCC  TTT TAC AT 
PRH Reverse GAA GGC TGG ATG GAT CGG C 
VEGFR-1 Forward  TGG CCA TCA CTA AGG AGC ACT CC 
VEGFR-1 Reverse GGA ACT GCT GAT GGC CAC TGT G 
VEGFR-2  Forward  TTA GTG ACC AAC ATG GAG TCG TG 
VEGFR-2  Reverse TAG TAA AGC CCT TCT TGC TGT CC 
GAPDH Forward  TGA TGA CAT CAA GAA GGT GGT GAA G 
GAPDH Reverse TCC TTG GAG GCC ATG TGG GCC AT 
Goosecoid Forward  CTT CTC AAC CAG CTG CAC TGT CG 
Goosecoid Reverse ACT CCT CTG ATG AGG ACC GCT TC 
Neuropilin Forward  TAT TCC CAG AAG TCT GCC C 
Neuropilin Reverse TGT CAT CCA CAG CAA TCC CA 
ESM-1 Forward  TCG AGC ACT GTC CTC TTG CA 
ESM-1 Reverse GTG GAC TGC CCT CAA CAC TGT 
SATB1 Forward  TGC AAA GGT TGC AGC AAC CAA AAG C 
SATB1 Reverse AAC ATG GAT AAT GTG GGG CGG CCT 
Endoglin  Forward  GCC GTG CTG GGC ATC ACC TT 
Endoglin  Reverse CGC TTG CTG GGG GAA CCT GG 
p53 Forward  CCT ATC CTT ACC ATC ATC ACA CTG 
p53 Reverse TTC TTC TGT ACG GCG GTC TC 
E-Cadherin Forward  GTA ACG ACG TTG CAC CAA CC 
E-Cadherin Reverse AGC CAG CTT GAA GCG AT 
Beta-actin Forward  TCA CCC ACA CTG TGC CCA TCT ACG A 
Beta-actin Reverse CAC CGG AAC CGC TCA TTG CCA ATG G 
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3. Characterisation of exogenous and endogenous 
PRH in multiple breast cell lines 
 
3.1 Introduction 
 
This chapter will first investigate the PRH/Hhex expression data present in the Gene 
Expression-Based Outcome for Breast Cancer Online (GOBO) database. The GOBO database 
contains mRNA expression data of 1881 breast cancer patients from 11 public data sets, 
which have been analysed using Affymetrix U133A arrays. The database allows genes or sets 
of genes to be examined using Gene Set Analysis (GSA), which correlate gene expression 
data with Kaplan-Meier plots of overall survival, and also compares expression for a 
particular gene (or set of genes) to breast cancer grade and type. The GOBO database also 
allows expression of a single gene to be interrogated across a large set of commonly used 
breast cell lines. Using this database, the correlation between PRH mRNA expression and 
breast tumour grade, subtype, survival and cell line type will be evaluated. Secondly, a new 
monoclonal antibody raised against PRH will be characterised and then used to investigate 
PRH protein expression levels in a set of breast tumour cell lines. Thirdly PRH protein 
expression, stability and sub-cellular localisation will be investigated in three well 
characterised breast cell lines: a non-tumourgenic immortalised cell line MCF-10A, and in 
MCF-7 and MDA-MB-231 tumour cell lines (Debnath et al., 2003a, Lacroix and Leclercq, 
2004a).  
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3.2 PRH mRNA expression correlates with increased survival 
 
When HHEX (PRH) is queried in the GOBO database, Kaplan-Meier plots show that PRH 
mRNA expression significantly correlates with overall survival over 10 years across all breast 
tumour subtypes (figure 3.1 (A)). As a comparison, mRNA expression of the tumour 
suppressor gene PTEN and the housekeeping gene GAPDH was also queried in the same 
database. Increased PTEN transcript expression also correlates with increased overall 
survival, whereas GAPDH does not (figure 3.1 (B and C)). Interestingly PRH transcript 
Figure 3.1. PRH is a marker for breast cancer survival. The GOBO database (Ringnér et al., 2011) was used to
query the expression levels of PRH (A), PTEN (B) or GAPDH (C) transcript in breast tumours of 1881 patients,
analysed using Affymetrix U133A arrays and na.30 gene probe set descriptions, and log2 expression values were
mean centered. This was used to produce Kaplan-Meier plots for low (grey), medium (red) and high (blue) gene
expression, with significance measured by Logrank test. Patients with high amounts of PRH transcript have
significantly increased chance of overall survival than those with low amounts of PRH transcript. PTEN expression
is also a positive marker for overall survival, whereas GAPDH is not. The GOBO database was also used to
correlate PRH expression with breast cancer type. Figure 1 (D) shows that PRH expression is significantly lower in
basal and HER2 amplified cancers, and is highest in Luminal A cancers. Figure 1 (E) shows that PRH expression is
significantly higher in ER+ breast tumours than ER- breast tumours. Figure 1 (F) shows that PRH expression is
significantly lower in grade 3 breast tumours than in grade 1 or 2 breast tumours.
p = 0.96837
p(ANOVA) < 0.00001 p(ANOVA) < 0.00001
(A)
(D) (E) (F)
(B) (C)PRH PTEN GAPDH
Grade
p = 0.00289p = 0.00624
p(ANOVA) < 0.00001
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expression is significantly higher in Luminal A tumours (which are usually the least 
aggressive), and is significantly lower in basal and HER2 amplified tumours (which are 
usually the most aggressive) (figure 3.1 (D)). Furthermore PRH mRNA expression is 
significantly higher in ER+ tumours than ER- tumours (figure 3.1 (E)), which agrees with 
figure 3.1 (D), as Luminal A tumours are typically ER+. When breast tumours are subdivided 
according to grade PRH mRNA expression is found to be significantly reduced in grade 3 
breast tumours, compared to grade 1 or 2 tumours (figure 3.1 (F)). Grade 3 tumours are 
tumours which histologically have low tubule formation, increased variation in nuclei shape 
and size, and an increased number of mitotic cells compared to grade 1 or 2 tumours. Thus 
decreased PRH mRNA expression appears to be a significant marker for poor prognosis and 
more aggressive breast tumours. 
 
3.3 Characterising the mouse monoclonal (M6) anti-PRH antibody 
 
K562 haematopoietic cells express PRH proteins that have previously been detected using in 
house polyclonal antibodies (Bess et al., 2003a, Soufi et al., 2009). Limited quantities of 
these well characterised PRH antibodies were available for PRH protein expression studies 
in breast cells, and there is a lack of reliable commercially available PRH antibodies. This led 
to the generation of a new mouse monoclonal antibody (M6). The M6 antibody was raised  
against a peptide in human PRH consisting of amino acids SPFLQRPLHK (amino acids 127-
136). This sequence lies 2 amino acids N-terminal to the homeodomain.  
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PRH protein has a predicted molecular weight of 30 kDa, but has an apparent molecular 
weight of 37 kDa on a SDS-PAGE gel because it is SDS resistant (Soufi et al., 2006). To 
determine whether the M6 monoclonal antibody recognises a 37kDa band corresponding to 
the PRH protein in K562 leukaemic cells, whole cell extracts were prepared and Western 
blotted as described in the Materials and methods section 2.3. Briefly, 20µg of protein was 
loaded in each lane of a SDS-PAG gel and the samples were electrophoresed to separate 
proteins according to size. Western blotting of the samples was performed with the M6 
antibody. The cell extracts were also probed with polyclonal anti-PRH antibody (M3) for 
comparison. The mouse polyclonal M3 antibody was raised against a GST-fusion protein 
containing the N-terminal domain of PRH (Bess et al., 2003b). Figure 3.2 shows that in K562 
extracts the M6 antibody (lane 1) recognises a triplet of bands at approximately 37kDa. The 
bands are of similar mobility to the single protein recognised by the M3 antibody (lane 2) 
suggesting that the M6 antibody is recognising endogenous PRH proteins in K562 cells, but 
that it may recognise more than one conformation of PRH, or that it may recognise PRH 
with different post-translational modifications. 
 
To determine whether M6 will detect endogenous PRH in breast cells, protein extracts 
prepared from MDA-MB-231 cells were electrophoresed and Western blotted with M6 
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antibody as before. Figure 3.3 shows that the M6 antibody recognises a protein of 
approximately 37kDa. To confirm that this protein is PRH, MDA-MB-231 cells were knocked 
down for PRH expression using a lentivirus that expresses an inducible shRNA against PRH. 
Details of the method are outlined in Materials and methods section 2.5. Whole cell extracts 
prepared from MDA-MB-231 control and knockdown cells were Western blotted with M6 
antibody and M3 antibody and with Lamin antibody. Lamin protein levels were used as a 
control for equal protein loading. Figure 3.3 shows that the 37kDa PRH protein is reduced in 
intensity in PRH knockdown cells probed with both M3 and M6 antibodies (figure 3.3). 
Interestingly the PRH protein is also observed as a triplet of bands of approximately 37kDa 
in MDA-MB-231 extracts (see figures 3.3 and 3.4). Knockdown of PRH results in a decrease 
in all 3 bands. In conclusion, these studies together demonstrate that the M6 antibody can 
recognise endogenous PRH, and that M6 antibody recognises multiple post-translational 
forms of PRH or multiple conformations of the PRH protein.  
 
To determine whether M6 recognises recombinant PRH protein, MDA-MB-231 cells were 
transfected with Myc-PRH and GFP-PRH expression plasmids. The Myc-PRH plasmid encodes 
the human PRH with a Myc-tag replacing the first 7 amino acids of PRH (Swingler et al., 
2004). The GFP-PRH plasmid encodes the entirety of PRH in frame with GFP, resulting in 
expression of a fusion protein (both plasmids were previously constructed in the laboratory 
and are described in Materials and methods section 4.12). Whole cell protein extracts from 
untransfected cells and transfected cells were Western blotted as described above. Figure 
3.4 shows that as expected a protein of approximately 37 kDa corresponding to endogenous 
PRH is recognised in extracts from un-transfected (lane 1) and transfected cells (lanes 2 and 
3). Unexpectedly there is not an additional protein band detected by the M6 antibody that  
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Figure 3.3: PRH knockdown can be detected by the mouse monoclonal anti-PRH antibody. MDA-MB-231 cells
were infected with lentivirus coding for IPTG inducible shRNA targeting either PRH or a control shRNA that does
not target any known mammalian gene. Selection for transfected cells was then performed 48 hours post-
infection using 0.5 µg/ml puromycin; puromycin resistant mixed cell population cell lines were generated. The
shRNA was induced using 1mM IPTG for 7 days in both PRH and control shRNA cell lines. Cells were then lysed
and the protein was then analysed using Western blotting with M6, M3 and Lamin A/C antibodies.
Representative of three experiments.
Lamin A
M6
PRHControlshRNA
M335 kDa
35 kDa
55 kDa
Figure 3.4: Monoclonal mouse anti-PRH antibody detects endogenous PRH and exogenous GFP-PRH. MDA-MB-
231 extracts (20ug ) prepared from cells transfected with Myc-PRH or GFP-PRH expression plasmids were probed
using M6 antibody, Myc 9B11 monoclonal antibody and Lamin A/C rabbit polyclonal antibody. A triplet of bands
appear at 37kDa in all three samples. The M6 antibody also detects a faint triplet of bands at 72 kDa (lane 3).
Myc-PRH can be detected with the Myc 9B11 antibody but not the M6 antibody (lane 2). Lamin A/C was used as a
control for protein loading. Representative of three experiments.
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would correspond to the transfected Myc-tagged PRH protein (lane 2). Re-probing the blot 
with a Myc 9B11 antibody confirmed that Myc-PRH is present in the cell extract. In the GFP-
PRH transfected cell extracts an additional band is detected by the M6 antibody (lane 3). 
This band has a mobility of 72 kDa which is in accordance with the expected size of the GFP-
PRH fusion protein. This experiment was repeated several times by coworkers in the 
laboratory and always produced the same result. Thus it appears the Myc-PRH fusion 
protein is not recognised by the M6 antibody, although it does recognise the GFP-PRH 
fusion protein.  
 
In conclusion the M6 monoclonal antibody recognises endogenous PRH in haematopoietic 
and breast cell extracts, and it can also recognise recombinant GFP-PRH. However, it is 
unable to detect Myc-PRH. One reason for this could be that the presence of the Myc tag at 
the extreme N-terminus alters the conformation of the protein, occluding the M6 epitope 
adjacent to the homeodomain. This may be a consequence of the octameric nature of the 
protein as the N-terminus of the protein is known to interact with the homeodomain and C-
terminus  (Soufi et al., 2006). 
 
3.4 PRH expression in breast cell lines 
 
To compare PRH protein and mRNA expression levels in a range of breast tumour cell lines, 
the PRH mRNA levels were first determined in breast cell lines using the GOBO database, as 
described previously. A description of the molecular profile of each cell type is shown in 
table 3.1.  As can be seen in figure 3.5 (A), MDA-MB-231 cells express the highest amount of 
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Cell line ER PR HER2 Original tissue Cell type Form tumours 
in nude mice
HB2 Unknown Unknown Unknown Luminal 
epithelial cells 
from milk 
Epithelial No
MCF-10A Negative (Pilat, 
et al., 1996)
Negative (Hevir, 
et al., 2011)
Not amplified Human 
fibrocystic
Mammary tissue 
Epithelial No
BT20 Negative Negative Not Amplified Primary breast 
tumour
Epithelial Yes
BT474 Positive Positive Not Amplified Primary breast 
tumour
Weakly-
epithelial
Yes *
T47D Positive Positive Not Amplified Metastatic (PE) Epithelial Yes *
MCF-7 Positive Positive Not Amplified Metastatic (PE) Epithelial Yes *
ZR751 Positive Positive Not Amplified Metastatic
(Ascites)
Epithelial Yes *
MDA-MB-231 Negative Negative Not Amplified Metastatic (PE) Basal Yes
Table 3.1: Cell lines used for PRH expression analysis. Cell lines used in figure 3.5, detailing their Oestrogen Receptor
(ER), Progesterone Receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) status, as well as their
original tissues and their ability to form tumours in nude mice (data from Lacroix and Leclercq 2004, unless otherwise
stated) . * With oestrogen supplementation. PE = Pleural effusion
Figure 3.5: PRH expression from different breast cell lines. (A) Data from the GOBO database (Ringlér et al., 2011)
was extracted, and PRH mRNA expression data from different breast cell lines was plotted. (B) PRH protein
expression was quantified by densiometric quantification of two Western blots of cell lines using the M6 anti-PRH
antibody , and Lamin C as a loading control. Grey bars and red bars refer to basal cell lines, and blue bars refer to
luminal cell lines. (C) shows a representative Western Blot with 20μg of protein loaded for each cell line. Note HB2
cells are not featured in the GOBO database.
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PRH transcript, whilst BT20 and ZR751 cells express the lowest amounts. Protein extracts 
from each of these cell lines were then Western blotted with the M6 antibody. The M6 
antibody detects high levels of PRH protein expression in MDA-MB-231 cells, intermediate 
levels in MCF-10A, MCF-7, T47D and HB2 cells, and relatively low levels of expression in 
BT20, BT474 and ZR751 cells (figure 3.5 (C)). When two Western blots from two 
independent protein extracts taken for each cell line were quantified for PRH protein 
expression (as determined by the M6 antibody), using densitometric analysis and Lamin C as 
a loading control, the level of PRH protein expression is very similar to that observed for the 
PRH mRNA expression data from the GOBO database (figure 3.5 (B)). MDA-MB-231 cells 
express the most PRH, with BT20, BT474 and ZR751 cells expressing the lowest amounts. 
Therefore, PRH protein levels as detected by the M6 antibody correlate well with PRH 
mRNA expression data from the GOBO database. Moreover, the M6 antibody appears to be 
a useful antibody for investigating PRH protein in many cell lines. Additionally it can be 
concluded that PRH protein is expressed in normal breast cell lines and most tumour cell 
lines investigated.  
 
 
 
3.5 Characterising PRH expression in MCF-10A, MCF-7 and MDA-MB-231 cells 
 
To determine if there are differences in characterisation of PRH protein in luminal and basal 
cancer cells compared to normal cells, PRH protein stability and localisation was examined 
in MCF-10A, MCF-7 and MDA-MB-231 cells. The MCF-10A cell line represents a good model 
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for normal breast epithelial cell proliferation and differentiation, as it retains the ability to 
differentiate in a 3D culture model, where it forms acini reminiscent of breast 
differentiation to ducts and lobules (Debnath et al., 2003b). MCF-10A cells are not 
oestrogen dependent and are derived from the human fibrocystic breast epithelium (Soule 
et al., 1990a).  Gene expression profiling of MCF-10A cells has shown that they are similar to 
breast cells of basal origin (Charafe-Jauffret et al., 2005). The MCF-7 tumour cell line is an 
ER+ and PR+ cell line of luminal origin, whereas the MDA-MB-231 tumour cell line is an ER- 
and PR- cell line of basal origin (Lacroix and Leclercq, 2004a). 
 
As mentioned previously, PRH expression, stability and localisation has been characterised 
in human K562 leukaemic cells using in-house mouse or rabbit polyclonal antibodies. The 
mouse polyclonal antibody (M3) was raised against a GST-fusion protein containing the 
avian PRH N-terminal domain (Bess et al., 2003c). The rabbit YKN5 polyclonal antibody was 
raised against histidine tagged full length avian PRH protein (Soufi et al., 2009). Both 
antibodies specifically recognise a 37kDa band corresponding to PRH in human 
haematopoietic cells (Soufi et al., 2009). Western blotting experiments with extracts 
prepared from cells incubated with inhibitors of Protein Kinase CK2 (CK2), showed a loss of 
recognition of the 37kDa PRH protein with the rabbit antibody, but not with the mouse 
antibody (Soufi et al., 2009). Furthermore, incubation of PRH with CK2 and ATP lead to 
increased recognition of the phospho-protein by the YKN5 antibody, and decreased 
recognition by the M3 antibody (Soufi et al., 2009). Moreover, incubation of the phospho-
PRH protein by Calf intestinal phosphatase (CIP) increased recognition by the M3 antibody, 
and decreased recognition by the YKN5 antibody (Soufi et al., 2009). Thus the mouse M3 
antibody recognises hypophosphorylated PRH, whereas the YKN5 rabbit antibody 
Chapter 3. Characterisation of exogenous and endogenous PRH in multiple breast cell lines 
 
91 
 
recognises a phosphorylation-specific conformation of PRH (Soufi et al., 2009). The rabbit 
antibody  also recognises a truncated 27kDa phosphorylated PRH protein (PRHΔC) which 
plays a trans-dominant negative role over full length PRH in K562 leukaemic cells (Noy et al., 
2012c). Given that the phosphorylated PRH and PRHΔC forms of PRH represent proteins 
that are unable to repress PRH target genes, and can block the activity of 
hypophosphorylated PRH in leukaemic cells, it is of interest to determine the relative 
amounts of these proteins in normal and tumourgenic breast cells.  
 
To determine the endogenous levels of PRH, phosphorylated PRH and PRHΔC in MCF-10A, 
MCF-7 and MDA-MB-231 cells, whole cell extracts were probed with the M3, M6 and YKN5 
antibodies, and also with the Lamin A/C antibody as a protein loading control. In MCF-10A 
cells, a 37kDa PRH protein is detected by the M6, M3 and the YKN5 antibodies (figure 3.6, 
lane 1) showing that PRH and phosphorylated PRH is present in this cell line. The PRHΔC 
Figure 3.6: Detecting PRH in breast cell lines using M6, M3 and YKN5 antibodies. MCF-10A, MCF-7 and
MDA-MB-231 cell extracts (20μg) were probed with either M6, M3 or YKN5 anti-PRH antibodies. M6 detects
PRH protein in all 3 cell lines, whilst the M3 and YKN5 antibodies only detects 37kDa protein in MCF-10A and
MDA-MB-231 cells. The YKN5 antibody also detects the PRHΔC product in MCF-7 and MDA-MB-231 cells.
Representative of three experiments.
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product is not detected in this Western blot, although it is detected at very low levels in 
some MCF-10A lysates, therefore the PRHΔC product appears to be present in MCF-10A 
cells at low or variable levels.  
 
In MCF-7 cells, full length PRH protein is only detected by the M6 antibody (figure 3.6, lane 
2).  This suggests that the M6 antibody is more sensitive than the M3 and YKN5 antibodies, 
or that PRH is present in a conformation which can only be detected by the M6 antibody. 
The YKN5 antibody does however detect the PRHΔC product in this cell line. These results 
indicate that although PRH is present, little full length phosphorylated PRH is present, and 
most of the phosphorylated PRH is of the PRHΔC form. 
 
In MDA-MB-231 cells, full length PRH protein is detected by the M3, M6 and YKN5 
antibodies (figure 3.6, lane 3).  The M6 antibody in this cell line detects a triplet of proteins 
at 37kDa, whilst in the other 2 cell lines it only detects a doublet (also see figure 3.5 (C)). 
This suggests that another conformation of PRH is present in MDA-MB-231 cells which is not 
present in either MCF-10A or MCF-7 cells. The PRHΔC product is also detected in MDA-MB-
231 cells. Thus in MDA-MB-231 cells hypophosphorylated PRH, phosphorylated PRH and 
PRHΔC are present.  
 
In conclusion PRH is present in all of the cell types tested, but unexpectedly in MCF-7 cells 
the PRH conformations recognised by the YKN5 and M3 antibodies are either absent or at 
levels below detection. MDA-MB-231 tumour cells express all forms of PRH, and express a 
greater amount of PRH detected by the M6 antibody compared to MCF-10A cells. An 
interesting finding is that the PRHΔC protein is present in both tumour cell lines, as well as in 
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normal cells. However, this protein appears to be expressed at a higher level relative to full 
length PRH in MCF-7 cells.  
 
3.6 Characterising PRH protein localisation in MCF-10A, MCF-7 and MDA-MB-231 cells 
 
To examine the subcellular localisation of PRH proteins detected by M6 antibody in MCF-
10A cells, immunostaining with the M6 and YKN5 antibodies was carried out and proteins 
visualised using confocal microscopy. Insufficient M3 antibody was available for these 
immunofluorescence experiments. Experimental details are outlined in Materials and 
methods section 2.6.1 and immunostaining and confocal imaging were carried out by Emma 
Fallon and Dr. Rachael Kershaw. Briefly, cells were plated onto cover slips and fixed with 4% 
formaldehyde. The cells were then permeabilised using 0.2% triton and proteins denatured 
using 0.5% SDS to allow better exposure of the antibody epitopes. The cells were then 
incubated with the M6 or YKN5 antibodies, and secondary anti-mouse FITC conjugated 
antibody (for M6, λ emission 520nm) and anti-rabbit TRITC conjugated antibody (for YKN5, λ 
emission 572nm). Cells were also incubated with TO-PRO-3 Iodide, a DNA binding dye that 
was used for nuclei staining (λ emission 660nm). The fluorescence maxima for emission for 
the three fluorophores differ sufficiently to allow co-staining.  
 
Figure 3.7 (A) shows that the M6 antibody (green) predominantly stains PRH in the 
cytoplasm, with fainter staining in the nucleus. The YKN5 antibody (red) stains for 
phosphorylated PRH predominantly in the nucleus, with fainter cytoplasmic staining. 
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Indicating that phosphorylated PRH is predominantly nuclear. TO-PRO-3 staining appears 
blue in the nuclei.  
 
To further examine the subcellular localisation of PRH proteins, biochemical fractionation 
followed by Western blotting with PRH antibodies  was  carried out as described by 
Desjobert et al. (Desjobert et al., 2009). Briefly, 1x106 cells were pelleted, and incubated in 
buffer containing NP-40 detergent. This lyses the cytoplasmic membrane, but does not 
disrupt the nuclear membrane. The nuclei were obtained by centrifugation, and the 
supernatant containing the post-nuclear fraction was removed and frozen. The remaining 
pellet was lysed using buffer containing 0.1% w/v sodium dodecyl sulphate (SDS), which 
disrupts the nuclear membrane. The extract was then pelleted and the supernatant which 
contains the soluble nuclear fraction was then frozen. An equal percentage of protein from 
each fraction was then loaded onto a SDS-PAG electrophoresis gel, Western blotted and 
probed using the M3, M6 and YKN5 antibodies. The quality of the subcellular fractionation 
was assessed by blotting with antibodies for the nuclear protein Lamin A/C and for the 
cytoplasmic protein Tubulin. The nuclear fractionation contains proteins which are tightly 
held in the nucleus, whilst the post-nuclear fraction contains cytoplasmic proteins as well as 
proteins which are not tightly held in the nucleus (Desjobert et al., 2009).  Figure 3.7 (B) 
shows that for MCF-10A cells, PRH protein as detected by the M6 antibody is present in 
both the nuclear and post-nuclear fractions. The YKN5 antibody detects 37kDa 
phosphorylated PRH in the nuclear fraction, which is in agreement with the 
immunostaining. In these extracts no PRHΔC is detectable. The M3 antibody detects PRH in 
the post-nuclear fraction, indicating this form of PRH is either cytoplasmic or is not tightly 
held to the nucleus. The Tubulin and Lamin A/C antibodies indicate that the fractionation 
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was efficient. The fractionation was carried out twice independently with identical results. 
In summary PRH is present in the cytoplasm and nucleus of MCF-10A cells. However, the 
forms of PRH detected by each antibody differ in their nuclear retention properties, with full 
length phosphorylated PRH being tightly retained in the nuclear compartment.  
 
Immunostaining was carried out for MCF-7 cells exactly as described above by Dr. R. 
Kershaw and E. Fallon. The immunostaining shows that the M6 antibody predominantly 
detects PRH in the cytoplasm, with very faint staining in the nucleus. The YKN5 antibody 
detects protein in both the nucleus and cytoplasm of the cells (Figure 3.8 (A)). Biochemical 
fractionation of MCF-7 cells was then carried out as described above. The YKN5 antibody 
detects the PRHΔC protein product alone, and this is only detected in the post-nuclear 
Figure 3.7: PRH localisation in MCF-10A cells. (A) MCF-10A cells were immunostained with the M6 and YKN5
antibodies, and were also incubated with TO-PRO-3 to stain for nuclei. Cells were then stained with FITC (for M6)
and TRITC (for YKN5) secondary conjugated antibodies, against murine and rabbit IgG respectively. Pictures were
taken at 400x magnification. (B) MCF-10A cells were biochemically fractionated into nuclear (N) and post-nuclear
(PN) fractions as described in the text. The fractions were then Western blotted for PRH expression using M6, M3 and
YKN5 antibodies. Lamin A/C and Tubulin antibodies were used as loading controls for nuclear and post-nuclear
fractions respectively. Representativeof two experiments.
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fraction. This therefore suggests that the nuclear PRH detected by the YKN5 antibody during 
immunostaining is not tightly held. After fractionation the M6 antibody predominantly 
detects PRH in the nuclear fraction, although there is a fainter band in the post-nuclear 
fraction as well (figure 3.8 (B)). The M3 antibody was not used as it fails to detect PRH 
protein in this cell type (figure 3.6). In MCF-7 cells there is weak diffuse nuclear PRH staining 
and strong PRH staining appears localised in the cytoplasm, as detected by immunostaining. 
This is similar to the staining observed in MCF-10A cells. Unexpectedly, biochemical 
fractionation indicates that the PRH protein detected by M6 antibody is associated with the 
nuclear and tightly held protein fraction, with weaker staining in the cytoplasmic/post-
nuclear protein fraction. Since there is little full length phosphorylated PRH protein in MCF-7 
cells, it can be inferred that the YKN5 antibody in immunostaining is detecting the PRHΔC 
protein, which is present in both compartments but is not tightly held in the nuclear 
fraction.  
 
In MDA-MB-231 cells, PRH protein as determined by the M6 antibody seems to be 
predominantly cytoplasmic as determined by immunostaining, but M6 also detects some 
nuclear PRH protein (figure 3.9 (A)). Therefore the distribution of PRH protein as determined 
by immunostaining for MDA-MB-231 cells with M6 antibody is similar to that of MCF-10A 
and MCF-7 cells. The YKN5 antibody detects nuclear and cytoplasmic phosphorylated PRH in 
immunostaining (figure 3.9 (A)). Biochemical fractionation of MDA-MB-231 cell extracts 
probed with the M6 antibody shows that PRH protein is predominantly retained in the 
nuclear fraction, although some is still present in the post-nuclear fraction (figure 3.9 (B)).  
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MCF-7
Figure 3.8: PRH localisation in MCF-7 cells. (A) MCF-7 cells were immunostained with the M6 and YKN5 antibodies,
and were also incubated with TO-PRO-3 to stain for nuclei. Cells were then stained with FITC (for M6) and TRITC (for
YKN5) secondary conjugated antibodies, against murine and rabbit IgG respectively. Pictures were taken at 630x
magnification. (B) MCF-7 cells were biochemically fractionated into nuclear (N) and post-nuclear (PN) fractions as
described in the text. The fractions were then stained for PRH expression using M6 and YKN5 antibodies. Lamin A/C
and Tubulin antibodies were used as loading controls for nuclear and post-nuclear fractions respectively.
Representative of two experiments.
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Figure 3.9: PRH localisation in MDA-MB-231 cells. (A) MDA-MB-231 cells were immunostained with the M6 and
YKN5 antibodies, and were also incubated with TO-PRO-3 to stain for nuclei. Cells were then stained with FITC (for
M6) and TRITC (for YKN5) secondary conjugated antibodies, against murine and rabbit IgG respectively. Pictures
were taken at 630x magnification. (B) MDA-MB-231 cells were biochemically fractionated into nuclear (N) and post-
nuclear (PN) fractions as described in the text. The fractions were then stained for PRH expression using M6, M3 and
YKN5 antibodies. Lamin A/C and Tubulin antibodies were used as loading controls for nuclear and post-nuclear
fractions respectively. Representative of two experiments.
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The YKN5 antibody primarily detects 37kDa phosphorylated PRH protein in the nuclear 
fraction, and the PRHΔC protein product is primarily detected in the post-nuclear fraction. 
The M3 antibody detects full length PRH protein in the post-nuclear fraction (figure 3.9 (B)).  
 
In summary, immunostaining in the three cell lines gave similar results when probed with 
the M6 antibody, which showed that PRH is predominantly present in the cytoplasm, with 
fainter nuclear staining. Biochemical fractionation experiments indicate that PRH proteins 
fractionate in a similar way in all three cell lines, and therefore there is no difference 
detected in PRH localisation between the non-tumourgenic MCF-10A cells and the 
tumourgenic MCF-7 and MDA-MB-231 cells, as detected by these assays.  However, the 
differences between detection of PRH by M6 and M3 antibodies, as determined by Western 
blotting, is not likely due to sensitivity, since M3 detects PRH in the post-nuclear fraction, 
and M6 detects PRH in the nuclear fraction.  Also, phosphorylated full length PRH is detected 
in MCF-10A and MDA-MB-231 cells, whilst it is present at very low levels in MCF-7 cells by 
the YKN5 antibody. However, the YKN5 antibody does detect PRHΔC in MCF-7 cells.  
 
3.7 Determining the stability of PRH in MCF-10A, MCF-7 and MDA-MB-231 cells 
 
Transcription factors are often regulated by post-transcriptional modifications or proteolytic 
processing. PRH protein is regulated by phosphorylation and proteosomal processing in 
K562 cells (Noy et al., 2012c). The product of the processing, PRHΔC, has trans-dominant 
activity over the transcriptional repression activity of PRH in leukaemic cells. Since the 
cancer cell types express phosphorylated PRH and PRHΔC at different ratios from that 
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observed in MCF-10A cells it was hypothesised that the three different breast cell types may 
have intrinsic differences in PRH stability and activity. 
 
To assess the stability of PRH we chose to examine the stability of the PRH protein detected 
by the M6 antibody. MCF-7, MDA-MB-231 and MCF-10A cells were incubated with 10µg/ml 
of the translation inhibitor anisomycin for 8 and 16 hours, or left untreated (time 0). The 
cells were then lysed, protein extracts produced and Western blotted as previously 
described, and lysates were probed with the M6 antibody. Lamin antibody was used as a 
protein loading control. In MCF-10A cells, PRH protein is significantly decreased after 8 
hours anisomycin treatment, and has virtually disappeared after 16 hours (figure 3.10 (A)). 
In MCF-7 cells, the lower mobility protein of the PRH doublet is lost after 8 hours, but the 
faster mobility PRH protein remains present after 16 hours anisomycin treatment (figure 
3.10 (B)). In MDA-MB-231 cells, levels of expression for all PRH proteins have significantly 
decreased after 8 hours (figure 3.10 (C)).   
 
As the endogenous levels of PRH protein are quite different between the cell lines, this 
makes it difficult to compare stability of endogenous PRH. A more useful approach would be 
to determine whether there is a difference in the stability of exogenous Myc-PRH, which is 
detected only as a single protein by the Myc antibody. Therefore, the same experiment was 
carried out by infecting cells with an adenovirus that expresses the Myc-PRH protein. The 
Ad-PRH vector and infection of each cell with Ad-PRH virus are described in Materials and 
methods section 2.4 and in chapter 4 section 4.2.1. Briefly, cells were incubated with an 
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adenovirus expressing Myc-PRH (Ad-PRH) at a multiplicity of infection (MOI) of 50 for 24 
hours. Cells were then incubated with 10µg/ml anisomycin (or the corresponding amount of 
DMSO as a control) for 16 hours. Cells were then lysed, and protein extracts were produced. 
Myc-PRH expression was analysed using Western blotting with Myc 9B11 antibody. In MCF-
7 cells, Myc-PRH is degraded after 16 hours anisomycin treatment figure 3.11, lane 2), and 
this also occurs in MDA-MB-231 cells (figure 3.11, lane 4). However, in MCF-10A cells Myc-
PRH is still present even after 16 hours anisomycin treatment. This demonstrates that 
exogenous PRH is more stable in MCF-10A cells than in the two tumour cell lines.  
 
3.8 Subcellular fractionation of Myc-PRH in MCF-10A, MCF-7 and MDA-MB-231 cells 
 
To establish whether exogenous PRH is similar to endogenous PRH in its subcellular 
localisation, all three cell lines were infected with Ad or Ad-PRH for 48 hours, before 
biochemical fractionation. An equal percentage of nuclear and post-nuclear fraction lysate 
was loaded for each cell line. The fractions were then Western blotted and probed using the 
Myc and YKN5 antibodies (The M3 and M6 antibodies do not detect exogenous Myc-PRH). 
For clarity only fractions with Ad-PRH are shown. It can be seen that Myc-PRH is present in 
the post-nuclear fraction in all cell lines, as detected by Myc and YKN5 antibodies (figure 
3.12).   
 
Since exogenous Myc-PRH proteins in all cell lines are present in the post-nuclear fraction, 
the difference in stability between MCF-10A, MCF-7 and MDA-MB-231 cells cannot be 
accounted for by differences in subcellular localisation. Therefore, the decreased stability of 
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exogenous PRH in tumour cell lines compared to MCF-10A cells likely reflects increased 
proteolytic cleavage activities of cancer cells.  
 
 
3.9 Discussion 
 
Expression of PRH protein has been shown to be clinically relevant in human cancer. For 
example, expression of a NUP98-PRH fusion protein (which transforms PRH from a 
transcriptional repressor to a transcriptional activator) has been shown to be a causative 
event in acute myeloid leukaemia (Jankovic et al., 2008). Here it is shown that high PRH 
mRNA expression is also clinically relevant to breast cancer, as data extracted from the 
GOBO database shows that PRH mRNA expression is positively associated with increased 
overall survival in breast cancer patients. Therefore, PRH mRNA levels are a marker for 
Figure 3.12: Biochemical fraction of Myc-PRH in different breast cell lines. MCF-10A, MCF-7 and
MDA-MB-231 cells were infected with Ad-PRH for 48 hours. Cells were then biochemically
fractionated into nuclear (N) and post-nuclear (PN) fractions as described in the text. The fractions
were then stained for Myc-PRH expression using Myc 9B11 and YKN5 antibodies. Lamin A/C and
Tubulin antibodies were used as loading controls for nuclear and post-nuclear fractions respectively
(n=3).
PN     N
YKN5-PRH
Myc-PRH
Tubulin
Lamin A/C
35 kDa
35 kDa
55 kDa
55 kDa
MCF-7MCF-10A MDA-MB-231
1      2        3     4     5       6
PN     N PN     N
Chapter 3. Characterisation of exogenous and endogenous PRH in multiple breast cell lines 
 
103 
 
overall survival in breast cancer, like the well known tumour suppressor PTEN. PRH mRNA 
expression is also generally correlated with the less aggressive forms of breast cancer, with 
PRH expression highest in ER+, Luminal A and grade 1 and 2 breast cancers, and lowest in 
basal, HER2 amplified, ER- and grade 3 breast cancers.  
 
A new M6 monoclonal antibody against PRH shows that the relative amounts of PRH protein 
correlate well with the relative amount of PRH mRNA, as determined by the GOBO 
database. Therefore it is concluded that the M6 antibody gives an accurate representation 
of PRH mRNA expression in breast cells. This antibody therefore may be a useful tool for 
further work, for example for assessing PRH protein levels in primary tumour cells, and how 
these levels compare with patient prognosis. It would also be of interest to determine 
whether this antibody shows decreased PRH staining in tumour cells compared to adjacent 
normal breast tissue.  
 
It has been shown previously that PRH protein is present in both nuclear and cytoplasmic 
compartments in normal breast cells, whilst PRH protein is predominantly cytoplasmic in 
breast carcinomas (Puppin et al., 2006). Puppin et al. also showed that T47D and MCF-7 cell 
lines contain predominantly cytoplasmic/nucleolar PRH in immunohistochemistry 
experiments with an antibody against human PRH. In immunostaining experiments with M6 
antibody it is shown that PRH is predominantly present in the cytoplasm in MCF-10A, MCF-7 
and MDA-MB-231 cells, however some protein is also present in the nucleus of all three cell 
lines. Biochemical fractionation also showed that in all cell lines M6 antibody detects PRH 
protein in both the nuclear and post-nuclear fractions. No significant differences in 
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localisation of PRH protein were seen with the M6 antibody in in vitro fractionation 
experiments between non-tumourgenic MCF-10A cells and the tumourgenic cell lines MCF-7 
and MDA-MB-231, as determined by these assays. However, further experiments performed 
by E. Fallon and Dr. R.Kershaw show that even though PRH is predominately cytoplasmic in 
all three cell lines, there is more tightly held nuclear PRH in MCF-10A cells compared to the 
tumour cells, as determined by in situ biochemical fractionations (R. Kershaw, E. Fallon and 
P.S. Jayaraman, personal communication). This finding correlates with what was seen by 
Puppin et. al., who showed that nuclear PRH is decreased in breast carcinomas (Puppin et 
al., 2006). The differences between the in vitro and the in situ fractionation experiments 
may have to do with the different compositions of the buffers used in the two protocols.  
 
Next the stability of PRH protein was examined in all three cell lines. It is not easy to 
compare the stability of endogenous PRH protein between cell lines using the M6 antibody 
as the antibody detects multiple forms of the protein each of which may have a different 
stability and because the steady state (starting levels) of the PRH proteins detected are 
extremely different. For example, endogenous PRH is expressed at much higher levels in 
MCF-10A cells than in MCF-7 cells. Western blotting with the M6 antibody would very likely 
detect a small decrease in the low level of PRH protein in MCF-7 cells but would not be able 
to detect the same decrease in PRH protein levels in MCF-10A cells. Therefore it was 
thought that is would be more informative if the stability of exogenous PRH protein was 
examined using Myc-PRH infected cells. In both tumour cell lines exogenously expressed 
PRH was less stable than in normal breast cells. Decreased PRH stability could be one 
mechanism through which PRH activity is downregulated in tumour cells. To determine the 
mechanism by which PRH protein is degraded in breast tumour cells, CK2 inhibitor TBB, 
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proteasome inhibitor MG132 and caspase inhibitors Z-VAD-FMK were used. However, these 
experiments were inconclusive due to the effect these compounds have on cell viability 
(data not shown).  Further experiments with CK2 and proteasome inhibitors will be required 
to investigate the mechanism responsible for the degradation of PRH in the three different 
cell lines. However the finding that PRH is expressed in tumour cell lines, and that its 
stability may be decreased in tumour cell lines is of consequence given that high PRH 
expression correlates with increased overall survival.  
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4.  The effect of PRH on normal and tumourgenic 
breast cell population growth 
 
4.1 Introduction 
 
PRH has been shown to influence the proliferation of cells in a variety of cell types. In K562 
leukaemic cells, over-expression of PRH leads to apoptotic cell death and decreased cell 
number, whilst shRNA knockdown of PRH increases cell number (Noy et al., 2010). In K562 
cells this has been shown to occur through increased survival signalling via elevated 
expression of the VEGF gene and VEGF receptor genes, as a consequence of derepression of 
multiple genes in the VEGF signalling pathway (Noy et al., 2010). Manipulation of PRH levels 
in MCF-7 cells also leads to changes in cell number and modulation of expression of VEGF 
signalling genes (Noy et al., 2010), but the effects of PRH on cell proliferation, cell survival 
and VEGF signalling have not been fully analysed in this cell type.  To further investigate the 
role of PRH in the growth of normal breast cells and breast tumour cells, the effect of 
exogenous PRH on cell number, apoptosis and proliferation will be determined in MCF-10A 
cells, MCF-7 cells and MDA-MB-231 cells. In addition the effect of knockdown of PRH on cell 
survival and proliferation will also be examined in the same cell lines. Finally the effect of 
alterations in PRH level on the expression of genes in the VEGF signalling pathway will be 
examined. 
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4.2 Effect of PRH overexpression on breast cell proliferation and survival 
 
4.2.1  Effect of PRH overexpression on cell number 
 
Adenoviruses were used to overexpress PRH in MCF-10A, MCF-7 and MDA-MB-231 cell 
lines. Adenoviruses are DNA viruses and are a useful experimental tool for transgene 
expression, as transfection efficiencies can reach 100% and can infect many mammalian cell 
types. The adenovirus which allows for exogenous PRH expression (henceforth known as 
Ad-PRH) contains a gene coding for the Myc-PRH fusion protein as described previously 
(chapter 3 section 3.3), cloned into the pDC-515 vector backbone (Soufi et al., 2006) (for 
plasmid map see Materials and methods section 2.12). Transgene expression is under the 
control of the murine cytomegalovirus (MCMV) promoter. An empty adenovirus which does 
not code for protein (Rad 66, referred to as Ad (Akrigg, 1992)), was used as a control, 
because expression of other control proteins (such as β-Galactosidase and GFP) could 
themselves exert effects on cell growth. To determine which multiplicity of infection (MOI) 
to use, MCF-7 cells were plated in 6-well plates at equal number, and infected with Ad at a 
MOI of 50 or 500, or left uninfected. Cells were then counted after 2 days to determine 
whether either viral load is toxic to cells.  Figure 4.1 (A) shows that for MCF-7 cells, a MOI of 
500 of control Ad reduces cell number, whilst a MOI of 50 seems to have little effect. To 
demonstrate that a MOI of 50 is not toxic in MCF-10A, MCF-7 and MDA-MB-231 cell lines, 
cells were left uninfected or infected with Ad at a MOI of 50 and equal numbers plated in 6-
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well plates. Cells were counted 2 days post-infection as described previously (figure 4.1 (B)). 
It can be seen that at an MOI of 50 Ad has little or no effect on cell viability in all cell lines. 
 
To determine whether infection of cells with Ad-PRH at MOI of 50 results in expression of 
Myc-PRH protein, MCF-10A, MCF-7 and MDA-MB-231 cells were infected with Ad and Ad-
PRH. Whole cell extracts were made 48 hours post-infection, and proteins were separated 
by SDS-PAGE and Western blotted with Myc 9B11 antibody as described in Materials and 
methods section 2.3. Figure 4.2 shows that Myc-PRH is expressed in all of the cell types 
tested and that no expression is detected in cells infected with control adenovirus. 
Therefore, it was determined that an MOI of 50 was to be used for all further 
overexpression experiments. 
 
To determine the effect of Myc-PRH expression on cell number for each cell line, cells were 
infected with Ad or Ad-PRH, and plated at equal cell number. Cell number was then counted 
every two days, using a haemacytometer and trypan blue for 6 days. Trypan blue staining 
allows the identification of viable cells as trypan blue dye is excluded from living cells 
(Strober, 2001). Figure 4.3 (A) shows that there are significantly fewer live Ad-PRH infected 
MCF-10A cells compared to Ad infected MCF-10A cells 4 days post infection. Similarly there 
are significantly fewer Ad-PRH infected MCF-7 cells than control Ad infected MCF-7 cells 6 
days post-infection (figure 4.3 (B)). However, in MDA-MB-231 cells, there was no difference 
in cell number between Ad-PRH and Ad control cells after 4 days, where the cells were 90% 
confluent (figure 4.3 (C)). To determine whether a reduction in MDA-MB-231 cells would be 
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Figure 4.1: Determining a useful multiplicity of infection (MOI). (A) 1x105 MCF-7 cells were
uninfected, or infected with control adenovirus at a MOI of 50 or 500. Cells were then counted 48
hours later using a haemacytometer and trypan blue exclusion dye. (B) MCF-10A, MCF-7 and
MDA-MB-231 cells were either uninfected or infected with Ad at a MOI of 50.
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Figure 4.2: Ad-PRH infection leads to PRH overexpression. (A) MDA-MB-231, MCF-7 and MCF-
10A cells were infected with control adenovirus (Ad) or PRH overexpressing adenovirus (Ad-PRH)
at a MOI of 50. 20μg of protein was Western blotted using Myc 9B11 antibody to detect
exogenous PRH expression. Lamin A/C was used as a loading control. (B) PRH gene expression
was carried out as in Materials and methods section 2.8, and analysed using quantitative PCR,
and quantified using the Pfaffl method (Pfaffl, 2001), using GAPDH as a housekeeping gene.
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seen at a later time point, the cells were re-plated at a lower density on day 4 and counted 
at 8 days post-infection. The total number of cells that would have grown was calculated 
from multiplying the cell number at day 8 and the cell dilution at replating on day 4. Figure 
4.3 (C) shows that at day 8 there is no significant difference between Ad and Ad-PRH 
infected cells. It can be concluded that Ad-PRH inhibits the rate of increase of the 
population of MCF-10A and MCF-7 cells but has apparently little effect on the rate of 
increase of the MDA-MB-231 cell population.  
 
4.2.2 DNA binding is required for PRH to decrease cell number in MCF-7 cells 
 
To determine whether the effect of ectopic PRH expression on cell number in MCF-7 cells 
requires DNA binding activity, cells were infected with an adenovirus expressing a mutated 
Myc-PRH protein. The mutated protein contains a point mutation in the homeodomain  
(N187A), that prevents PRH from forming PRH-DNA complexes (Desjobert et al., 2009; Soufi 
et al., 2010). It has also been shown that in K562 leukaemic cells, the PRH N187A mutant 
cannot repress transcription of the VEGF gene or induce apoptosis (Noy et al., 2010). 
 
MCF-7 cells were infected with Ad, Ad-PRH or Ad-N187A adenovirus at a MOI of 50, and 
expression of Myc-tagged PRH protein was checked after 24 hours with the Myc 9B11 
monoclonal antibody and Western blotting as described above. Figure 4.13 (A) shows that 
the PRH-N187A adenovirus is expressed at a higher level compared to wild-type PRH. 
Infected cells were counted over a period of six days post infection. Figure 4.13 (B) shows 
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Figure 4.3: Ad-PRH decreases breast cell growth
rate. 500,000 MCF-10A (A), MCF-7 (B) or MDA-
MB-231 (C) cells were infected with either Ad-PRH
or Ad control at a MOI of 50. Cells were then
trypsinised and counted using a haemacytometer
and trypan blue exclusion dye as described in the
text (n=3, p<0.05 two-tail homoscedastic t-test).
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Figure 4.4: DNA binding activity is required for PRH to decrease MCF-7 cell number. (A) 500,000
MCF-7 cells were infected with either Ad-PRH, Ad-PRH N187A or Ad control at a MOI of 50. Cells were
then lysed and Western blotted with the Myc 9B11 monoclonal antibody to detect exogenous PRH. (B)
Cells were infected with Ad, Ad-PRH and Ad-PRH N187A viruses as before, and were plated in equal
numbers in a T75 cm2 flask. Cells were then incubated with trypsin and counted 6 days post-infection
using a haemacytometer and trypan blue exclusion dye (n=3,3,3 one way ANOVA with Games-Howell
post-hoc *p<0.05).
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that the number of Ad-N187A infected cells is similar to that of Ad infected cells, whilst the 
number of Ad-PRH infected cells is significantly lower compared to the number of Ad-PRH 
N187A infected cells. Therefore, this implies that PRH needs to bind to DNA to bring about 
its growth inhibitory effects in MCF-7 cells.  
 
4.2.3  Effect of PRH over-expression on apoptosis 
 
Changes in cell number in MCF-10A and MCF-7 cells observed above could be caused by 
either increased cell apoptosis or decreased cell proliferation. To determine whether Ad-
PRH increases apoptosis in these cell lines, co-staining of cells with propidium iodide and 
Annexin-V-APC conjugated protein was carried out.  Both adherent and floating cells were 
retrieved from flasks by centrifugation. The DNA staining dye propidium iodide  (PI) will only 
bind to the DNA of cells that do not have an intact cell membrane (Jones and Senft, 1985). 
Staining with PI therefore assesses the number of viable and dying cells. Phospatidylserine is 
normally found only in the inner cell membrane in viable cells, however when cells undergo 
apoptosis this protein is present in the outer membrane where it can be detected by the 
Annexin V-APC conjugated protein (Bret Verhoven, 1995). PI and Annexin V-APC have 
different fluorescence emission maxima allowing simultaneous detection of both reagents 
using a flow cytometer (λ617nm for PI and λ660nm for APC). Flow cytometry of cells co-
stained with both PI and Annexin V-APC allows discrimination between viable cells, early 
and late apoptosis and cells dying through other mechanisms. Thus viable cells are cells 
which are not stained with either reagent, early apoptotic cells are stained with Annexin V-
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APC but not PI, late apoptotic cells stain with both Annexin V and PI and cells that are dying 
but not apoptotic stain only with PI. The distribution of viable cells and apoptotic cells in Ad 
and Ad-PRH infected MCF-7 cells is shown in a scatter plot (figures 4.5 (A) and (B)). Figure 
4.5 (B) shows that Ad-PRH increases the percentage of apoptotic cells from 15% to 26% in 
this experiment. The experiment was repeated three times and the mean and standard 
error are represented in figures 4.5 (C) and (D). It can be seen that two days post-infection 
there are slightly more apoptotic cells in the Ad-PRH population than in the control Ad 
population, however this change is not statistically significant (figure 4.5 (C)). However after 
4 days there is a significant increase in the total number of early apoptotic cells (figure 4.5 
(D)). This correlates with a significant decrease in the percentage of non-apoptotic cells 
detected (figure 4.5 (D)). Therefore, overexpression of PRH in MCF-7 cells causes a decrease 
in cell number, which can be explained at least in part by an increase in apoptosis of these 
cells.  
 
In MCF-10A cells, there is no significant increase in apoptotic cells either 2 days or 4 days 
post infection with Ad-PRH compared to Ad (figure 4.6). This shows that the decrease in 
MCF-10A cell number caused by PRH overexpression in figure 4.3 is not through increased 
apoptosis. 
 
MDA-MB-231 cells were also assessed, to see whether Myc-PRH had any effect on cell 
apoptosis. MDA-MB-231 cells were infected with Ad or Ad-PRH as described previously, and 
Annexin V/PI assays were carried out 2 and 4 days post-infection as described above.  There 
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Figure 4.5: Ad-PRH increases apoptosis in
MCF-7 cells. MCF-7 cells were incubated
with control Ad or Ad-PRH for either 2 (C) or
4 (D) days, before being stained with
10µg/ul propodium iodide and 5µl of
Annexin V-APC antibody (BD Biosciences).
Cells were then analysed by flow
cytometery to determine live cells (PI-, AV-),
or apoptotic cells (PI-, AV+ or PI+. AV+).
Representative plots are shown for Ad (A)
and Ad-PRH (B) infected cells at 4 days post
infection (n=3, two-tail homoscedastic t-test
*p<0.05).
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Figure 4.6: Ad-PRH does not increase apoptosis in MCF-10A cells. MCF-10A cells were incubated with
control Ad or Ad-PRH for either 2 (A) or 4 (B) days, before being stained with 10µg/ul propodium iodide
and 5µl of Annexin V-APC antibody (BD Biosciences). Cells were then analysed by flow cytometery to
determine live cells (PI-, AV-), or apoptotic cells (PI-, AV+ or PI+. AV+) (n=3, two-tail homoscedastic t-
test).
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is no statistically significant difference between the proportions of viable, early apoptotic 
and late apoptotic cells at either 2 or 4 days post-infection (figure 4.7). The rate of apoptosis 
however is quite high in these cells (approximately 30%, compared to around 10-15% for 
MCF-10A and MCF-7 cells). This could be due to this cell line being particularly sensitive to 
trypsin, or the flow cytometery process.  
 
4.2.4  Effect of overexpressed PRH on cell proliferation 
 
To determine whether the decrease in cell number observed upon PRH overexpression in 
MCF-10A and MCF-7 cells is through alterations in cell proliferation, two assays were carried 
out. The first assay was a cell cycle assay, which measures the percentage of cells in each 
phase of the cell cycle through intensity of PI staining. During G1 phase, the cell has 2N 
number of chromosomes (diploid in normal human cells, although many cancer cells tend to 
Figure 4.7: Ad-PRH does not increase apoptosis in MDA-MB-231 cells. MDA-MB-231 cells were
incubated with control Ad or Ad-PRH for either 2 (A) or 4 (B) days, before being stained with 10μg/μl
propodium iodide and 5μl of Annexin V-APC antibody (BD Biosciences). Cells were then analysed by
flow cytometery to determine live cells (PI-, AV-), or apoptotic cells (PI-, AV+ or PI+. AV+) (n=3, two-
tail homoscedastic t-test).
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have large chromosomal abnormalities). As the cell progresses through S phase, the amount 
of total DNA in the cell increases until the cell has reached G2 phase, where the cell now 
possesses 4N number of chromosomes (tetraploid in normal human cells). Therefore, the 
proportion of cells at different stages of the cell cycle can be identified by DNA content 
(Krishan, 1977). The assay involves the incubation of cells with PI, which binds non-
specifically to DNA by intercalating between the base pairs (Krishan, 1975). As PI cannot 
penetrate through the cell membrane, cells are first permeabilised with 1% IGEPAL. Flow 
cytometry is then used to differentiate cells that stain brightly with PI (G2/M) from those 
that stain more weakly (G1). To show that this assay can be used to examine growth arrest, 
that is an increase in the percentage of cells in the G1 or G2 phase of the cell cycle, MCF-7 
cells were treated 1mM hydroxyurea for 24 hours. Hydroxyurea is a DNA synthesis inhibitor, 
that does not allow the cell to progress past S-phase, thus arresting cells in G1 (Koç et al., 
2004). Figure 4.8 shows that hydroxyurea induces G1 arrest.  
 
Untreated Hydroxyurea
Figure 4.8: Hydroxyurea causes an increase in G1 phase. MCF-7 cells were incubated with
1mM hydroxyurea (or left untreated) for 24 hours, before being permeabilised with 1%
IGEPAL, and DNA stained with 50μg/ml propidium iodide. Cells were then analysed by flow
cytometery to determine cell cycle phase.
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Figure 4.9: Ad-PRH does not affect cell cycle distribution in MCF-10A cells. MCF-10A cells were
incubated with control Ad or Ad-PRH for either 2 (A) or 4 (B) days, before being permeabilised
with 1% IGEPAL, and DNA stained with 50μg/ml propidium iodide. Cells were then analysed by
flow cytometery to determine cell cycle phase (n=3, two-tail homoscedastic t-test).
(A) (B)
2 Days 4 Days
0
10
20
30
40
50
60
G1/0 S G2/M
P
e
rc
e
n
ta
ge
 o
f 
ce
lls
Cell cycle phase
Ad-
PRH
Ad
0
10
20
30
40
50
60
G1/0 S G2/M
P
e
rc
e
n
ta
ge
 o
f 
ce
lls
Cell cycle phase
Ad-
PRH
Ad
Figure 4.10: Ad-PRH does not affect cell cycle distribution in MCF-7 cells. MCF-7 cells were
incubated with control Ad or Ad-PRH for either 2 (A) or 4 (A) days, before being permeabilised with
1% IGEPAL, and DNA stained with 50μg/ml propidium iodide. Cells were then analysed by flow
cytometery to determine cell cycle phase (n=3, two-tail homoscedastic t-test).
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Cell cycle staining was carried out with Ad-PRH and control Ad infected MCF-10A, MCF-7 
and MDA-MB-231 cells at 2 and 4 days post-infection. In MCF-10A cells there is no 
significant difference in the cell cycle distribution at either 2 or 4 days post infection (figure 
4.9). In MCF-7 cells, there is also no significant change in cell cycle between the Ad and Ad-
PRH infected cells at either 2 or 4 days post-infection (figure 4.10). However, Ad-PRH did 
have a significant effect on cell cycle in MDA-MB-231 cells, as the proportion of Ad-PRH 
infected cells in G1 phase was increased compared to cells infected with control Ad at both 
2 and 4 days post-infection (figure 4.11).  
 
Figure 4.11: Ad-PRH increases the proportion of cells in G1 phase in MDA-MB-231 cells. MDA-MB-231
cells were incubated with control Ad or Ad-PRH for either 2 (A) or 4 (B) days, before being
permeabilised with 1% IGEPAL, and DNA stained with 50μg/ml propidium iodide. Cells were then
analysed by flow cytometery to determine cell cycle phase. Representative plots are shown in (C) and
(D) for Ad and Ad-PRH respectively 4 days post infection, with (E) showing an overlay of the two plots
(n=3, two-tail homoscedastic t-test *p<0.05).
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A more direct assay to measure rate of cell proliferation is the bromodeoxyuridine (BrdU) 
incorporation assay. BrdU is a nucleoside which can substitute for thymidine during DNA 
replication. Cells are incubated with 5’-bromodeoxycytidine, which is deaminated to BrdU 
by the cell. The incorporated BrdU is then detected by immunohistochemistry using 
antibodies against BrdU, and secondary or tertiary antibodies conjugated to horse radish 
peroxidase (HRP). When tertiary antibodies are used the signal from the primary antibody is 
amplified by use of a biotinylated secondary antibody. The uptake of BrdU can be quantified 
by scoring for HRP staining, and the rate of uptake over a defined time is used as a measure 
of the rate of proliferation (Hoshino T, 1985).   
 
BrdU assays were performed as described in Materials and methods section 2.6.2. A sub-
selection of slides was also blindly double-scored to ensure there was no bias in counting. In 
MCF-10A cells, very few cells infected with Ad-PRH incorporate BrdU, indicating that PRH 
significantly inhibits proliferation in MCF-10A cells (figure 4.12). Significantly, the Ad-PRH 
N187A mutant has no effect on MCF-10A proliferation. This demonstrates that PRH needs to 
bind to DNA to produce its proliferation inhibitory phenotype (figure 4.12).  MCF-7 cells 
could not be assessed for BrdU staining, as Ad-PRH infected cells would not stay attached to 
the plate when plated at the densities required for this protocol. In MDA-MB-231 cells, Ad-
PRH infected cells incorporate significantly less BrdU than control Ad infected cells, 
indicating that they are less proliferative (figure 4.13). Again, Ad-PRH-N187A had little effect 
on proliferation, as BrdU uptake was similar to control cells. This demonstrates that PRH 
needs to bind to DNA to carry out its anti-proliferative effect in MDA-MB-231 cells (figure 
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Ad-PRH
Ad
Figure 4.12: Overexpression of PRH inhibits MCF-
10A proliferation as determined by BrdU staining.
MCF-10A cells were infected with Ad or Ad-PRH as
described previously. 5x105 cells were then seeded
on a 6-well plate and left for 48 hours, and were
then incubated with 10µM BrdU for 6 hours. Cells
were then fixed and stained for BrdU positivity as
described in text (n=3,3,2, one way ANOVA with
Games-Howell post-hoc *p<0.05).
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Figure 4.13: Overexpression of PRH inhibits MDA-
MB-231 proliferation as determined by BrdU
staining. MDA-MB-231 cells were infected with Ad or
Ad-PRH as described previously. 5x105 cells were
then seeded on a 6-well plate and left for 48 hours,
and were then incubated with 10µM BrdU for 6
hours. Cells were then fixed and stained for BrdU
positivity as described in text (n=3,3,2 one way
ANOVA with Games-Howell post-hoc *p<0.05
**p<0.01).
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4.13).  The proportion of BrdU positive cells seen in these experiments are similar to that 
seen in other studies (Zhang et al., 2012, Bosco et al., 2007) 
 
To summarise, Ad-PRH infection decreases the cell number of MCF-10A and MCF-7 cells, but 
no change in cell number was detected in MDA-MB-231 cells. Ad-PRH infection inhibits 
MCF-10A proliferation as determined by BrdU assays, but no effect is seen in Annexin V/PI 
assays or cell cycle assays. This inhibition of cell proliferation by PRH is dependent on PRH 
binding to DNA. Ad-PRH infection increases MCF-7 cell apoptosis, but does not affect the 
cell cycle profile, and BrdU assays were not possible in this cell type. Although PRH does not 
appear to decrease cell number in MDA-MB-231 cells, PRH is exerting an inhibitory effect on 
cell proliferation. A small increase in the percentage of cells in G1 phase is observed in Ad-
PRH infected MDA-MB-231 cells, and this correlates with a decrease in BrdU staining, 
indicating that the cells are less proliferative. This effect however may be too small to detect 
in cell counting assays. In conclusion, PRH overexpression inhibits cell proliferation in all 
three cell lines, and the effects are mediated by DNA binding. 
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4.3 Effect of PRH knockdown on breast cell proliferation and survival 
 
4.3.1  Generating PRH knockdown lentiviruses 
 
To further investigate the role of PRH in breast cell survival and proliferation, we wished to 
decrease PRH protein in all the cell lines through the use of small hairpin RNA (shRNA) 
against PRH. ShRNA molecules consist of 2 self-complimentary sequences between 19-29 
base pairs long, one of which is homologous to the target gene, separated by an 8 
nucleotide loop (Paddison et al., 2002). ShRNA is transcribed by the cell and then exported 
to the cytoplasm, and is then incorporated into the RNA induced silencing complex (RISC), 
where the shRNA is then cleaved into a guide and passenger strand. The guide strand is 
complementary or near complementary to the target mRNA. The target mRNA is then 
cleaved (in the case of perfect complementarity), or translation of the protein is inhibited (in 
the case of imperfect complementarity) causing decreased expression of the target protein 
(Wang et al., 2011).   
 
Previous shRNA vectors used in the Jayaraman laboratory were plasmid based vectors that 
can integrate randomly into the genome and constitutively express the shRNA. This 
approach has been problematic as it has been observed in the laboratory that PRH 
knockdown decreases over time, possibly due to silencing of the promoter expressing the 
shRNA in the region where integration has taken place, and thus knockdown of PRH has 
disappeared before cells have grown in sufficient numbers to be assayed. Small interfering 
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RNA (siRNA) was also used to knockdown PRH in these breast cells, however as this 
produces a relatively short-term effect, no decrease in PRH protein levels could be observed 
using Western blotting. Presumably one reason for this is that PRH has been shown to be a 
relatively long-lived protein in leukaemic cells (Bess et al., 2003b), and our own studies 
(section 3.7) confirm this to be the case in breast cells. 
 
Therefore, to produce cell lines which have reduced PRH expression that can be detected by 
Western blotting, a lentiviral plasmid vector with puromycin resistance and containing an 
inducible shRNA was obtained (Sigma, see figure 2.4 in Materials and methods). This 
plasmid also allows constitutive expression of LacI repressor protein. The shRNA is under 
control of a modified human U6 promoter with 3 LacO sequences. In the absence of IPTG, 
LacI protein binds to the LacO sequences, preventing expression of the shRNA. When ITPG is 
bound to LacI, the conformation of LacI changes, and LacI can no longer bind to the LacO 
sequences, allowing transcription of the shRNA. This plasmid can be used to produce IPTG 
inducible lentiviruses. These lentiviruses can also infect a greater variety of cell types then 
adenoviruses, including non-dividing cells (Fassati, 2006). Another advantage of this method 
is that lentiviruses integrate their DNA directly into the chromosome relatively efficiently, 
and puromycin resistant clones can be propagated, allowing efficient and stable expression 
of the shRNA upon induction with IPTG. In the absence of IPTG cells can be expanded in 
large numbers and this facilitates biochemical experiments after IPTG induction.  
Firstly PRH knockdown and control lentiviruses were made. This was achieved by co-
transfecting plasmids psPAX2 (expressing Gag and Pol), pMD2.G (expressing envelope 
protein VSV-G) and pLKO-puro-IPTG-3xLacO (expressing the shRNA) into HEK-293T 
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packaging cells (see Materials and methods figures 2.5-2.7 for maps). The media from these 
cells containing the virus was then harvested and centrifuged 48 hours later, purifying the 
virus (see Materials and methods section 2.5.1). To create PRH knockdown and control 
(shRNA coding for no known mammalian gene) shRNA polyclonal cells, cells from each cell 
line were infected with lentiviruses at an approximate MOI of 0.1 (see Materials and 
methods section 2.5.2). Infected cells were then selected 48 hours later, by incubating cells 
with 0.5µg/ml of puromycin for 7 days. 100% of uninfected cells die within 7 days of 
puromycin treatment. Puromycin resistant cells were then cultured in 1mM IPTG to induce 
shRNA expression. 
 
Control and PRH knockdown MCF-7 cells were analysed for PRH protein levels using 
Western blotting with the M6 antibody at 2, 5 and 7 days post-IPTG induction. Figure 4.14 
shows that PRH protein expression as detected by the M6 antibody is reduced after 7 days 
of IPTG induction compared to controls, but that at 2 and 5 days post-induction no decrease 
in protein is visible. Lentiviral infection of MCF-7 cells was repeated several times 
independently to generate 3 independent PRH knockdown and 3 independent control 
puromycin resistant cell lines.  This protocol was repeated for MCF-10A and MDA-MB-231 
cells to produce three independent PRH and control shRNA cell lines for each cell type. 
Figure 4.15 shows that in MCF-10A, MCF-7 and MDA-MB-231 cells, PRH expression is 
significantly reduced in the PRH shRNA cells compared to the control cells, showing that for 
all 3 cell lines the inducible shRNA system works effectively at 7 days post IPTG induction. In 
all assays described below the effects of PRH knockdown were assessed in three 
independent knockdown cell lines.   
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Figure 4.14: Inducible knockdown of PRH in MCF-7 cells. Cells were infected with lentivirus
containing shRNA coding for either PRH (KD) or against no known mammalian gene as a
control (C). Infected cells were then selected using 0.5µg/ml puromycin for 7 days, and shRNA
expression was then induced using 1 mM IPTG. Cells were pelleted 2, 5 and 7 days post-
induction, and protein was extracted and probed using Western blotting with the M6 antibody
to check for successful knockdown.
PRH
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Figure 4.15: Inducible knockdown of PRH in MCF-10A, MCF-7 and MDA-MB-231 cells. Cells were
infected with lentivirus containing shRNA coding for either PRH (KD) or against no known
mammalian gene as a control (C). Infected cells were selected by incubating with 0.5µg/ml
puromycin for 7 days. ShRNA expression was then induced using 1 mM IPTG. (A) Cells were pelleted
7 days post-induction, and protein was extracted, separated by SDS-PAGE and probed using Western
blotting with the M6 antibody to check for successful knockdown. (B) PRH protein expression was
quantified by densitometric quantification of Western blots of three independent PRH knockdown
and control cell lines using the M6 anti-PRH antibody, and Lamin C as a loading control (n=3, two-tail
homoscedastic t-test, *p>0.05).
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4.3.2 Knockdown of PRH decreases MCF-7 cell number 
 
To determine whether changes in the level of endogenous PRH affect breast cell growth, cell 
counting assays were carried out. Cumulative growth curves were then calculated by 
multiplying the total cell number by the cell dilution at replating. For MCF-10A cells, there 
was very little difference in cell number between PRH knockdown cells and controls (figure 
4.16 (A)). For MCF-7 cells however, there were significantly more PRH knockdown cells than 
control cells (figure 4.16 (B)). Surprisingly, in MDA-MB-231 cells there were significantly less 
PRH knockdown cells than control cells (figure 4.16 (C)). To confirm these results 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were carried out. MTT 
assays measure the number of metabolically active cells, because the MTT compound is 
converted into an insoluble coloured formazan by the mitochondria of the cells. This 
product is dissolved in DMSO and can be measured by the absorption of the product at a 
wavelength of 600nm. The coloured formazan is proportional to the number of viable cells 
present, within a linear range (see Materials and methods section 2.2.2)  (Mosmann, 1983). 
Using this assay, no difference in viable cell number was observed between knockdown and 
control cells in MCF-10A cell lines (figure 4.17 (A)).   
 
MCF-10A cells are grown with high amounts of horse serum, as well as insulin, epidermal 
growth factor and cholera toxin. Thus they show a requirement for many growth factors. It 
was hypothesised that the high level of growth factor signalling could be masking any effect 
of PRH loss on the growth of this cell line. To determine whether PRH affected MCF-10A cell 
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Figure 4.16: PRH knockdown affects breast cancer
cell number, but not normal MCF-10A growth rates.
Cell counting assays were carried out with PRH
knockdown and control MCF-10A (A), MCF-7 (B) or
MDA-MB-231 (C) cells. ShRNA expression was
induced by incubating cells in 1mM IPTG for 7 days.
1x105 cells were then plated in a 25cm2 flask, and
cells were then counted 5 days after seeding. Cells
were then replated and the process repeated, and
the cumultive cell number was then determined by
multilplying the number of cells counted by the
dilution of cells at seeding. (n=3, *p<0.05 two-tail
homoscedastic t-test).
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Figure 4.17: PRH knockdown affects breast cancer
cell number, but not normal MCF-10A cell
number. MTT assays were carried out with PRH
knockdown and control MCF-10A (A), MCF-7 (B)
or MDA-MB-231 (C) cells. Cells were induced as in
figure 4.16. 2,000 cells were then seeded into a
well in a 96-well plate in quadruplicate for each
time point. After 24, 48, 72 and 96 hours (for MCF-
7 cells), cells were incubated with 500 µg/ml 2-
MTT for 2 hours, and the MTT crystals were then
dissolved with DMSO and the optical density was
then read at 600nm. (n=3, p<0.05 two-tail
homoscedastic t-test).
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number in sub-optimal growth conditions, the MTT assay was repeated as described above, 
but cells were cultured in media containing 1% horse serum rather than 5% horse serum. 
However, there was still no difference between PRH knockdown and control cell number in 
these conditions (figure 4.18), thus PRH knockdown appears to have little effect on the rate 
of increase of the MCF-10A population.  
 
In contrast, there were significantly more viable cells in MCF-7 PRH knockdown cell lines 
compared to controls at 72 hours post plating, in agreement with the results of cell counting 
experiments (figure 4.17 (B)). However in MDA-MB-231 cells, there were significantly fewer 
viable cells in the PRH knockdown cell lines compared to control cell lines (figure 4.17 (C)).  
Again this is in agreement with the results of cell counting experiments.  
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Figure 4.18: PRH knockdown does not affect MCF-10A cell number in 1% serum. MTT assays were
carried out with PRH knockdown and control MCF-10A cells, which were set up and induced as in
figure 4.17, but with reduced horse serum content (1% instead of 5%). After 24, 48 and 72 hours,
cells were incubated with 500 µg/ml 2-MTT for 2 hours, and the MTT crystals were then dissolved
with DMSO and the optical density was then read at 600nm (n=2) .
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4.3.3 Effect of PRH knockdown on cell cycle 
 
To investigate whether the effects of PRH knockdown observed in each cell line are a result 
of a change in cell proliferation or cell death, cell cycle and BrdU assays were carried out. 
MCF-10A control and PRH knockdown cells were induced for 7 days with IPTG and then 
plated into a 6 well plate. Twenty four hours later cells were analysed for DNA content by 
flow cytometery as described earlier. As expected MCF-10A control and PRH knockdown 
cells showed no significant difference in the percentage of cells in each phase of the cell 
cycle (figure 4.19 (A)). However, when MCF-7 control and knockdown cells were similarly 
induced and analysed a significant shift in the G1 peak was observed (figures 4.19 (B) and 
4.20). This could be due to an increased proportion of S-phase cells, or it could be due to 
increased amount of propidium iodide staining the cells. Further experiments need to be 
carried out to determine whether there is an increased amount of S-phase cells, or whether 
this result is an artefact.  Finally under similar induction and assay conditions, the MDA-MB-
231 control and PRH knockdown cells show little difference in distribution of cells in each 
stage of the cell cycle profile (figure 4.19 (C)). This is unexpected as it was observed that 
population growth for PRH knockdown MDA-MB-231 cells is slower than control cells. 
However, cell cycle assays only show if there are alterations in the distribution of cells, but 
do not measure the rate of proliferation. Thus BrdU assays were employed to determine 
whether decreased cell number was a consequence of alterations in the rate of 
proliferation.  
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Figure 4.19: Knockdown of PRH affects MCF-7 but not
MCF-10A or MDA-MB-231 cell cycle distribution. MCF-
10A (A), MCF-7 (B) and MDA-MB-231 (C) cells were
infected with lentivirus and induced as described in
figure 4.16. 5x105 cells were then seeded on a 6-well
plate and left for 24 hours, before being lysed with 1%
IGEPAL, and DNA stained with 50µg/ml propidium
iodide. Cells were then analysed by flow cytometery to
determine cell cycle phase (n=3, *p<0.05 two-tail
homoscedastic t-test).
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Figure 4.20: Knockdown of PRH affects MCF-7 cell cycle.
MCF-7 cells were infected with lentivirus and induced as
described in figure 4.16. 5x105 cells were then seeded on a
6-well plate and left for 24 hours, before being lysed with
1% IGEPAL, and DNA stained with 50µg/ml propidium
iodide. Cells were then analysed by flow cytometery to
determine cell cycle phase. Representative plots are shown
for control (A) and PRH knockdown (B), with an overlay
shown in (C).
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4.3.4 Effect of PRH knockdown on cell proliferation 
 
To determine whether PRH affects the rate of cell proliferation in these cell types, BrdU 
assays were carried out as previously described. MCF-10A control and PRH knockdown cells 
were induced for 7 days with IPTG and then plated into a 6 well plate. After 24 hours, cells 
were incubated in media containing 10mM BrdU for 6 hours, before the cells were fixed and 
immunostained using a monoclonal BrdU antibody (see Materials and methods section 
2.6.2). The percentage of BrdU positive cells was then counted in three fields for each 
knockdown and control cell line. PRH knockdown had no effect on the number of MCF-10A 
BrdU positive cells (figure 4.21), in agreement with the lack of difference seen in the 
cumulative growth curves and MTT assays seen in figures 4.16 and 4.17 respectively. PRH 
knockdown in MCF-7 cells significantly increased the percentage of BrdU positive cells in 
PRH knockdown cells compared to controls (figure 4.22), indicating that knockdown of PRH 
in this cell type increased the rate of cell proliferation. In contrast, PRH knockdown 
significantly reduced the proportion of BrdU positive MDA-MB-231 cells compared to 
Control cells, demonstrating that rate of cell proliferation is decreased (figure 4.23).  
 
4.3.5 Knockdown of PRH has no effect on cell apoptosis 
 
To determine whether the differences in cell growth in the knockdown cells are also a result 
of differences in cell apoptosis, PI/Annexin V co-staining assays were carried out. For each 
cell type, control and PRH knockdown cells were induced with IPTG for 7 days. Cells were 
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Figure 4.21: Knockdown of PRH has no effect on
MCF-10A proliferation as determined by BrdU
staining. MCF-10A cells were induced for shRNA
expression as described previously in figure 4.16.
5x105 cells were then seeded on a 6-well plate and
left for 24 hours, and were then incubated with
10µM BrdU for 6 hours. Cells were then fixed and
stained for BrdU positivity as described in the text
(n=3, two-tail homoscedastic t-test).
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Figure 4.22: Knockdown of PRH increases MCF-7
proliferation as determined by BrdU staining. MCF-7
cells were induced for shRNA expression as described
previously in figure 4.16. 5x105 cells were then seeded
on a 6-well plate and left for 24 hours, and were then
incubated with 10µM BrdU for 6 hours. Cells were then
fixed and stained for BrdU positivity as described in the
text (n=3, *p<0.05 two-tail homoscedastic t-test).
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then plated into a 6 well plate at a density of 5x105 cells per well, and 24 hours later the 
assays were performed in the same way as described previously. There was no effect of PRH 
on apoptosis in MCF-10A, MCF-7 or MDA-MB-231 cells (figure 4.24). 
 
To summarise, loss of PRH in MCF-10A cells had no observable affect on cell number. Loss of 
PRH in MCF-7 cells leads to an increase in cell number, and this occurred through increased 
cell proliferation measured in BrdU and cell cycle assays. Surprisingly, loss of PRH in MDA-
MB-231 cells leads to a decrease in cell number and proliferation, as determined using BrdU 
assays.  
 
The results of PRH overexpression and knockdown are summarised in tables 4.1 and 4.2.   
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staining. MDA-MB-231 cells were induced for shRNA
expression as described previously in figure 4.16.
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4.4 PRH and regulation of VEGF signalling genes 
 
4.4.1 Gene expression analysis of VEGF signalling genes 
 
Changes in cell proliferation and cell survival can both be mediated by VEGF signalling in 
endothelial and leukaemic cells (Noy et al., 2010, Nakagawa et al., 2003). In breast tumours 
VEGF acts in an autocrine manner, as well as in a paracrine manner on endothelial cells 
(Weigand et al., 2005). Microarray studies have identified many genes as targets for 
regulation by PRH (Nakagawa et al., 2003, Kubo et al., 2010). Genes from the VEGF signalling 
pathway (VSP) are direct targets of PRH in leukaemic cells, and are involved in promoting 
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Figure 4.24: Knockdown of PRH does not affect cell
apoptosis. MCF-10A (A), MCF-7 (B) and MDA-MB-
231 (C) cells were induced for shRNA expression as
described previously in figure 4.16. 5x105 cells were
then seeded on a 6-well plate and left for 24 hours,
before being stained with 10μg/ul propodium iodide
and 5μl of Annexin V-APC antibody (BD Biosciences).
Cells were then analysed by flow cytometery to
determine live cells (PI-, AV-), or apoptotic cells (PI-,
AV+ or PI+. AV+) (n=3, two-tail homoscedastic t-
test).
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PRH overexpression MCF-10A MCF-7 MDA-MB-231
Cell number Decrease in viable 
cells
Decrease in viable cells No change
Cell cycle No change No change Increase in G1
BrdU Decrease in cell 
proliferation
Not assessed Decrease in cell 
proliferation
Apoptosis No change Increased apoptosis No change
Table 4.1: Summary of the effect of PRH overexpression in MCF-10A, MCF-7 
and MDA-MB-231 breast cell lines.
PRH knockdown MCF-10A MCF-7 MDA-MB-231
Cell number No change Increase in viable cells Decrease in viable 
cells
MTT No change Increase in viable cells Decrease in viable 
cells
Cell cycle No change Apparent decrease in 
G1 phase and increase
in S phase
No change
BrdU No change Increased proliferation Decreased 
proliferation
Apoptosis No change No change No change
Table 4.2: Summary of the effect of PRH knockdown in MCF-10A, MCF-7 and 
MDA-MB-231 breast cell lines.
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cell survival (Noy et al., 2010). Therefore, one possibility is that PRH alters the growth of 
breast tumour cells by directly binding and regulating the expression of VEGF signalling 
genes. The effect of PRH on the expression of VSP target genes was assessed in both tumour 
cells lines and MCF-10A cells using quantitative real-time PCR. For all knockdown 
experiments, control and PRH knockdown cells were pelleted 7 days after IPTG induction. 
RNA extraction and cDNA synthesis was carried out as described in Materials and methods 
section 2.8. PCR reactions were then set up using a mastermix containing SYBR green (which 
binds non-specifically to double stranded DNA), as described in Materials and methods 
section 2.8.3. The Ct and efficiency of the reaction was then calculated for the gene of 
interest and the GAPDH housekeeping gene unless otherwise stated, and the relative 
expression ratios were determined using the Pfaffl method (Pfaffl, 2001b). Statistical 
analysis was carried out using two-tailed Student’s t-test according to Materials and 
methods section 2.8.3.  
 
For MCF-10A cells, overexpression of PRH significantly represses the VEGFA transcript 
(figure 4.25 (A)).  Expression of VEGF Receptors VEGFR1, VEGFR2 and NRP1 mRNA is also 
lower in the Ad-PRH infected cells but this decrease is not statistically significant in the three 
biological repeats (figure 4.25 (A)). For the PRH knockdown MCF-10A cells, there is no 
significant difference in expression of VEGF, VEGFR2 or NRP1 mRNA between knockdown 
and control cells (Figure 4.25 (B)). The VEGFR1 transcript is expressed in these cells, but the 
transcript is at a low expression level and not reproducibly detected. Therefore quantitative 
PCR for VEGFR1 mRNA was not possible with these samples. In summary, there appears to 
be little regulation of VSP genes by endogenous PRH in normal MCF-10A cells. However, in 
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Figure 4.25: The effect of PRH on gene expression of VEGF signalling genes in MCF-10A cells. (A)
MCF-10A cells were infected with either Ad or Ad-PRH at a MOI of 50 for 48 hours. Cells were
then pelleted and RNA was extracted using a Bioline ISOLATE II kit, and complementary DNA was
then synthesised. Gene expression was analysed using quantitative PCR, and quantified using the
Pfaffl method (Pfaffl, 2001), using GAPDH as a housekeeping gene. (B) The same process was
repeated but with PRH knockdown cells, which were induced for shRNA expression as previously
described, however beta-actin was used as a housekeeping gene as GAPDH expression was too
variable in these experiments (n=3, *p<0.05, two-tail homoscedastic t-test).
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Figure 4.26: The effect of PRH on gene expression of VEGF signalling genes in MCF-7 cells. (A)
MCF-7 cells were infected with either Ad or Ad-PRH at a MOI of 50 for 48 hours. Cells were then
pelleted and RNA was extracted using a Bioline ISOLATE II kit, and complementary DNA was then
synthesised. Gene expression was analysed using quantitative PCR, and quantified using the Pfaffl
method (Pfaffl, 2001), using GAPDH as a housekeeping gene. (B) The same process was repeated
but with PRH knockdown cells, which were induced for shRNA expression as previously described
(n=3, *p<0.05, two-tail homoscedastic t-test ).
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overexpression experiments exogenous PRH may be able to bind at VEGFA promoter 
regions and effect some repression. Additional repeats will be required to achieve statistical 
significance at promoters of VEGF receptors/co-receptors. However it is possible that 
elevated PRH expression is modestly repressing several genes in the VSP.  
 
For MCF-7 cells, PRH over-expression causes a significant repression in VEGFR2 and NRP1 
mRNA expression (Figure 4.26 (A)). In the same experiment, VEGFA mRNA expression shows 
an apparent 50% increase in Ad-PRH infected MCF-7 cells, however this change is not 
statistically significant. Again VEGFR1 mRNA is not expressed at a high enough level to be 
analysed by qPCR. In the PRH knockdown MCF-7 cells, VEGF and VEGFR2 mRNA expression 
was almost two-fold higher than in control cells, but this change is not statistically 
significant when statistical analysis is carried out for three independent knockdown cell lines 
(figure 4.26 (B)). Previous experiments with a different shRNA knockdown in MCF-7 cells do 
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Figure 4.27: The effect of PRH on gene expression of VEGF signalling genes in MDA-MB-231
cells. (A) MDA-MB-231 cells were infected with either Ad or Ad-PRH at a MOI of 50 for 48 hours.
Cells were then pelleted and RNA was extracted using a Bioline ISOLATE II kit, and
complementary DNA was then synthesised. Gene expression was analysed using quantitative
PCR, and quantified using the Pfaffl method (Pfaffl, 2001), using GAPDH as a housekeeping gene.
(B) The same process was repeated but with PRH knockdown cells, which were induced for
shRNA expression as previously described (n=3, *p<0.05, two-tail homoscedastic t-test).
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show a statistically significant increase in VEGFA and VEGFR2 mRNA expression in MCF-7 
cells (Noy et al., 2010).  Therefore it is possible that if more cell lines had been assayed three 
times this change might have been statistically significant. There is no change in NRP1 
expression levels. Overexpression of PRH does show repression of VSP genes VEGFR2 and 
NRP1, however the VEGFA gene does not seem to be regulated by PRH.  One reason for this 
lack of repression at the VEGFA gene could be the existence of a feedback loop between 
VEGF receptors and VEGFA, as reduction in VEGF receptor expression might result in the 
upregulation of the VEGF ligand in these cells.  
 
For MDA-MB-231 cells, PRH overexpression did not lead to statistically significant repression 
or activation of any of the VEGF receptor genes. However as observed in MCF-7 cells, PRH 
overexpression did lead to an apparent increase in VEGFA mRNA expression. Moreover, in 
the PRH knockdown cells, there was a significant decrease in the VEGFA transcript (figure 
4.27 (B)), suggesting that endogenous PRH increases VEGFA mRNA expression. However, 
there was no statistically significant change in mRNA expression of VEGFR2 or NRP1. 
Therefore, PRH does not repress transcription of the VEGF receptors in MDA-MB-231 cells, 
but rather endogenous and exogenous PRH appears to activate expression of the VEGFA 
gene.  
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4.5 Discussion 
 
It has been shown previously that PRH decreases the proliferation of leukaemic cells and 
hepatocarcinoma Hepa1-6 cells (Noy et al., 2010, Su et al., 2012). In this chapter it is shown 
that over expression of PRH decreases MCF-10A cell number. Overexpression of PRH 
drastically decreases the rate of proliferation in MCF-10A cells; however there was 
apparently no effect on the cell cycle or apoptosis. Surprisingly PRH knockdown did not 
show a marked increase in MCF-10A cell number either by MTT or by cell counting over a 20 
day time period, and there were no changes detected by cell cycle profiling or by BrdU 
incorporation. Additionally, growth of MCF-10A cells in sub-optimal conditions, with low 
serum, failed to show a difference in growth between control and PRH knockdown cells. 
However it remains possible that there is a modest increase in cell number that will be 
apparent over a longer period of time.  
 
One reason for the lack of a phenotype on cell proliferation observed for PRH knockdown in 
this cell type could be that PRH activity with regards to growth suppression shows 
redundancy with other tumour suppressor genes. Knockdown of endogenous PRH had little 
effect on the expression of any of the genes in the VEGF signalling pathway, indicating that 
endogenous PRH may not be important for regulating this pathway in normal breast cells. 
Despite this, exogenous PRH was able to effect repression of the VEGF gene, as well as have 
a modest effect on the receptors (albeit not in a statistically significant fashion in this 
experiment). Therefore it can be concluded that although exogenous PRH protein may be 
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able to bind weakly at the VEGF signalling gene promoters in MCF-10A cells, endogenous 
PRH does not appear to regulate the VSP in these cells. This agrees with the effects of PRH 
on cell proliferation, for example, overexpression of PRH causes a decrease in VEGF mRNA 
expression, whereas knockdown of endogenous PRH expression has no effect on genes in 
the VSP, and no effect on cell number. 
 
In MCF-7 cells, overexpression of PRH leads to a decrease in MCF-7 cell number, through 
increased apoptosis. It cannot be ruled out that the rate of proliferation is also decreased, 
as BrdU assays were not possible with these cells. Interestingly PRH overexpression also 
significantly downregulated mRNA expression of the VEGF receptors VEGFR2 and NRP1, in 
agreement with experimental data previously published (Noy et al., 2010). Since repression 
of VSP genes leads to decreased survival signalling, which can lead to increased apoptosis in 
this cell type (Ge et al., 2009), it can be inferred that this may account for some of the 
decrease in cell number in Ad-PRH infected cells. Conversely, PRH knockdown leads to an 
increase in cell number, and there is a modest upregulation of VEGFA and VEGFR2 mRNA 
expression (although this is not statistically significant). However, this increase in cell 
number occurs through an increase in the rate of cell proliferation rather than a decrease in 
cell apoptosis.  Although it is likely that some of the effects of PRH on cancer cell growth are 
occurring via regulation of the VSP, PRH could also be exerting its growth control effects by 
regulating expression of additional genes outside the VEGF signalling pathway. This will be 
further examined in the next chapter.  
In MDA-MB-231 cells, overexpression of PRH reduced cell proliferation, increasing the 
proportion of cells in G1, and decreasing BrdU uptake of Ad-PRH infected cells. This however 
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did not translate into a decrease in cell number. One reason for  exogenous PRH having little 
effect on cell number is that Myc-PRH is more unstable in MDA-MB-231 cells than in MCF-
10A cells (see section 3.7), and hence the effect of exogenous PRH on the phenotype of this 
cell could be short-lived, and hence not strong enough to be accurately measured in a cell 
counting assay. There is little effect of PRH overexpression on most VSP genes in this cell 
line, although there may be a modest increase in VEGFA transcript. Surprisingly, knockdown 
of PRH decreased MDA-MB-231 cell growth which is opposite to the increased population 
growth phenotype observed in PRH knockdown MCF-7 cells, K526 leukaemic cells (Noy et 
al., 2010) and in PNT-2C2 prostate cells (Y.H. Siddiqui, K.L. Gaston and P.S. Jayaraman, 
personal communication). In addition there is a significant reduction in VEGF mRNA 
expression in MDA-MB-231 PRH knockdown cells. This suggests that endogenous PRH may 
actually activate expression of the VEGF gene in MDA-MB-231 cells. Increased autocrine 
signalling through the VSP, leading to increased proliferation and invasion, may be a reason 
for the requirement for PRH in MDA-MB-231 cell proliferation (Bachelder et al., 2002). 
However, the pro-proliferative PRH phenotype is at odds with the role of PRH in MCF-7 and 
K562 cells where it acts as a transcriptional repressor of this gene.  
 
In conclusion, overexpression of PRH is having significant inhibitory effects on the growth of 
all three cell lines. However, knockdown of PRH has very different effects in each of the 
three cell lines. This implies that the context in which PRH is expressed is important for 
determining the phenotype which PRH exerts on the cell. 
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5. The effect of PRH expression on breast cell 
migration, invasion and cancer initiating cells 
 
5.1 Introduction 
 
The ability of cancerous cells to migrate and metastasise is of huge importance to clinical 
outcome, as metastasis is the cause of death for 90% of patients with solid tumours (Gupta 
and Massagué, 2006). Since overexpression of PRH has been shown to negatively regulate 
HUVEC migration and invasion (Nakagawa et al., 2003), we wished to determine whether 
PRH affects breast tumour cell migration and invasion. To this end, PRH was overexpressed 
and knocked down in MCF-7, and MDA-MB-231 cells. Since MCF-10A cells migrate very 
slowly and are non-invasive, only the effects of PRH knockdown were assessed in these 
cells.  
 
5.2 Effect of PRH on migration and invasion of breast cells 
 
5.2.1 Effect of PRH overexpression on the migration of MCF-7 and MDA-MB-231 cells 
 
The movement of cells can be measured in two ways - measurement of overall cell motility, 
known as chemokinesis, and measurement of movement towards a chemoattractant, 
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known as chemotaxis. To measure the effect of overexpression of PRH on MCF-7 cell 
chemotaxis, scratch wound assays were performed. One million MCF-7 cells were infected 
with Ad or Ad-PRH as described previously, and plated in a 6-well plate and left for 24 hours, 
so that they were 100% confluent. A scratch was then made with a P200 pipette tip, and 
images were taken of the scratch at time zero. The scratch was then re-imaged 24 hours 
later, and the area of the scratch was quantified at both timepoints using ImageJ software. 
Cell proliferation was inhibited throughout the assay by incubating cells with 1mM  
hydroxyurea (as shown figure 4.8). The results show that overexpression of PRH decreases 
MCF-7 chemokinesis (figures 5.1 (A) and (B)).  
 
To measure the effect of exogenous PRH on MCF7 chemotaxis, transwell assays were 
carried out.  MCF-7 cells were infected with Ad-or Ad-PRH as described previously. After 24 
hours 40,000 cells were then placed in the top chamber of a transwell in media containing 
2% serum. The bottom chamber contains media with 10% serum as the chemoattractant. 
The transwell chamber contains a membrane with 8μm pores for the cells to migrate 
through (see figure 5.1 (C)). The cells were left for 48 hours, before washing and fixing with 
2% formaldehyde. Cells on either side of the membrane were then stained with 
bisbenzamide to visualise their nuclei. The membrane was cut out and the percentage of 
migrated cells was counted in at least three fields using a fluorescent microscope at 100x 
magnification. Figure 5.1 (D) shows that there is a significant decrease in the percentage of 
Ad-PRH infected MCF-7 cells that migrate to the lower surface of the membrane compared 
to controls.  
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Figure 5.1: Overexpression of PRH in MCF-7 cells causes decreased migration. (A) 1 million MCF-7 cells were
plated onto a 6 well plate and were infected with either Ad control (left) or Ad-PRH adenovirus (right) for 24
hours. A scratch was then created using a P200 pipette tip and pictures were taken 0 hours and 24 hours
post-scratch. (B) Wound closure was then quantified using ImageJ software (n=3, *p<0.05 two-tail
homoscedastic t-test). (C) MCF-7 cells were infected with Ad or Ad-PRH at a MOI of 50. 24 hours later 4x104
cells were placed in an inner chamber of a transwell containing 2% serum, with the outer chamber containing
10% serum. (D) Cells were then left to migrate for 24 hours, and the number of migrated cells was quantified
(n=3, *p<0.05 two-tail homoscedastic t-test).
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To determine whether exogenous PRH affects MDA-MB-231 chemokinesis, scratch wound 
assays were carried out as described previously, however the assay was carried out over 6 
hours rather than 24 as MDA-MB-231 cells are more migratory than MCF-7 cells. Figures 5.2 
(A) and (B) shows that Ad-PRH infected MDA-MB-231 cells display less chemokinesis 
compared to control cells. Transwell assays were also carried out as previously described; 
however the assay was carried out over 24 hours rather than 48 hours. Figure 5.2 (C) shows 
that Ad-PRH infection significantly inhibited migration of MDA-MB-231 cells towards the 
chemoattractant, compared to control cells. Thus exogenous PRH inhibits the migration of 
both breast tumour cell types. 
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Figure 5.2: Overexpression of PRH in MDA-MB-231 cells causes decreased migration. (A) 1 million
MDA-MB-231 cells were plated onto a 6 well plate and were infected with either Ad control (left) or
Ad-PRH (right) adenovirus for 24 hours. A scratch was then created using a P200 pipette tip and
pictures were taken 0 hours and 6 hours post-scratch. (B) Wound closure was then quantified using
ImageJ software (n=3, *p<0.05 two-tail homoscedastic t-test). MDA-MB-231 cells were infected with
Ad or Ad-PRH at a MOI of 50. (C) 24 hours later 4x104 cells were placed in an inner chamber of a
transwell containing 2% serum, with the outer chamber containing 10% serum. Cells were then left
to migrate for 24 hours, and the number of migrated cells was quantified (n=3, *p<0.05 two-tail
homoscedastic t-test).
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 5.2.2 Effect of PRH knockdown in MCF-7 and MDA-MB-231 cells 
 
To determine if endogenous PRH had effects on MCF-7 and MDA-MB-231 chemokinesis, 
scratch wound assays were carried out as described previously. MCF-7 PRH knockdown and 
control cells were induced for shRNA expression as described in the previous chapter. PRH 
knockdown significantly increased MCF-7 chemokinesis (figures 5.3 (A) and (B)). The effect 
of PRH knockdown on MCF-7 chemotaxis was also assayed, by carrying out transwell assays 
as previously described, over 48 hours. PRH knockdown significantly increased MCF-7 
chemotaxis compared to controls (figure 5.3 (C)). The experiments were repeated in MDA-
MB-231 PRH knockdown and control cells.  Note that IPTG seems to decrease cell migration. 
 
Figures 5.4 (A) and (B) show that there is little or no difference in chemokinesis between 
PRH knockdown and control cells. Since MDA-MB-231 cells are highly migratory, transwell 
assays were carried out over 6 hours. In this experiment, PRH knockdown significantly 
increased MDA-MB-231 chemotaxis compared to controls (figure 5.4 (C)). Thus knockdown 
of PRH increases chemotaxis of both breast tumour cell lines. Note that IPTG seems to 
decrease cell migration. 
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Figure 5.3: Knockdown of PRH in MCF-7 cells causes increased migration. (A) PRH or control knockdown MCF-7
cells were induced for shRNA expression as previously described. 1x106 cells were then plated onto a 6 well plate
and were left for 24 hours to adhere. A scratch was then created using a P200 pipette tip and pictures were taken 0
hours and 24 hours post-scratch. (B) Wound closure was then quantified using ImageJ software (n=3, *p<0.05 two-
tail homoscedastic t-test). (C) 4x104 cells were placed in an inner chamber of a transwell containing 2% serum, with
the outer chamber containing 10% serum. Cells were then left to migrate for 48 hours, and the percentage of
migrated cells was quantified (n=3, *p<0.05 two-tail homoscedastic t-test).
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Figure 5.4: Knockdown of PRH in MDA-MB-231 cells causes decreased chemotaxis but not chemokinesis. (A)
PRH or control knockdown MDA-MB-231 cells were induced for shRNA expression as previously described. 1x106
cells were then plated onto a 6 well plate and were left for 24 hours to adhere. A scratch was then created using
a P200 pipette tip and pictures were taken 0 hours and 6 hours post-scratch. (B) Wound closure was then
quantified using ImageJ software (n=3, *p<0.05 two-tail homoscedastic t-test). (C) 4x104 cells were placed in an
inner chamber of a transwell containing 2% serum, with the outer chamber containing 10% serum. Cells were
then left to migrate for 6 hours, and the percentage of migrated cells was quantified (n=3, *p<0.05 two-tail
homoscedastic t-test).
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5.2.3 Effect of PRH knockdown in MCF-10A cells 
 
To determine if endogenous PRH had effects on MCF-10A chemokinesis, scratch wound 
assays were carried out as previously described, with the assay carried out over 24 hours. 
ShRNA expression in MCF-10A cells was induced as described in the previous chapter. There 
was no difference in chemokinesis between PRH knockdown and control MCF-10A cells 
(figures 5.5 (A) and (B)). MCF-10A chemotaxis was also assayed, by carrying out transwell 
assays, however epidermal growth factor (EGF) was used as a chemoattractant in this case, 
as it has been previously shown that MCF-10A cells are migratory towards EGF in this assay 
(Irie et al., 2005). The assay was carried out over 48 hours, as these cells are not known to 
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Figure 5.5: Knockdown of PRH in MCF-10A cells affects chemotaxis but not chemokinesis. (A) PRH or
control knockdown MCF-10A cells were induced for shRNA expression as previously described. 1x106 cells
were then plated onto a 6 well plate and were left for 24 hours to adhere. A scratch was then created using
a P200 pipette tip and pictures were taken 0 hours and 24 hours post-scratch. (B) Wound closure was then
quantified using ImageJ software (n=3, *p<0.05 two-tail homoscedastic t-test). (C) 4x104 cells were placed in
an inner chamber of a transwell containing no EGF, with the outer chamber containing 10ng/ml EGF. Cells
were then left to migrate for 24 hours, and the number of migrated cells was quantified (n=3, *p<0.05 two-
tail homoscedastic t-test).
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be migratory. Figure 5.5 (C) shows that PRH knockdown significantly increased MCF-10A    
chemotaxis compared to controls. It can be concluded that PRH inhibits cell migration in 
normal breast cells, and in breast cancer cells.  Note that IPTG seems to decrease cell 
migration. 
 
5.2.4 PRH inhibits cell invasion  
 
To determine whether PRH has effects on breast cell invasiveness, transwell invasion assays 
were performed. This assay involves coating the porous membrane with reconstituted 
basement membrane (Matrigel) (Albini et al., 1987).  The assay assesses whether cells can 
produce enzymes that can degrade the extracellular matrix proteins present in the Matrigel, 
and then migrate across the membrane.  
 
To determine the effects of PRH overexpression on invasion by MDA-MB-231 cells (which 
are known to be highly invasive), a 2-10% serum gradient was used as a chemoattractant. 
However infection with the control adenovirus (at a MOI of 50) decreases the invasion of 
MDA-MB-231 cells compared to uninfected cells. Therefore, an alternative method for 
overexpressing PRH in these cells was used. Cells were transfected with plasmids using 
Lipofectamine 2000 (experiment carried out by Dr. Rachael Kershaw). Briefly, cells were co-
transfected with plasmids coding for GFP (pEGFP-C1) and a plasmid coding for Myc-PRH 
(pMUG1 Myc-PRH) or an empty vector plasmid (pMUG1) (for plasmid maps see Materials 
and methods section 4.12). Transwell invasion assays through a transwell membrane coated 
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with Matrigel were then carried out 24 hours post-transfection, and the number of GFP 
positive cells that invaded through the membrane was then quantified. PRH overexpressing 
MDA-MB-231 cells overexpressing PRH were less invasive than control cells (figure 5.6). 
MCF-10A cells are not invasive, and MCF-7 cells invade very poorly, hence the effect of 
overexpression of PRH could not be determined. However, it was reasoned that 
endogenous PRH might be inhibiting invasion in these cell types. To investigate this 
hypothesis, MCF-10A PRH knockdown and control cells were used. EGF was used as a   
chemoattractant, and cells were left to invade the transwell chamber coated with Matrigel 
for 48 hours, before cells were fixed and stained with bisbenzamide. Figure 5.7 (A) shows 
that there are significantly more invasive PRH knockdown MCF-10A cells than control cells. 
This suggests that the loss of PRH causes MCF-10A cells to become invasive. The invasion 
assay was carried out in an identical way in MCF-7 cells, apart from 10% serum being used 
as the chemoattractant rather than EGF. PRH knockdown also significantly increased MCF-7 
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Figure 5.6: Overexpression of PRH decreases MDA-MB-231 invasion. MDA-MB-231 cells were transfected
with 1.5μg of GFP plasmid and 1.5 μg of either empty pMUG1 vector (EV) or with pMUG1 vector coding for
Myc-PRH (PRH). 4x104 cells were placed in an inner chamber of a transwell (precoated with 50μl Matrigel)
24 hours later, containing 2% serum, with the outer chamber containing 10% serum. Cells were then left to
invade for 24 hours, and the number of invasive GFP-positive cells was quantified (n=3, *p<0.05 two-tail
homoscedastic t-test).
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cell invasion (figure 5.7 (B)). It can be concluded that PRH inhibits invasion of immortalised 
breast cells and breast tumour cells. 
 
 
 5.3 Effect of PRH on expression of genes involved in EMT/migration/invasion 
 
 
5.3.1 Gene expression analysis of genes involved in EMT/migration/invasion 
 
To better understand the effects of PRH overexpression and knockdown on cell migration 
and invasion, the effect of PRH on genes that are known to be regulated by PRH in other cell 
types, and that are associated with migration/invasion/EMT, were analysed. PRH directly 
binds and represses the goosecoid (GSC) and ESM1 genes within their promoter regions 
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Figure 5.7: Knockdown of PRH increases MCF-10A and MCF-7 invasion. (A) IPTG inducable PRH and control
shRNA MCF-10A cells were subject to transwell assays. 4x104 cells were placed in an inner chamber of a
transwell (precoated with 50μl Matrigel) containing no EGF, with the outer chamber containing 10ng/μl EGF.
Cells were then left to invade for 48 hours, and the number of invasive cells was quantified (n=3, *p<0.05
two-tail homoscedastic t-test). (B) 4x104 MCF-7 PRH knockdown and control cells were placed in an inner
chamber of a transwell (precoated with 50μl Matrigel) containing 2% serum, with the outer chamber
containing 10% serum. Cells were then left to invade for 48 hours, and the number of invasive cells was
quantified (n=3, *p<0.05 two-tail homoscedastic t-test).
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(Cong et al., 2006, Brickman et al., 2000, Williams et al., 2008), and both of these genes are 
associated with migration or invasion. Overexpression of Goosecoid lead to increased cell 
motility in human mammary epithelial cells (Hartwell et al., 2006), whilst knockdown of 
ESM1 has been shown to decrease invasion in hepatocarcinoma cells  (Kang et al., 2011). 
PRH is also known to regulate mRNA expression of T53, SATB1 and endoglin (ENG) in various 
cell types, but the mechanism of regulation is not known (Nakagawa et al., 2003, Su et al., 
2012, Guo et al., 2003). As mentioned previously in the introduction, p53 inhibits EMT in 
breast tumour cells (Neilsen et al., 2013), SATB1 increases migration and invasion of breast 
tumour cells (Han et al., 2008a), and Endoglin can inhibit or promote migration and 
invasion, depending on  the cell type (Henry et al., 2011, Oxmann et al., 2008).  
 
Quantitative PCR was used to assess gene expression of each of these genes, exactly as 
described previously in section 4.4.1 and in Materials and methods section 2.8.3. As can be 
see in figure 5.8, in MCF-10A cells, overexpression of PRH causes significant upregulation of 
endoglin, and PRH knockdown causes significant repression of this mRNA. PRH over-
expression also seems to decrease e-cadherin (CDH1) mRNA expression two-fold, although 
this decrease is not statistically significant, and PRH knockdown does not affect e-cadherin 
mRNA expression (figure 5.8). PRH overexpression and knockdown does not affect ESM1 or 
TP53 mRNA expression in MCF-10A cells. SATB1 and goosecoid (GSC) are not expressed at a 
high enough level in this cell type to be quantified by qPCR. These results demonstrate that 
endoglin transcript expression is regulated by PRH in MCF-10A cells, and that PRH is an 
activator of endoglin mRNA expression.  
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Figure 5.8: The effect of PRH overexpression and knockdown on expression of genes involved in EMT/migration in
MCF-10A cells. (A) MCF-10A cells were infected with either Ad or Ad-PRH at a MOI of 50 for 48 hours. Cells were then
pelleted and RNA was extracted using a Bioline ISOLATE II kit, and complementary DNA was then synthesised. Gene
expression was analysed using quantitative PCR, and quantified using the Pfaffl method (Pfaffl, 2001), using GAPDH as
a housekeeping gene (n=3, *p<0.05, two-tail homoscedastic t-test). (B) The same process was repeated but with PRH
knockdown cells, which were induced for shRNA expression as previously described, however beta-actin was used as
a housekeeping gene as GAPDH expression was too variable (n=3, *p<0.05, two-tail homoscedastic t-test).
*
(A) (B)
*
0.1
1
10
CDH1 ENG TP53 GSC
R
el
at
iv
e 
ge
n
e 
ex
p
re
ss
io
n Control
PRH KD
Figure 5.9: The effect of PRH overexpression and knockdown on expression of genes involved in
EMT/migration in MCF-7 cells. (A) MCF-7 cells were infected with either Ad or Ad-PRH at a MOI of 50 for 48
hours. Cells were then pelleted and RNA was extracted using a Bioline ISOLATE II kit, and complementary
DNA was then synthesised. Gene expression was analysed using quantitative PCR, and quantified using the
Pfaffl method (Pfaffl, 2001), using GAPDH as a housekeeping gene (n=3, *p<0.05, two-tail homoscedastic t-
test). (B) The same process was repeated but with PRH knockdown cells, which were induced for shRNA
expression as previously described (n=3, *p<0.05, two-tail homoscedastic t-test).
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In MCF-7 cells, PRH overexpression does not significantly affect TP53, CDH1 or GSC mRNA 
expression (figure 5.9 (A)). However, knockdown of PRH significantly decreased TP53 and 
CDH1 expression (figure 5.9 (B)). GSC mRNA expression was also lower in PRH knockdown 
cells, although this effect was not statistically significant (figure 5.9 (B)). PRH overexpression 
led to increased endoglin transcript expression, which correlates with what was seen in 
MCF-10A cells, but unexpectedly ENG mRNA was also significantly increased when PRH was 
knocked down in MCF-7 cells. One reason for this could be that the PRH knockdown MCF-7 
cells have undergone EMT, and become more tumourgenic and invasive. This is suggested 
by the decrease in e-cadherin and TP53 mRNA observed, and the increased invasion of MCF-
7 PRH knockdown cells. Thus regulation of this gene may be aberrant and occur through 
other factors, and no longer appropriately regulated by PRH in the PRH knockdown cells. 
SATB1 transcript was not expressed at a high enough level at this cell type to be quantified 
by qPCR. 
 
Figure 5.10: The effect of PRH overexpression and knockdown on expression of genes involved in
EMT/migration in MDA-MB-231 cells. (A) MDA-MB-231 cells were infected with either Ad or Ad-PRH at a MOI of
50 for 48 hours. Cells were then pelleted and RNA was extracted using a Bioline ISOLATE II kit, and
complementary DNA was then synthesised. Gene expression was analysed using quantitative PCR, and quantified
using the Pfaffl method (Pfaffl, 2001), using GAPDH as a housekeeping gene (n=3, *p<0.05, two-tail
homoscedastic t-test). (B) The same process was repeated but with PRH knockdown cells, which were induced for
shRNA expression as previously described (n=3, *p<0.05, two-tail homoscedastic t-test).
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In MDA-MB-231 cells, overexpression of PRH causes a significant repression of ESM1 mRNA 
expression (figure 5.10 (A)), however PRH knockdown does not cause a corresponding 
increase in ESM1 transcript expression, and is in fact slightly lower (figure 5.10 (B)). PRH 
overexpression or knockdown did not significantly affect SATB1 or endoglin mRNA 
expression in these cells (figure 5.10). GSC, CDH1 and TP53 were not assessed as their 
transcripts are not expressed (or mutated in the case of TP53) in this cell type. It can be 
concluded that PRH has no effect on ENG or SATB1 mRNA expression, and PRH 
overexpression decreases ESM1 transcript expression in this cell type.  
 
5.4 Effect of PRH on cancer initiating cells 
 
5.4.1 Overexpression of PRH leads to a decrease in MCF-7 mammosphere formation 
 
In previous sections it was shown that over expression of PRH decreased MCF-7 cell number 
and migration, whilst knockdown of PRH increased MCF-7 cell proliferation, migration and 
invasion. It has been reported that MCF-7 tumour cells are a heterogeneous population, of 
which only a minority of cells are cancer initiating cells (Phillips et al., 2006). One technique 
of enriching this cancer-initiating cell (CIC) population 1000 fold is by growing cells in non-
adherent conditions, and in mammosphere media, which causes the bulk cell population to 
die through anoikis (a form of programmed cell death when cells become detached from 
the extracellular matrix) (Phillips et al., 2006). This then leaves the CICs, which proliferate as 
spheroid mammospheres. To determine whether PRH overexpression will affect the survival 
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of the CIC, or will only inhibit the survival of the bulk progeny, MCF-7 cells were infected 
with either Ad or Ad-PRH. Infected cells were then plated into MammoCult (commercial  
mammosphere media) 24 hours later. The number of mammospheres formed was then 
counted 7 days thereafter. Ad-PRH infected cells form a reduced number of mammospheres 
compared to Ad infected cells (figure 5.11 (A)). To see whether this effect was permanent as 
would be expected if the number of CICs had been decreased, or whether this effect was  
transient, the mammospheres were dissociated, counted, and were replated under the 
same conditions to form secondary mammospheres. Ad-PRH infected cells did not show a 
decrease in number of secondary mammospheres compared to control cells (figure 5.11 
(B)). It can be inferred from this that it is the proliferation or survival of the MCF-7 CIC 
progeny that is decreased but that the proportion of CICs (i.e. self-renewal of CICs) is not 
affected by PRH overexpression. The mammosphere formation of PRH knockdown cells was 
also assessed. PRH and control knockdown cells was induced with IPTG for 7 days as 
described previously, and cells were then plated into ultra-low adherrant plates containing 
MammoCult media (with 1mM IPTG added) as before. There was no significant difference in 
primary mammosphere number between PRH knockdown and control cells (figure 5.11 (C)). 
This might be expected if PRH plays no role in the self-renewal of the CIC.  
 CD44+/CD24-/low  have been shown to be markers for CIC’s (sometimes termed cancer stem 
cells) and sorting MCF-7 for this population leads to identification of cells which are 
approximately 1000 times more tumourgenic than the rest of the MCF-7 cell population 
(Phillips et al., 2006).  To confirm that PRH has little effect on self renewal of CIC’s, Ad-PRH 
or Ad infected MCF-7 cells were analysed by flow cytometery 24 hours post-infection for 
their CD24/CD44 expression, or were plated in mammosphere media for another 24 hours 
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before flow cytometery analysis of their CD24/CD44 expression. Figure 5.12 shows that 
there is not a significant difference between the CD44+/CD24-/low population of PRH 
overexpressed and control-infected cells at 24 hours post-infection. This time point is before 
infected cells are replated in non-adherrant media. The same assay was used to measure 
the amount of CD44+/CD24-/low cells in Ad or Ad-PRH mammospheres 48 hours post-
infection and after 24 hours incubation in mammosphere media. Although the proportion of 
CD44+/CD24-/low  cells was much higher in the MCF-7 cell population grown for 24 hours 
under mammosphere conditions, there was no difference in the CD44+/CD24-/low population 
between the Ad and Ad-PRH infected MCF-7 cells (figure 5.13). Therefore, PRH 
overexpression does not seem to affect the CIC population of these cells.  
 
To determine whether the decrease in mammosphere formation by exogenous PRH was 
due to increased cell apoptosis, an Annexin-V-APC assay was carried out 24 hours post 
infection with Ad-PRH, as well as at 48 hours post infection and 24 hours after seeding into 
mammosphere media. Similar to results shown previously in figure 4.4, PRH increases 
Figure 5.11: Ad-PRH decreases the number of MCF-7 mammospheres. (A) MCF-7 cells were infected with either Ad
or Ad-PRH for 24 hours at a MOI of 50. 4x104 cells were then plated into ultra-low adherant 6-well plates containing
MammoCult media, and were left for 7 days. The number of primary mammospheres was then quantified using a
counting grid (n=8, two-tail homoscedastic t-test *p<0.05). (B) Mammospheres were then dissociated using trypsin,
and the number of cells was then quantified using a haemacytometer and Trypan blue exclusion dye. 4x104 cells
were then seeded in the same way as before, and the number of secondary mammospheres was then quantified
(n=8, two-tail homoscedastic t-test ns=not significant). (C) PRH and control knockdown MCF-7 cells were then
induced for shRNA expression as described previously, and were then plated as described above to form primary
mammospheres (n=3, two-tail homoscedastic t-test *ns=not significant).
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Figure 5.12: PRH overexpression does not affect the percentage of CD24lowCD44+ cells. CD24lowCD44+ cells
have been shown when enriched to be markers for the mammosphere-forming sub-population of MCF-7
cells (Phillips et. al. 2006). MCF-7 cells were incubated with either control adenovirus or Ad-PRH at a MOI
of 50 for 24 hours. Cells were then stained with CD24-FITC and CD44-PE for 30 minutes at 4°C before being
analysed by flow cytometery (*p<0.05, n=3 two-tail homoscedastic t-test).
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Figure 5.13: PRH overexpression does not affect the percentage of CD24lowCD44+ cells in
mammospheres. MCF-7 cells were incubated with either control adenovirus or Ad-PRH at a MOI of 50 for
24 hours. Cells were then scraped and cultured in MammoCult media in non-adherrant 6-well plates for
another 24 hours. Cells were then stained with CD24-FITC and CD44-PE for 30 minutes at 4°C before being
analysed by flow cytometery (*p<0.05, n=3 two-tail homoscedastic t-test).
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Figure 5.14: Ad-PRH increases apoptosis in MCF-7 cells. MCF-7 cells were incubated with Ad-PRH for 24
hours, before being stained with 10µg/μl propodium iodide (PI) and 5µl of Annexin V-APC antibody (BD
Biosciences). Cells were then analysed by flow cytometery to determine live cells (PI-, AV-), early apoptotic
(PI-, AV+) and late apoptotic (PI+. AV+) (n=3, *p<0.05 two-tail homoscedastic t-test)
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Figure 5.15: Ad-PRH does not increase apoptosis in MCF-7 mammospheres. MCF-7 cells were incubated
with Ad-PRH for 24 hours. Cells were then scraped and cultured in MammoCult media in non-adherrant
6-well plates for another 24 hours. Cells were then stained with 10µg/μl propodium iodide and 5µl of
Annexin V-APC antibody (BD Biosciences). Cells were then analysed by flow cytometery to determine live
cells (PI-, AV-), early apoptotic (PI-, AV+) and late apoptotic (PI+. AV+) (n=3, *p<0.05 one-tail
homoscedastic t-test).
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apoptosis of adherent MCF-7 cells (figure 5.14). It should be noted that the particularly high 
number of apoptotic cells observed is likely to be due to cells needing to be detached using 
a cell scraper, as trypsin reduces the efficiency of mammosphere formation. The pro-
apoptotic effect of Ad-PRH is lost at 48 hours post infection when the cells are cultured 
under mammosphere conditions for 24 hours (figure 5.15).  
It is not clear exactly why a decreased number of mammospheres were observed when PRH 
is overexpressed. The effects of PRH on mammosphere formation occur either 
predominantly through the increased apoptosis of MCF-7 cells prior to plating in 
mammosphere media, or through decreased proliferation of cells within the mammosphere 
population during the 7 day mammosphere assay. Unfortunately, BrdU proliferation assays 
were not possible, due to the low cell number and the three-dimensional growth of 
mammospheres, making quantification difficult. In conclusion, these experiments show that 
PRH overexpression decreases the number of bulk cancer cells but not the proportion of 
CICs. This decrease may be either through increased apoptosis occurring before cells are 
plated in MammoCult media, or through a decrease in the proliferation rate during the 7 
day mammosphere assay.  
 
5.4.2 PRH increases MCF-7 tumour growth in vivo 
 
Although PRH does not decrease CIC in MCF-7 cells, our studies suggest that PRH 
overexpression can decrease the growth of the bulk MCF-7 cancer cells. In addition our 
studies show that PRH overexpression decreases the migratory properties of MCF-7 cells. To 
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assess the affect of PRH overexpression in vivo, xenograft experiments were carried out, 
whereby MCF-7 cells are injected into a murine host, and allowed to develop tumours over 
a 6 week period. MCF-7 cells were infected with either Ad, Ad-PRH at a MOI of 50 or left 
uninfected. After 24 hours cells were harvested and viable cells were counted using trypan 
blue exclusion dye. Approximately 5 x106 cells were then injected into each mammary fat 
pad of a female 6 week old Balb/c nude mouse, with eight mice being used for Ad and Ad-
PRH infected cells. Additionally 4 mice were injected with MCF-7 cells that had not been 
infected with adenovirus. Each mouse was supplemented with 17β-oestradiol tablets which 
were inserted sub-cutaneously. 17β-Oestradiol is required to supply a high continuous dose 
of oestrogen in the mouse, which allows the ER-positive MCF-7 tumour to grow. Tumour 
size was then measured three times per week (using the modified ellipsoid formula 0.5 x 
length x width2 (Euhus et al., 1986)), until the mice were culled. Unexpectedly, there is a 
significant increase in tumour size in mice injected with Ad-PRH infected MCF-7 cells 
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Figure 5.16: Ad-PRH increases MCF-7 tumour size in vivo. (A) MCF-7 cells were infected at a MOI of
50 with Ad-PRH, control adenovirus or with no virus for 24 hours. 5 million cells were then injected
into each mammary fat pad of a female Balb/c nude mouse. Tumour size was then measured using
the equation 0.5 x w x h x h (n=8, *p<0.05 **p<0.01 ***p<0.001 two-tail homoscedastic t-test). (B) A
sample of cells were taken before injection (day 1) and after 7 days in cell culture (day 7) to show
that infection by the Ad-PRH virus was successful, and to show that Myc-PRH protein is expressed in
MCF-7 cells for at least a week, by Western blotting as described previously.
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compared to mice injected with Ad infected or uninfected MCF-7 cells (Figure 5.16). Thus, in 
in vivo experiments PRH overexpression results in an entirely unexpected oncogenic 
phenotype. 
 
5.5 Discussion 
 
In scratch wound assays, overexpression of PRH inhibited chemokinesis by MCF-7 and MDA-
MB-231 cells (MCF-10A cells were not used, as they are not migratory, and thus it would be    
difficult to see a further decrease in migration). Knockdown of PRH increases scratch wound 
closure by MCF-7 cells. However, it failed to have the same effect in MDA-MB-231 cells. One 
reason for this discrepancy could be because MDA-MB-231 cells are highly migratory 
mesenchymal cells, and thus it may be difficult to increase their migration even further. PRH 
knockdown also has no effect on chemokinesis in MCF-10A cells. The difference in effect of 
PRH knockdown between MCF-7 and MCF-10A cells could be because proteins are present 
which inhibit MCF-10A migration, and these are either mutated or absent in MCF-7 cells, 
allowing the PRH knockdown phenotype to be more easily observed. 
 
In chemotaxis assays, in all three cell types tested (MCF-7, MDA-MB-231 and MCF-10A), 
knock-down of PRH expression leads to increased migration. Thus, knockdown of PRH has 
effects on chemotaxis in MCF-10A and MDA-MB-231 cells, even though no effects on 
chemokinesis can be detected. For MCF-10A cells, the enhanced chemotaxis may be 
observed because EGF is used as a chemoattractant. One possibility is that PRH could be 
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repressing expression of EGF receptor and/or signalling proteins in the EGF pathway. It 
should also be noted that only 7% of PRH knockdown cells migrate over 24 hours. 
Therefore, this increase in chemotaxis may be too small to detect in non-directional cell 
mobility scratch wound assays. The same could also be true in MDA-MB-231 cells. 
Overexpression of PRH in MCF-7 and MDA-MB-231 cells leads to decreased migration (MCF-
10A cells could not be used in this assay, as they are not sufficiently migratory). In each cell 
type, PRH is a regulator of genes associated with migration; endoglin in MCF-10A cells, e-
cadherin and endoglin in MCF-7 cells and ESM1 in MDA-MB-231 cells. Taken together, 
expression of PRH is an important factor in determining the chemotactic abilities of breast 
cells.  
 
Invasion assays were also carried out on PRH knockdown MCF-7 cells. More PRH knockdown 
cells were invasive than control cells. This shows that PRH is also an important factor in cell 
invasion. It is thought that as cancer cells become more invasive, they undergo an epithelial 
to mesenchymal transition (EMT). Therefore, it is possible that PRH is a determining factor 
for whether a cell undergoes EMT or not. This is further suggested by the observation that 
both TP53 and e-cadherin mRNA expression is lower in PRH knockdown cells than control 
cells.  
 
Unusually Endoglin transcript expression is increased when PRH expression is knocked down 
in MCF-7 cells, as well as when PRH is overexpressed in the same cell type. This could be due 
to the “dual nature” of TGF-β signalling, where TGF-β has apparently opposing effects 
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depending on the context in which it is acting. This is not totally surprising, as Endoglin is 
known to inhibit migration in less tumourgenic cell types, but can act to promote cell 
migration in more aggressive cell types (Oxmann et al., 2008, Henry et al., 2011). Therefore, 
knockdown of PRH could be transforming the MCF-7 cells into a more mesenchymal, and 
hence more aggressive cell type, and thus this changes the role that Endoglin plays with 
respect to migration. Exogenous PRH has been shown to bind directly to the ENG promoter 
in both MCF-10A and MCF-7 cells (Kershaw et al., 2013b). It could not be determined 
whether endogenous PRH in wild type MCF-7 cells regulates ENG in this way as well, as no 
suitable anti-PRH antibody could be found for endogenous ChIP at the endoglin promoter. It 
is possible that the upregulation of endoglin transcript  in PRH knockdown MCF-7 cells is due 
to the changed morphology and more mesenchymal nature of the PRH knockdown cells (R. 
Kershaw and P.S. Jayaraman, personal communication). 
 
A link has been made between EMT and CICs, whereby CIC have an more “mesenchymal-
like” phenotype, suggesting that EMT leads to the production of more CICs (Mani et al., 
2008). Therefore, it could be hypothesised that if knockdown of PRH leads to EMT in MCF-7 
cells, that there may be an increase in the number of CICs. This was not found to be the 
case, as there was no increase in mammosphere formation in PRH knockdown cells 
compared to control cells. One explanation for this could be that additional factors are 
required for CIC self-renewal that are not needed for EMT.  
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The decrease in  cell number when PRH is overexpressed in MCF-7 cells in both 2D and 3D 
cultures led to the hypothesis that overexpression of PRH would lead to a decrease in MCF-7 
tumor growth in xenograft experiments. However, overexpression of PRH in these cells 
surprisingly led to an increase in MCF-7 xenograft growth. This could be caused by a number 
of factors, including effects on the host immune system, the effects of hypoxia, high 
oestrogen levels in vivo and PRH causing mesenchymal-to-epithelial transition (MET), which 
will be discussed further in the next chapter.  
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6. General discussion 
This thesis demonstrates that PRH plays an important role in regulating cell proliferation, 
survival and the migratory phenotypes shown by breast cancer cells. Moreover, this thesis 
provides evidence that PRH is a regulator of cell invasion and that PRH can influence the 
expression of key genes involved in the epithelial-to-mesenchymal transition. These findings 
provide a possible explanation for the association between PRH expression and breast 
cancer prognosis.  
 
6.1 PRH and patient prognosis 
 
In chapter three, interrogation of a database that correlates gene expression profile with 
breast cancer prognosis showed that decreased PRH mRNA expression in breast cancer 
patients correlates with decreased overall survival (Ringnér et al., 2011). Interestingly, PRH 
mRNA is poorly expressed in the basal and HER2+ subtypes, which are the most aggressive 
forms of breast cancer. PRH transcript expression is also observed to be significantly 
decreased in grade 3 breast cancers, which are the least differentiated cancer cell type. This 
is a similar result to that seen in hepatocarcinoma patients, where PRH protein expression is 
significantly lower in the least differentiated tumours (Su et al., 2012). Taken together, these 
studies indicate that PRH mRNA expression could function as a novel marker for breast 
cancer survival. 
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6.2 PRH protein levels, localisation and modifications in different breast cell lines 
 
This thesis demonstrates that PRH protein is found in most of the normal and tumourgenic 
breast cell lines tested in this study. The amount of PRH protein detected by the M6 
antibody correlates with the PRH mRNA levels in the corresponding cell lines, as measured 
in microarray studies  (Ringnér et al., 2011). Therefore, just as PRH mRNA could function as 
a marker for overall survival for breast cancer, the M6 anti-PRH antibody could also be used 
as a marker for breast cancer prognosis. Interestingly, the other anti-PRH antibodies used 
(M3 and YKN5) detect different forms of PRH, which are expressed at quite different levels 
in each cell type. The significance of this is not fully understood, and requires further 
investigation into the nature of the post-translational modifications and oligomerisation 
state of the PRH protein. It is of interest to note that the truncated PRHΔC product is 
expressed at high levels in both MCF-7 and MDA-MB-231 tumour cells. This product has 
been shown to act in a dominant negative way over full length PRH in leukaemic cells (Noy 
et al., 2012c). It is likely that the presence of PRHΔC will also influence the activity of full-
length PRH in breast tumour cells, and therefore measurement of full length PRH levels may 
not be a good indicator of the amount of transcriptionally active PRH levels in the cell.  
Additional studies examining the role of PRHΔC in influencing PRH or TLE activity in breast 
cancer cells would be useful. For example, TLE proteins are negative regulators of Wnt 
signalling  (Daniels and Weis, 2005), therefore it would be of interest to investigate whether 
PRHΔC activates Wnt signalling by sequestration of TLE protein in breast cancer cells.  
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Subcellular fractionation and staining with the M6 antibody showed that the localisation of 
PRH is predominantly cytoplasmic in both the non-tumourgenic and tumourgenic cell lines. 
However, further in situ fractionation experiments showed that even though PRH is 
predominantly cytoplasmic in MCF-10A cells there appears to be significantly more tightly 
held nuclear PRH in MCF-10A cells compared to MCF-7 and MDA-MB-231 cells, (R. Kershaw, 
E. Fallon and P-S Jayaraman, personal communication). Therefore, the in situ subcellular 
fractionation experiments do correlate with the findings of Puppin et. al., who found out 
that nuclear PRH is reduced in breast tumour cells compared to control cells (Puppin et al., 
2006). This result is not observed in in vitro cell fractionation experiments where retention 
of nuclear proteins is measured, but this could be because in situ fractionation and in vitro 
fractionation experiments are carried out using very different detergent conditions.  
 
It is interesting to note that exogenous PRH stability is lower in the tumourgenic cell lines 
than the non-tumourgenic cell line MCF-10A. It has been shown previously in breast cancer 
patients that their serum levels have higher proteolytic activity compared to healthy 
individuals (Roth et al., 2011). Therefore, it is possible that in tumour cells PRH activity is 
reduced not just by a reduction in PRH transcript, but also by an increase in protein 
degradation as well. The mechanism of PRH degradation could be investigated further, using 
caspase and proteasome inhibitors, to see whether these affect PRH stability. The 
mechanism of phosphorylation of PRH is also of interest, and warrants further investigation. 
This could be achieved by disrupting the activity of CK2 (either by using CK2 inhibitors such 
as DMAT/TBB, or by siRNA knockdown of a CK2 subunit) and determining whether this 
affects phosphorylated PRH levels in breast cells. The mechanism of regulation of PRH 
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activity will certainly be of significance if PRH protein levels prove to be an indicator of 
tumour prognosis.  
 
6.3 PRH and cell growth 
 
In chapter four, cell counting assays showed that exogenous PRH in MCF-10A and MCF-7 
cells, significantly reduced cell number. In MCF-10A cells, this was due in part to a reduction 
in proliferation, as determined by BrdU assays, whilst exogenous PRH increased MCF-7 
apoptosis. PRH also decreased proliferation in MDA-MB-231 cells, as determined by BrdU 
and cell cycle assays. Thus in all cases exogenous PRH appears to decrease cell growth.  
 
The differences in the effect of exogenous PRH (i.e on proliferation or apoptosis) between 
the cell lines very likely reflects the genetic background of the cell line. For example, MDA-
MB-231 cells express mutated p53 (R280K), therefore are presumably more resistant to 
apoptosis, whereas MCF-7 cells express wild-type p53. Differences in the levels of 
endogenous PRH in each cell line may also account for the apparent difference of 
exogenous PRH on the phenotype of each cell line This could explain why the effects of 
exogenous PRH are greater in MCF-7 cells (which express moderate levels of PRH) compared 
to MDA-MB-231 cells (which express high levels of PRH). This could occur because 
exogenous PRH has to compete with endogenous PRH at PRH binding sites within gene 
promoters/enhancers. Therefore, cells with low endogenous PRH in the cell will be more 
affected by exogenous PRH than cells already expressing high amount of PRH protein.  Also, 
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the relative levels of PRH co-activators and co-repressors will vary between the cell types, 
which will influence PRH activity. It has been shown in K562 cells that PRH needs to bind to 
the co-repressor TLE to exert its transcriptional repression activity (Noy et al., 2010). 
Therefore, differing endogenous levels of TLE (or sequesterisation of TLE by PRHΔC, for 
example) could be one reason why exogenous PRH has different effects in different cell 
lines. Finally, genes which are quite lowly expressed in certain cell lines may not be 
repressed further by increased PRH, and conversely, genes which are highly expressed may 
not show increased expression when PRH levels are increased. Another reason that 
exogenous PRH has apparently different effects in each cell line could be that exogenous 
PRH is less stable in some cell lines. For example, Myc-PRH appears to be less stable in MDA-
MB-231 cells than MCF-10A cells, and thus the effects of PRH may be more transitory in 
MDA-MB-231 cells, compared to non-tumourgenic MCF-10A cells. In accordance with this 
idea, the observed inhibition of proliferation by PRH is much greater in MCF-10A cells than 
in MDA-MB-231 cells, and although exogenous PRH did cause a decrease in MDA-MB-231 
proliferation, this did not translate to a decrease in cell number in cell counting 
experiments.  Therefore, the difference in PRH stability between the cell lines (possibly due 
to increased phosphorylation by CK2) could also lead to an apparent difference in 
exogenous PRH activity.   
 
PRH has been shown to decrease proliferation of U937 lymphoma cells via a non-
transcriptional mechanism (Topisirovic et al., 2003).  In this cell line PRH binds to the 
translation factor protein eIF-4E, and inhibits nucleo-cytoplasmic transport of cyclin d1 
mRNA (Topisirovic et al., 2003).  However, PRH can also inhibit gene expression by directly 
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binding to promoters, leading to repression of gene expression (Noy et al., 2010). Since the 
PRH N187A DNA binding mutant failed to decrease MCF-10A and MDA-MB-231 
proliferation, or to decrease MCF-7 cell number, it can be inferred that binding to eIF-4E is 
not significantly involved in the growth inhibitory activities of exogenous PRH in the three 
breast cell lines tested. Thus in all breast cell lines DNA binding activity is required for 
population growth inhibitory phenotypes. In MCF-7 cells at least two PRH regulated genes 
(endoglin and VEGFR2) are directly bound by exogenous PRH at the promoter region of 
these genes. Further experiments are needed to determine the precise mechanism(s) by 
which PRH regulates expression of these genes (for example, whether PRH needs to bind to 
TLE, or to another co-activator/repressor, to regulate genes in this cell type).  
 
Knockdown of PRH caused three different effects in the three breast cell lines, causing no 
observable effect on proliferation in MCF-10A cells, increasing proliferation in MCF-7 cells, 
and decreasing proliferation in MDA-MB-231 cells. In MCF-10A cells it is likely that, as in 
other normal cell types, there are many redundant mechanisms to control cell proliferation 
(reviewed in Huang and Ingber, 1999). Therefore, reduction of PRH expression in itself may 
not be enough to increase cell proliferation, or increase expression of VSP genes.  
Alternatively, it is possible that the level of knockdown of PRH in this cell type was not 
sufficient to observe a phenotype.   
In MCF-7 cells, reduction of PRH protein leads to an increase in cell number, whilst 
conversely overexpression of PRH results in decreased cell number, therefore in this cell line 
the overexpression and knockdown of PRH results generally correlate with each other. 
However, overexpression of PRH did not inhibit the cell cycle progression, whilst knockdown 
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of PRH results in faster progression through the cell cycle (through an increase in the 
percentage of cells in S-phase). In PRH overexpressing MCF-7 cells, increased cell apoptosis 
could occur through decreased autocrine signalling by VEGF signalling genes, whereas 
knockdown of PRH expression may have less of an effect on increasing expression of genes 
in this pathway, as expression levels may be near their maximal levels in this cell type. 
Similarly in wild-type MCF-7 cells, TP53 transcript may be expressed at its maximal levels, 
preventing exogenous PRH further increasing expression of this gene. Knockdown of PRH 
shows that endogenous PRH does play a role in regulation of the TP53 gene (in these cells) 
(see figure 6.1).  
 
Microarray studies show that PRH mRNA levels are significantly lower in basal breast 
cancers (as seen in chapter 3). Therefore, it is unusual to find that the basal tumour cell line 
EMT
Migration
Invasion
Figure 6.1: Model of PRH activity in MCF-7 cells. Reduction of PRH expression leads to EMT, and an
increase in proliferation, migration and invasion. This correlates with a reduction in TP53 and e-cadherin
(CDH1) mRNA expression. Increased PRH leads to apoptosis of MCF-7 cells, which correlates with
decreased expression of the pro-survival genes NRP1 and VEGFR2.
Apoptosis
Proliferation
PRH Expression
TP53 ↓
CDH1↓
VEGFR2↓
NRP1↓
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MDA-MB-231 expresses relatively high levels of PRH protein compared to the other cell 
lines used in this study. Knockdown of PRH in MDA-MB-231 cells also leads to a decrease in 
cell proliferation and a decrease in VEGFA mRNA expression. This is unexpected, as 
overexpression of PRH also leads to a decrease in cell proliferation. The reason for the 
inconsistencies of knockdown and overexpression of PRH in these results could be that 
endogenous PRH activity is aberrant in this cell line, resulting in it activating genes it is 
known to repress in other cell lines, such as MCF-10A cells, K562 leukaemic cells and    
HUVECs (Nakagawa et al., 2003, Noy et al., 2010), and also resulting in PRH promoting 
tumour growth. This aberrant activity may be, as mentioned before, due to the expression 
of other mutant PRH interacting partner proteins, which alter PRH activity in this cell line. 
Alternatively, the endogenous PRH gene may be mutated in this cell type. Therefore, 
characterisation of this cell line (by RNA sequencing) could determine how the activity of 
endogenous PRH is altered in this cell type.  
 
6.4 PRH in the regulation of EMT and invasion 
 
In chapter 5, it is shown that the overall effect of PRH is that it decreases migration in all 
three cell types, either via overexpression or knockdown of PRH. Therefore, unlike the effect 
of PRH on breast cancer cell proliferation, the effect of PRH on migration appears to be 
more consistent and less context-dependent. Exogenous PRH expression also decreases the 
invasion of breast tumour cells, and knockdown of PRH increases their invasion. One 
explanation for the more consistent inhibition of migration/invasion, compared to the more 
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variable phenotype on cell growth from PRH, could be that the genes regulating 
migration/invasion are more tightly regulated by endogenous PRH than genes involved in 
regulating cell growth. Therefore, even a small decrease in PRH levels leads to increased 
migration and invasion. Another possibility is that cofactors regulating migration and 
invasion are the same in all cell types, whereas cofactors regulating growth may be 
different. Since loss of PRH in non-tumourgenic cells increases their invasive properties, and 
as metastasis is the cause of 90% of cancer deaths (Mehlen and Puisieux, 2006), increased 
invasion could provide an explanation for the finding that decreased PRH expression 
correlates with decreased survival in breast tumour patients. 
 
Homeodomain proteins typically play a key role in the development of the embryo and the 
adult organs, and one process which is regulated during development is EMT (Yilmaz and 
Christofori, 2009, Nunes et al., 2003). Examples of homeodomain proteins that induce EMT 
in breast cancer cells include Paired Mesoderm Homeobox Protein 1 (PRRX1), Ladybird 
Homeobox 1 (LBX1), Homeobox B7 and Homeobox B9 (Wu et al., 2006a, Yu et al., 2009, 
Chiba et al., 2012, Ocaña et al., 2012). Therefore, it is highly likely that PRH, being a 
homeodomain protein mislocalised in breast cancer, can also affect EMT in breast cancer 
cells. In MCF-7 cells, knockdown of endogenous PRH was shown to decrease e-cadherin and 
TP53 mRNA expression. As PRH knockdown also increased MCF-7 migration and invasion, it 
is possible that these cells may be undergoing EMT. Further evidence for this hypothesis has 
now been obtained in the laboratory in Western blotting experiments. Knockdown of PRH 
causes a decrease in E-Cadherin protein expression, and an increase in the expression of 
several transcription factors required for EMT (Snail, Slug and Vimentin) (R. Kershaw and 
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P.S. Jayaraman, personal communication). Furthermore, the morphology of the PRH 
knockdown cells is elongated and more mesenchymal (R.K. and P.S.J). It has previously been 
shown that PRH is involved in the EMT process during murine development (Hallaq et al., 
2004). Taken together, this strongly suggests that PRH is involved in inhibiting EMT in MCF-7 
breast cancer cells (see figure 6.1).  
 
In MCF-10A cells, endoglin mRNA is up-regulated by PRH over-expression, and is down-
regulated when PRH expression is knocked down, indicating that PRH is an activator of 
endoglin mRNA expression in this cell type. Surprisingly, endoglin transcript was significantly 
upregulated by both knockdown and overexpression of PRH in MCF-7 cells. Exogenous PRH 
has been shown to bind directly to the ENG promoter in both of these cell types, suggesting 
that PRH regulates ENG directly (Kershaw et al., 2013b). As mentioned before, PRH 
knockdown also appears to induce EMT in MCF-7 cells (and they acquire a more migratory 
and invasive phenotype). This may account for the increase in endoglin mRNA levels in MCF-
7 PRH knockdown cells, whereby other factors which are upregulated during EMT activate 
ENG instead of PRH. Upregulation of Endoglin in non-tumour cells acts to inhibit cell 
migration, whereas upregulation of Endoglin in the more aggressive tumour cells promotes 
cell migration (Oxmann et al., 2008, Henry et al., 2011). This correlates with the “dual roles” 
that TGF-β signalling has in cancer development, inhibiting tumourgenesis in less 
transformed cells, and promoting tumour migration in more transformed cells (Bierie and 
Moses, 2006). Therefore, the transcription factors involved in the regulation of Endoglin 
(and TGF-β signalling) are presumably very different in the less aggressive tumours 
compared to the more aggressive tumour cell types.  
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6.5 PRH in xenografts 
 
This thesis demonstrates that overexpression of PRH inhibits the growth of MCF-7 cells in 
both adherant and in mammosphere cultures, by increasing apoptosis. Moreover it shows 
that overexpression of PRH decreases migration of these cells. However, Ad-PRH infected 
MCF-7 cells are significantly more tumourgenic than Ad infected MCF-7 cells in mouse   
xenografts. There are many factors which could explain the discrepancies between the in 
vitro and the in vivo growth assays. For the tumour to be established, it must first settle in 
the stroma micro-environment, which is a different process from cell survival. Therefore, 
one possibility is that although PRH increases apoptosis of MCF-7 cells, the cells that survive 
are more adapted to settle in the mouse stroma. It has been suggested that cells that 
undergo metastasis undergo mesenchymal-epithelial transition to colonise their secondary 
sites (Hanahan and Weinberg, 2011). Therefore, as knockdown of PRH allows cells to 
undergo increased EMT in MCF-7 cells, it is possible that overexpression of PRH will lead to  
increased MET, allowing greater colonisation of MCF-7 cells in xenografts. 
 
The murine immune system could also interact with the Ad-PRH infected MCF-7 cells, 
increasing tumourgenesis. The mice used are Balb/c nude mice, which have a mutation in 
the FOXN1 gene, resulting in a dysfunctional thymus (Mecklenburg et al., 2001). This results 
in mice that lack T-cell activity, but maintain normal B-cell and innate immune system 
activity (Mecklenburg et al., 2001). Tumourgenesis is increased by inflammation, by 
increasing concentrations of matrix metalloproteinases (MMPs) in the stroma (leading to 
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increased tumour invasion), increasing reactive oxygen species (ROS) (and therefore 
increasing DNA damage in the tumour microenvironment) and by increasing angiogenesis, 
which promote epithelial tumour cell survival (Rakoff-Nahoum, 2006, Grivennikov et al., 
2010). Therefore, an increase in apoptotic MCF-7 cells could lead to an increase in the 
inflammatory response, which in turn could make the stroma micro-environment more 
hospitable for tumour cells.  
 
As mentioned previously in the introduction, VEGF receptor genes increase tumour 
angiogenesis, and in turn make the tumour cells less hypoxic. Also, it has been shown that 
primary breast tumour CICs can differentiate directly into endothelial cells, and form 
intratumour vessels (Bussolati et al., 2009). As exogenous PRH decreases VEGFR2 and NRP1 
mRNA expression in MCF-7 cells, it is possible that overexpression of PRH reduces the pro-
angiogenic activity of MCF-7 CICs as well. This may paradoxically allow the tumour to 
become more aggressive, as decreased angiogenesis may result in increased hypoxia within 
the MCF-7 tumour, which has been shown to lead to increased EMT (Chen et al., 2009a). 
Furthermore, it has been shown that anti-VEGF therapies, such as sunitinib, whilst 
decreasing the size of the initial tumour, frequently recur, leading to more aggressive 
tumours (Ebos et al., 2009). It has also been shown that anti-angiogenic agents increase the 
frequency of breast CICs as well (Conley et al., 2012). Therefore, inhibition of VSP genes by 
PRH in certain contexts could actually result in increased tumourgenesis.  
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6.6 Further experiments 
 
To further determine whether PRH is pro- or anti-tumourgenic in vivo, the xenograft 
experiment could be set up in a slightly different way, by waiting approximately 2 weeks for 
the tumour to be established before infecting the tumour with adenovirus. Therefore, if the 
resulting tumours get smaller, or at least fail to increase in size, it can be shown that PRH 
can affect MCF-7 cell growth in vivo, and that the results seen previously were due to an 
increase in establishment of the initial tumour, rather than increased tumour growth. The 
experiment could also be repeated with the PRH knockdown MCF-7 cells, to determine 
whether this shows the opposite effect to that is seen with PRH over-expression. It would 
also be of interest to determine whether knockdown or overexpression of PRH can cause 
increased breast cancer cell metastasis in vivo. This has previously been achieved using 
highly metastatic MDA-MB-231 cells, which express GFP (Hartwell et al., 2006). This would 
further verify whether PRH is a repressor of tumour cell invasion, and whether this affects 
tumour metastasis in vivo.   
 
Although it is shown that PRH directly regulates genes involved in breast cell survival and 
migration, the studies were limited to genes which have previously been shown to be 
regulated by PRH. To determine the global role of PRH as a transcription factor in the 
regulation of cell growth and migration, microarray analysis, RNA-sequencing and ChIP-
sequencing could be carried out. This would determine whether PRH regulates genes in 
other pathways which are involved in cancer survival.  
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To conclude, PRH is an important regulator of breast cancer growth, migration, and invasion 
in a variety of breast cell types, and disruption of PRH activity can lead to more aggressive 
phenotypes.   
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